
<html lang="en"     class="pb-page"  data-request-id="7ff12420-ffae-45dd-a9d4-f340db119ec6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm2009925;website:website:acspubs;issue:issue:10.1021/jmcmar.2012.55.issue-3;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E" /></meta><meta name="dc.Creator" content="Martin W.  Rowbottom" /></meta><meta name="dc.Creator" content="Raffaella  Faraoni" /></meta><meta name="dc.Creator" content="Qi  Chao" /></meta><meta name="dc.Creator" content="Brian T.  Campbell" /></meta><meta name="dc.Creator" content="Andiliy G.  Lai" /></meta><meta name="dc.Creator" content="Eduardo  Setti" /></meta><meta name="dc.Creator" content="Maiko  Ezawa" /></meta><meta name="dc.Creator" content="Kelly G.  Sprankle" /></meta><meta name="dc.Creator" content="Sunny  Abraham" /></meta><meta name="dc.Creator" content="Lan  Tran" /></meta><meta name="dc.Creator" content="Brian  Struss" /></meta><meta name="dc.Creator" content="Michael  Gibney" /></meta><meta name="dc.Creator" content="Robert C.  Armstrong" /></meta><meta name="dc.Creator" content="Ruwanthi N.  Gunawardane" /></meta><meta name="dc.Creator" content="Ronald R.  Nepomuceno" /></meta><meta name="dc.Creator" content="Ianina  Valenta" /></meta><meta name="dc.Creator" content="Helen  Hua" /></meta><meta name="dc.Creator" content="Michael F.  Gardner" /></meta><meta name="dc.Creator" content="Merryl D.  Cramer" /></meta><meta name="dc.Creator" content="Dana  Gitnick" /></meta><meta name="dc.Creator" content="Darren E.  Insko" /></meta><meta name="dc.Creator" content="Julius L.  Apuy" /></meta><meta name="dc.Creator" content="Susan  Jones-Bolin" /></meta><meta name="dc.Creator" content="Arup K.  Ghose" /></meta><meta name="dc.Creator" content="Torsten  Herbertz" /></meta><meta name="dc.Creator" content="Mark A.  Ator" /></meta><meta name="dc.Creator" content="Bruce D.  Dorsey" /></meta><meta name="dc.Creator" content="Bruce  Ruggeri" /></meta><meta name="dc.Creator" content="Michael  Williams" /></meta><meta name="dc.Creator" content="Shripad  Bhagwat" /></meta><meta name="dc.Creator" content="Joyce  James" /></meta><meta name="dc.Creator" content="Mark W.  Holladay" /></meta><meta name="dc.Description" content="The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAFV600E re..." /></meta><meta name="Description" content="The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAFV600E re..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 23, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm2009925" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm2009925" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm2009925" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm2009925" /></link>
        
    
    

<title>Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm2009925" /></meta><meta property="og:title" content="Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0016.jpeg" /></meta><meta property="og:description" content="The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAFV600E results in constitutive activation of the MAPK pathway, which can lead to uncontrolled cellular growth. Herein, we describe an SAR optimization campaign around a series of quinazoline derived BRAFV600E inhibitors. In particular, the bioisosteric replacement of a metabolically sensitive tert-butyl group with fluorinated alkyl moieties is described. This effort led directly to the identification of a clinical candidate, compound 40 (CEP-32496). Compound 40 exhibits high potency against several BRAFV600E-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAFV600E versus those containing wild-type BRAF. Compound 40 also exhibits an excellent PK profile across multiple preclinical species. In addition, significant oral efficacy was observed in a 14-day BRAFV600E-dependent human Colo-205 tumor xenograft mouse model, upon dosing at 30 and 100 mg/kg BID." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAFV600E results in constitutive activation of the MAPK pathway, which can lead to uncontrolled cellular growth. Herein, we describe an SAR optimization campaign around a series of quinazoline derived BRAFV600E inhibitors. In particular, the bioisosteric replacement of a metabolically sensitive tert-butyl group with fluorinated alkyl moieties is described. This effort led directly to the identification of a clinical candidate, compound 40 (CEP-32496). Compound 40 exhibits high potency against several BRAFV600E-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAFV600E versus those containing wild-type BRAF. Compound 40 also exhibits an excellent PK profile across multiple preclinical species. In addition, significant oral efficacy was observed in a 14-day BRAFV600E-dependent human Colo-205 tumor xenograft mouse model, upon dosing at 30 and 100 mg/kg BID." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0016.jpeg" /></meta><meta name="twitter:title" content="Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm2009925"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm2009925">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm2009925&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm2009925&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm2009925&amp;href=/doi/10.1021/jm2009925" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1082-1105</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm200912j" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2010207" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+W.++Rowbottom">Martin W. Rowbottom</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Raffaella++Faraoni">Raffaella Faraoni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qi++Chao">Qi Chao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+T.++Campbell">Brian T. Campbell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andiliy+G.++Lai">Andiliy G. Lai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eduardo++Setti">Eduardo Setti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maiko++Ezawa">Maiko Ezawa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kelly+G.++Sprankle">Kelly G. Sprankle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sunny++Abraham">Sunny Abraham</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lan++Tran">Lan Tran</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Struss">Brian Struss</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Gibney">Michael Gibney</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+C.++Armstrong">Robert C. Armstrong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ruwanthi+N.++Gunawardane">Ruwanthi N. Gunawardane</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ronald+R.++Nepomuceno">Ronald R. Nepomuceno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ianina++Valenta">Ianina Valenta</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helen++Hua">Helen Hua</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+F.++Gardner">Michael F. Gardner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Merryl+D.++Cramer">Merryl D. Cramer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dana++Gitnick">Dana Gitnick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Darren+E.++Insko">Darren E. Insko</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julius+L.++Apuy">Julius L. Apuy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Jones-Bolin">Susan Jones-Bolin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arup+K.++Ghose">Arup K. Ghose</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Torsten++Herbertz">Torsten Herbertz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Ator">Mark A. Ator</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+D.++Dorsey">Bruce D. Dorsey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce++Ruggeri">Bruce Ruggeri</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Williams">Michael Williams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shripad++Bhagwat">Shripad Bhagwat</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joyce++James">Joyce James</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+W.++Holladay">Mark W. Holladay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Ambit Biosciences, 4215 Sorrento Valley Boulevard, San Diego, California 92121, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 1-858-334-2115. Fax: 1-858-334-2192. E-mail: <a href="/cdn-cgi/l/email-protection#660b14091104091212090b26070b040f12040f094805090b48"><span class="__cf_email__" data-cfemail="1c716e736b7e73686873715c7d717e75687e7573327f737132">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm2009925&amp;href=/doi/10.1021%2Fjm2009925" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1082–1105</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 14, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 July 2011</li><li><span class="item_label"><b>Published</b> online</span>23 January 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 February 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm2009925" title="DOI URL">https://doi.org/10.1021/jm2009925</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1082%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMartin%2BW.%2BRowbottom%252C%2BRaffaella%2BFaraoni%252C%2BQi%2BChao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D3%26contentID%3Djm2009925%26title%3DIdentification%2Bof%2B1-%25283-%25286%252C7-Dimethoxyquinazolin-4-yloxy%2529phenyl%2529-3-%25285-%25281%252C1%252C1-trifluoro-2-methylpropan-2-yl%2529isoxazol-3-yl%2529urea%2BHydrochloride%2B%2528CEP-32496%2529%252C%2Ba%2BHighly%2BPotent%2Band%2BOrally%2BEfficacious%2BInhibitor%2Bof%2BV-RAF%2BMurine%2BSarcoma%2BViral%2BOncogene%2BHomologue%2BB1%2B%2528BRAF%2529%2BV600E%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1105%26publicationDate%3DFebruary%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm2009925"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5496</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">39</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm2009925" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;W. Rowbottom&quot;},{&quot;first_name&quot;:&quot;Raffaella&quot;,&quot;last_name&quot;:&quot;Faraoni&quot;},{&quot;first_name&quot;:&quot;Qi&quot;,&quot;last_name&quot;:&quot;Chao&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;T. Campbell&quot;},{&quot;first_name&quot;:&quot;Andiliy&quot;,&quot;last_name&quot;:&quot;G. Lai&quot;},{&quot;first_name&quot;:&quot;Eduardo&quot;,&quot;last_name&quot;:&quot;Setti&quot;},{&quot;first_name&quot;:&quot;Maiko&quot;,&quot;last_name&quot;:&quot;Ezawa&quot;},{&quot;first_name&quot;:&quot;Kelly&quot;,&quot;last_name&quot;:&quot;G. Sprankle&quot;},{&quot;first_name&quot;:&quot;Sunny&quot;,&quot;last_name&quot;:&quot;Abraham&quot;},{&quot;first_name&quot;:&quot;Lan&quot;,&quot;last_name&quot;:&quot;Tran&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Struss&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Gibney&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;C. Armstrong&quot;},{&quot;first_name&quot;:&quot;Ruwanthi&quot;,&quot;last_name&quot;:&quot;N. Gunawardane&quot;},{&quot;first_name&quot;:&quot;Ronald&quot;,&quot;last_name&quot;:&quot;R. Nepomuceno&quot;},{&quot;first_name&quot;:&quot;Ianina&quot;,&quot;last_name&quot;:&quot;Valenta&quot;},{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;Hua&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;F. Gardner&quot;},{&quot;first_name&quot;:&quot;Merryl&quot;,&quot;last_name&quot;:&quot;D. Cramer&quot;},{&quot;first_name&quot;:&quot;Dana&quot;,&quot;last_name&quot;:&quot;Gitnick&quot;},{&quot;first_name&quot;:&quot;Darren&quot;,&quot;last_name&quot;:&quot;E. Insko&quot;},{&quot;first_name&quot;:&quot;Julius&quot;,&quot;last_name&quot;:&quot;L. Apuy&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Jones-Bolin&quot;},{&quot;first_name&quot;:&quot;Arup&quot;,&quot;last_name&quot;:&quot;K. Ghose&quot;},{&quot;first_name&quot;:&quot;Torsten&quot;,&quot;last_name&quot;:&quot;Herbertz&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Ator&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;D. Dorsey&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;Ruggeri&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Shripad&quot;,&quot;last_name&quot;:&quot;Bhagwat&quot;},{&quot;first_name&quot;:&quot;Joyce&quot;,&quot;last_name&quot;:&quot;James&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;W. Holladay&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;1082-1105&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm2009925&quot;},&quot;abstract&quot;:&quot;The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAFV600E results in constitutive activation of the MAPK pathway, which can lead to uncontrolled cellular growth. Herein, we describe an SAR optimization campaign around a series of quinazoline derived BRAFV600E inhibitors. In particular, the bioisosteric replacement of a metabolically sensitive tert-butyl group with fluorinated alkyl moieties is described. This effort led directly to the identification of a clinical candidate, compound 40 (CEP-32496). Compound 40 exhibits high potency against several BRAFV600E-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAFV600E versus those containing wild-type BRAF. Compound 40 also exhibits an excellent PK profile across multiple preclinical species. In addition, significant oral efficacy was observed in a 14-day BRAFV600E-dependent human Colo-205&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2009925&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2009925" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2009925&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2009925" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2009925&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2009925" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm2009925&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2009925&amp;href=/doi/10.1021/jm2009925" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm2009925" /></input><a href="/doi/pdf/10.1021/jm2009925" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm2009925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm2009925%26sid%3Dliteratum%253Aachs%26pmid%3D22168626%26genre%3Darticle%26aulast%3DRowbottom%26date%3D2012%26atitle%3DIdentification%2Bof%2B1-%25283-%25286%252C7-Dimethoxyquinazolin-4-yloxy%2529phenyl%2529-3-%25285-%25281%252C1%252C1-trifluoro-2-methylpropan-2-yl%2529isoxazol-3-yl%2529urea%2BHydrochloride%2B%2528CEP-32496%2529%252C%2Ba%2BHighly%2BPotent%2Band%2BOrally%2BEfficacious%2BInhibitor%2Bof%2BV-RAF%2BMurine%2BSarcoma%2BViral%2BOncogene%2BHomologue%2BB1%2B%2528BRAF%2529%2BV600E%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D3%26spage%3D1082%26epage%3D1105%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292271" title="Urea">Urea</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/3" title="Go to Volume 55, Issue 3"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jmcmar.2012.55.issue-3/production/jmcmar.2012.55.issue-3.largecover.jpg" alt="Go to Volume 55, Issue 3"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAF<sup>V600E</sup> results in constitutive activation of the MAPK pathway, which can lead to uncontrolled cellular growth. Herein, we describe an SAR optimization campaign around a series of quinazoline derived BRAF<sup>V600E</sup> inhibitors. In particular, the bioisosteric replacement of a metabolically sensitive <i>tert</i>-butyl group with fluorinated alkyl moieties is described. This effort led directly to the identification of a clinical candidate, compound <b>40</b> (CEP-32496). Compound <b>40</b> exhibits high potency against several BRAF<sup>V600E</sup>-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAF<sup>V600E</sup> versus those containing wild-type BRAF. Compound <b>40</b> also exhibits an excellent PK profile across multiple preclinical species. In addition, significant oral efficacy was observed in a 14-day BRAF<sup>V600E</sup>-dependent human Colo-205 tumor xenograft mouse model, upon dosing at 30 and 100 mg/kg BID.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25510" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25510" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the transduction of signals from cell surface receptors to the nucleus, regulating both cell proliferation and survival.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The RAF members of this pathway consist of the serine/threonine kinases ARAF, BRAF, and CRAF (also known as RAF1), which phosphorylate and activate downstream MEK1/2. A number of activating mutations of the <i>BRAF</i> gene have been identified, with a single point mutation (Val600 → Glu) accounting for more than 90% of those described. Constitutively activated BRAF<sup>V600E</sup> is 500 times more active than wild-type BRAF and is found to be present in approximately 7% of all cancers, being most frequently associated with melanoma (50–70%), papillary thyroid (∼50%), colorectal (∼15%), and ovarian (∼30%) carcinomas.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The presence of BRAF<sup>V600E</sup> in certain tumors is correlated with increased malignancy and decreased response to chemotherapy.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> It is therefore not surprising that BRAF<sup>V600E</sup> has emerged as a target of considerable interest, based on the rationale that inhibition of BRAF<sup>V600E</sup> should result in clinical benefit for patients with carcinomas expressing this enzyme.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a>As such, numerous reports describing small-molecule inhibitors of BRAF<sup>V600E</sup> have emerged,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> with several investigational drugs, including RAF265 (Chiron/Novartis, <b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) and vemurafenib (PLX-4032, Daiichi Sankyo/Roche, <b>2</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) having advanced into human clinical trials.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6-9)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of known RAF inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Some time ago, we initiated our own efforts to identify novel inhibitors of BRAF<sup>V600E</sup>. To identify appropriate chemical starting points, we employed the KINOME<i>scan</i> technology platform to screen the Ambit compound collection. The utilization of KINOME<i>scan</i> allows for the rapid screening of large compound collections across several hundred individual human kinase targets (including mutants of known therapeutic value).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> This technology represents an extremely powerful tool for aiding in the identification of hit series for any given kinase target and for gaining a greater understanding of the kinome selectivity profile of such hits.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Analysis of the data set obtained from screening of the Ambit internal compound collection across the KINOME<i>scan</i> panel led to the identification of several hit series exhibiting high affinity for BRAF<sup>V600E</sup>. One such series is represented by the diaryl amide derivative <b>3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), and an initial hit to lead the optimization campaign described elsewhere led to the identification of 4-quinazolinyloxy-diaryl urea derivative <b>4</b>.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Herein we describe further optimization of the 4-quinazolinyloxy-diaryl urea series, in particular SAR around the left-hand aryl urea moiety. This effort ultimately led to the discovery of the clinical candidate compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> (CEP-32496),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> a highly potent and orally efficacious inhibitor of BRAF<sup>V600E</sup>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Evolution of the 4-quinazolinyloxy-diaryl urea series of b-Raf<sup>V600E</sup> inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0019.gif" alt="" id="g1" /></img></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All compounds described herein were prepared as illustrated in Schemes <a class="ref internalNav" href="#sch2" aria-label="2">2</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Final derivatives incorporating substituted isoxazole urea moieties were obtained <i>via</i> the corresponding intermediate isoxazole carbamates. These isoxazole carbamates were obtained from the corresponding aminoisoxazoles, which in turn were prepared from substituted ketonitriles <b>5</b> (Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Reaction of substituted ketonitriles with hydroxylamine can result in the formation of regioisomeric 3- or 5-aminoisoxazoles (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Results summarized by Takase et al.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>indicated a general preference for formation of 5-aminoisoxazoles <b>6</b> (or their corresponding hydrolysis products) resulting from initial attack of the hydroxylamine nitrogen on the keto group of the ketonitrile. Nevertheless, these workers found specific conditions (initial reaction at pH ∼ 8 at 60–100 °C, followed by ring closure under acidic conditions at 70–100 °C) under which, when R<sup>1</sup> = <i>tert</i>-butyl, attack of the hydroxylamine nitrogen on to the nitrile is favored, leading to formation of the 3-aminoisoxazole product. However, under these conditions the 5-amino product still prevailed for R<sup>1</sup> = Me, isopropyl, and Ph, suggesting a considerable steric contribution in the case of R<sup>1</sup> = <i>tert</i>-butyl. Consistent with the expectations from these previously reported results,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> treatment of several ketonitriles (R<sup>1</sup> = cyclopentyl, <b>5b</b>; C(CF<sub>3</sub>)Me<sub>2</sub>, <b>5f</b>; C(CH<sub>2</sub>F)<sub>2</sub>Me, <b>5j</b>; and <i>tert</i>-butyl) with hydroxylamine in the presence of an extra equivalent of hydroxide resulted in predominant formation of 5-aminoisoxazoles (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). In our hands, 5-aminoisoxazoles were also the predominant products when the starting pH was adjusted to ∼7.5 for R<sup>1</sup> = isopropyl (<b>5a</b>), CFMe<sub>2</sub> (<b>5c</b>), CF<sub>2</sub>Me (<b>5d</b>), C(CN)Me<sub>2</sub> (<b>5g</b>), and cyclobutyl-1-CF<sub>3</sub> (<b>5i</b>). Some combination of lower steric demand, compared with <i>tert</i>-butyl, together with increased electrophilicity of the ketonitrile carbonyl when electron-withdrawing groups (F, CN) are present, presumably contributes to disfavoring formation of the 3-amino isomer under these conditions. This is despite the similarity to the initial conditions in which the 3-amino isomer was ultimately formed when R<sup>1</sup> = <i>tert-</i>butyl.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> For a couple of the above R<sup>1</sup> groups (C(CF<sub>3</sub>)Me<sub>2</sub>, <b>5f</b>, and C(CH<sub>2</sub>F)<sub>2</sub>Me, <b>5j</b>), initial reaction in the presence of excess NaHCO<sub>3</sub> in aqueous MeOH followed by cyclization under acidic conditions resulted in good yields of the corresponding 3-aminoisoxazoles. Interestingly, these conditions also provided a good yield of the 3-amino regioisomer when R<sup>1</sup> = cyclopropyl-1-CF<sub>3</sub>. Comparing this result to those described above for R<sup>1</sup> = cyclobutyl-1-CF<sub>3</sub>, the latter bicarbonate conditions seem to be particularly suitable for favoring initial events (presumably reaction of the hydroxylamine nitrogen with the nitrile group of the ketonitrile) that lead ultimately to the 3-aminoisoxazole regiochemistry. 3-Aminoisoxazole derivatives <b>8h</b> (R<sup>1</sup> = isopropyl), <b>8i</b> (R<sup>1</sup> = cyclopentyl), and <b>8j</b> (R<sup>1</sup> = CFMe<sub>2</sub>), inaccessible <i>via</i> the aforementioned procedures, were prepared <i>via</i> alternate routes involving protection of the ketonitrile carbonyl moiety, as described in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Protection of the carbonyl of <b>5a</b> and <b>5b</b><i>via</i> conversion to the 1,3-dioxolane moiety gave intermediates <b>10a</b> and <b>10b</b>, respectively. Subsequent reaction of <b>10a</b> and <b>10b</b> with hydroxylamine yielded exclusively the required amidoxime intermediates that upon treatment with concentrated HCl underwent carbonyl deprotection followed by cyclization to give the required 3-aminoisoxazole derivatives <b>8h</b> and <b>8i</b>, respectively. All attempts to convert ketonitrile <b>5c</b> to the corresponding 1,3-dioxolane derivative failed. As a result, <b>5c</b> was converted to the corresponding methyl enol ether <b>11</b><i>via</i> treatment with (trimethylsilyl)diazomethane. Subsequent reaction of <b>11</b> with hydroxylamine followed by heating in the presence of HCl gave the desired 3-aminoisoxazole derivative <b>8j</b>, albeit in low yield (13%). The reason for the lower than expected yield was not clearly apparent; however, enough <b>8j</b>was prepared to be utilized in the next step. In a similar manner, an attempt was made to gain access to 5-(trifluoromethyl)isoxazole-3-amine. Thus, ketonitrile <b>5e</b> was converted first to 4,4,4-trifluoro-3-methoxybut-2-enenitrile <i>via</i> treatment with (trimethylsilyl)diazomethane. However, subsequent treatment with hydroxylamine followed by heating in the presence of HCl failed to yield any of the desired 5-(trifluoromethyl)isoxazole-3-amine. Rather, for reasons that are unclear, only the corresponding 3-(trifluoromethyl)isoxazole-5-amine (<b>6e</b>) was obtained albeit in low yield (11%). All 5-aminoisoxazoles (<b>6</b>) and 3-aminoisoxazoles (<b>8</b>) were subsequently converted to the corresponding isoxazole carbamates <b>7</b> and <b>9</b>, respectively, <i>via</i> reaction with either phenyl chloroformate or 4-chlorophenyl chloroformate. The pyrazole carbamates required for the preparation of the pyrazole ring containing urea derivatives were prepared as described in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. The reaction of substituted ketonitriles with a variety of hydrazines in refluxing EtOH gave 5-aminopyrazoles <b>12</b> in moderate to good yields. Subsequent treatment of 5-aminopyrazoles <b>12</b> with phenyl chloroformate and potassium carbonate in THF or CH<sub>2</sub>Cl<sub>2</sub> gave the required pyrazole carbamates <b>13</b>. The desired urea compounds <b>18</b>–<b>51</b>and <b>54</b> were prepared as described in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. 3-Aminophenol (<b>14</b>) was reacted with cesium carbonate in THF to generate the corresponding cesium phenoxide, which was coupled <i>in situ</i> with 4-chloro-6,7-dimethoxyquinazoline to give <b>16</b> in quantitative yield. Similarly, 3-aminobenzenethiol (<b>15</b>) was treated first with sodium hydride in THF, followed by 4-chloro-6,7-dimethoxyquinazoline to give <b>17</b> in high yield. Direct coupling of <b>16</b> with 4-<i>tert</i>-butylphenyl isocyanate gave the 4-oxyquinazoline derivative <b>20</b>, whereas 4-(dimethylamino)pyridine-catalyzed coupling of <b>16</b> with phenyl 3-<i>tert</i>-butylphenylcarbamate gave compound <b>21</b>. 4-(Dimethylamino)pyridine-catalyzed coupling of <b>16</b> with isoxazole carbamates <b>7a</b>–<b>k</b> and <b>9a</b>–<b>j</b> gave the corresponding 4-oxyquinazoline derivatives <b>18</b> and <b>22</b>–<b>41</b>. Overall, yields for the final coupling step proved reasonable; however, for the case of the trifluoromethyl substituted derivative <b>31</b>, the recovery was low (5%) for reasons that are unclear. The 4-(dimethylamino)pyridine-catalyzed coupling of <b>17</b> with isoxazole carbamates <b>7c</b> and <b>9a</b>–<b>c</b> gave the corresponding 4-thioquinazoline derivatives <b>42</b>–<b>45</b>. In an analogous fashion, coupling of <b>16</b> with pyrazole carbamates <b>13a</b>–<b>g</b>gave the corresponding pyrazole containing 4-oxyquinazoline derivatives <b>46</b>–<b>51</b>. Pyrazole containing 4-oxyquinazoline derivative <b>54</b> was prepared in three steps from 1-<i>tert</i>-butyl-1<i>H</i>-pyrazol-4-amine <b>52</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Formation of Aminoisoxazoles from Ketonitriles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Isoxazol-5-yl-carbamates <b>7a</b>–<b>k</b> and Isoxazol-3-yl-carbamates <b>9a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, MeCN, THF, 75 °C, 15 h, 29–93%; (b) hydroxylamine hydrochloride, NaOH, water, 100 °C, 2.5 h, or hydroxylamine sulfate, NaOH, water/EtOH, 80 °C, 15 h; or (for <b>6e</b>) (i) TMSCHN<sub>2</sub>, Et<sub>2</sub>O, rt, 15 h, (ii) hydroxylamine hydrochloride, NaOMe, MeOH, 60 °C, 15 h, (iii) HCl, aq EtOH, 60 °C, 2 h; 11–100%; (c) PhOC(O)Cl or 4-Cl-PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 33–100%; (d) (i) hydroxylamine sulfate, NaHCO<sub>3</sub>, water/MeOH, 65 °C, or hydroxylamine hydrochloride, NaOH, water/EtOH, 65 °C, (ii) conc HCl, reflux, 26–71%.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Isoxazol-3-yl-carbamates <b>9h</b>–<b>j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethylene glycol, TMSCl, DCM, reflux, 15 h, 57–78%; (b) (i) hydroxylamine hydrochloride, NH<sub>3</sub>/MeOH, 8-hydroxyquinoline, 70 °C, 15 h, (ii) conc HCl, EtOH, reflux, 68–69% (over two steps); (c) PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 77–89%; (d) TMSCHN<sub>2</sub>, Et<sub>2</sub>O, rt, 15 h, 90%; (e) (i) hydroxylamine hydrochloride, NaOMe, MeOH, 70 °C, 16 h, (ii) conc HCl, 80 °C, 30 min, 13%; (f) 4-Cl-PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 100%.</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 1<i>H</i>-Pyrazol-5-yl-carbamates <b>13a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>2</sup>NHNH<sub>2</sub>, EtOH, reflux, 36–51%; (b) PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, DCM or THF, 0 °C or rt, 30–100%.</p></p></figure><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Quinazoline Derivatives <b>18</b>–<b>51</b> and <b>54</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) X = O, (i) Cs<sub>2</sub>CO<sub>3</sub>, THF, rt, 30 min, (ii) 4-chloro-6,7-dimethoxyquinazoline, 50 °C, 24 h, 100%; X = S, (i) NaH, THF, rt, 30 min, (ii) 4-chloro-6,7-dimethoxyquinazoline, rt, 15 h, 85%; (b) ArNCO, DMF, 50 °C; or <b>7a</b>–<b>k</b> or <b>9a</b>–<b>j</b> or <b>13a</b>–<b>g</b>, DIEA, cat. DMAP, THF, rt or 50 °C, 5–75%; (c) PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 15 h, 89%; (d) 3-aminophenol, THF, 120 °C, 2 h, 20%; (e) (i) Cs<sub>2</sub>CO<sub>3</sub>, THF, rt, 1 h, (ii) 4-chloro-6,7-dimethoxyquinazoline, 55 °C, 15 h, 43%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54368" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54368" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As part of our SAR campaign, all compounds described (Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) were profiled <i>in vitro</i> for activity against BRAF<sup>V600E</sup>, both in a biochemical binding assay and for their ability to inhibit BRAF<sup>V600E</sup>-mediated phosphorylation of MEK (pMEK formation) in the A375 cell line. In addition, each compound was further profiled for its ability to inhibit the proliferation of A375 cells over a 72 h period. As part of this profiling process, particular emphasis was placed on the potencies observed in the A375 cellular assays. The A375 cell line is dependent on signaling through BRAF<sup>V600E</sup>, and the observation of activity in these assays, coupled with suitable ADME properties, would be considered a reasonable predictive measure of activity in appropriate <i>in vivo</i> models of BRAF<sup>V600E</sup>-driven disease. We werealso interested in obtaining a preliminary understanding of the selectivity profile across the human kinome. This was facilitated by use of the KINOME<i>scan</i> technology platform.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Compounds prepared were screened at 10 μM concentration across a diverse panel of 290 individual wild-type kinases. Selectivity for each compound is represented by a selectivity <i>S</i>(10) score, which equals the fraction of kinase targets assayed exhibiting >90% competition (measured as <10% of control experiment), with lower <i>S</i>(10) scores indicating greater selectivity.<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Quinazoline-Derived BRAF<sup>V600E</sup> Inhibitors: Variation of the Aryl Urea Moiety</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Results are presented as mean values from experiments performed in duplicate. Variability between individual values is less than 2-fold.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Competition binding assay performed at rt for 1 h. <i>K</i><sub>d</sub> values were determined using eleven serial 3-fold dilutions.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Phosphorylation assay in A375 cells (expressing BRAF<sup>V600E</sup>). Cells were incubated with test compound for 2 h.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Cell Titer Blue proliferation assay in A375 cells (expressing BRAF<sup>V600E</sup>). Cells were incubated with test compound for 72 h.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Compounds were screened at 10 μM concentration against the KINOME<i>scan</i> panel consisting of 290 individual wild-type kinases (mutants being excluded from this analysis). Selectivity <i>S</i>(10) scores represent the fraction of kinase targets exhibiting >90% competition (measured as <10% of control experiment).</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Quinazoline-Derived BRAF<sup>V600E</sup> Inhibitors <b>22</b>–<b>51</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0015.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0020.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Results are presented as mean values from experiments performed in duplicate. Variability between individual values is less than 2-fold.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Competition binding assay performed at rt for 1 h. <i>K</i><sub>d</sub> values were determined using eleven serial 3-fold dilutions.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Phosphorylation assay in A375 cells (expressing BRAF<sup>V600E</sup>). Cells were incubated with test compound for 2 h.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Cell Titer Blue proliferation assay in A375 cells (expressing BRAF<sup>V600E</sup>). Cells were incubated with test compound for 72 h.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Compounds were screened at 10 μM concentration against the KINOME<i>scan</i> panel consisting of 290 individual wild-type kinases (mutants being excluded from this analysis). Selectivity <i>S</i>(10) scores represent the fraction of kinase targets exhibiting >90% competition (measured as <10% of control experiment).</p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">Not determined due to biphasic dose–response curves. Complete inhibition was observed at 5000 nM.</p></div></div><div></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Structure–Activity Relationships</h3><div class="NLM_p">The previously identified <i>tert</i>-butyl-isoxazole urea-containing quinazoline derivative <b>4</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) exhibited high binding affinity for BRAF<sup>V600E</sup> (<i>K</i><sub>d</sub> = 73 nM), and potent inhibition of both BRAF<sup>V600E</sup>-mediated pMEK activity (IC<sub>50</sub> = 121 nM) and proliferation (IC<sub>50</sub> = 328 nM) in A375 cells.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Compound <b>4</b> also proved moderately selective across the panel of 290 kinases, exhibiting an <i>S</i>(10) score of 0.286. An initial scan of alternate aryl urea moieties (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) indicated that the isoxazole regioisomer of <b>4</b>, the 3-(<i>tert</i>-butyl)isoxazole-5-urea derivative <b>18</b>, was equipotent in both binding and cellular assays and had a very similar <i>S</i>(10) score. Substitution of the isoxazole moiety for an <i>N</i>-1-(<i>tert</i>-butyl)pyrazole-4-urea motif gave compound <b>54</b>, which also exhibited good binding affinity for BRAF<sup>V600E</sup> and a somewhat improved kinome selectivity profile. However, compound <b>54</b> proved to be essentially inactive in the A375 cell proliferation assay. Compared to <b>54</b>, the related <i>N</i>-1-methyl-3-(<i>tert</i>-butyl)pyrazole-5-urea derivative <b>19</b> proved more potent in both the A375 pMEK and proliferation assays; however, potency in the proliferation assay was still 10-fold lower than that observed with the lead compound <b>4</b>. Incorporation of either a 4-(<i>tert</i>-butyl)phenyl urea (<b>20</b>) or a 3-(<i>tert</i>-butyl)phenyl urea moiety (<b>21</b>) led to a modest improvement in kinome selectivity. However, although potent in both the BRAF<sup>V600E</sup> binding and A375 pMEK cellular assays, these compounds again proved 5- to 10-fold less active than lead compound <b>4</b> in the A375 proliferation assay. Due to the promising cellular activity observed with the isomeric (<i>tert</i>-butyl)isoxazole-containing derivatives <b>4</b> and <b>18</b>, we decided to investigate the effect of varying the <i>tert</i>-butyl moiety to other functional groups. A range of different substituents were incorporated as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> (compounds <b>22</b>–<b>41</b>). Overall, it was observed that potency for BRAF<sup>V600E</sup> was governed by both the size and lipophilicity of this substituent. For example, substitution of the <i>tert</i>-butyl (<b>4</b>) for the smaller methyl group (<b>22</b>) led to a loss in both binding affinity (<i>K</i><sub>d</sub> = 678 nM) and cellular potency (IC<sub>50</sub> > 15000 nM in both assays). Compound <b>22</b> also exhibited reduced potencies across the broader panel of kinase targets, as indicated by an <i>S</i>(10) score of 0.062. Incorporation of the larger phenyl moiety, exemplified by compounds <b>25</b> and <b>28</b>, also led to much reduced BRAF<sup>V600E</sup> binding affinity and cellular potencies compared to the corresponding <i>tert</i>-butyl containing analogues <b>4</b> and <b>18</b>, respectively. Again both compounds <b>25</b> and <b>28</b> exhibited much reduced affinity across the broader panel of kinases, with the <i>S</i>(10) score being 0.052 for both. Overall, it was found that incorporation of substituents of similar size and lipophilicity to the <i>tert</i>-butyl group gave analogues with a more optimal potency profile. For instance, compared to <b>4</b>, the 5-isopropylisoxazol-3-yl derivative (<b>23</b>) and the 5-cyclopentylisoxazol-3-yl derivative (<b>24</b>) exhibited very similar potencies toward BRAF<sup>V600E</sup> in both binding and cellular assays. However, incorporation of the more polar hydroxyl-bearing <i>tert</i>-butyl group (<b>29</b>), although potent in the BRAF<sup>V600E</sup> binding assay (<i>K</i><sub>d</sub> = 49 nM), surprisingly led to much reduced cellular potencies. Other more polar substituents such as alkylamine-bearing <i>tert</i>-butyl groups were also incorporated; however, incorporation of such groups resulted in significantly lower affinity for BRAF<sup>V600E</sup> (data not shown). Also worth noting is the observation that the initial (<i>tert</i>-butyl)isoxazolyl isomers <b>4</b> and <b>18</b> exhibited a very similar potency profile, but such comparable activity of isoxazole regioisomers did not prove to be universal. Activity differences between corresponding isoxazole isomeric pairs depended upon the exact nature of the isoxazole substituent. For instance, compared with the corresponding 5-substituted isoxazol-3-yl isomers, the 3-isopropylisoxazol-5-yl (<b>26</b>) and the 3-cyclopentylisoxazol-5-yl derivatives (<b>27</b>) both exhibited reduced potencies in cells, particularly with respect to the A375 proliferation assay.</div><div class="NLM_p">As described, the (<i>tert</i>-butyl)isoxazole-containing derivatives <b>4</b> and <b>18</b> exhibited good potency against BRAF<sup>V600E</sup>. However, <i>in vitro</i> metabolite profiling studies on compound <b>4</b> indicated that, in both rat and human liver microsomes, hydroxylation of the <i>tert</i>-butyl moiety and subsequent oxidation to the carboxylate occurred to a significant degree (data not shown).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> As we had already demonstrated that the corresponding hydroxylated <i>tert</i>-butyl-containing derivative (<b>29</b>) exhibits much reduced cellular activity compared to the nonhydroxylated analogue <b>4</b>, we were interested in finding replacements for the <i>tert</i>-butyl group that would both be well tolerated by BRAF<sup>V600E</sup> yet be less prone to such oxidative metabolic processes. It was clear from earlier SAR that the incorporation of polar groups was not an attractive option. However, we expected that the selective incorporation of fluorine would lead to more stable derivatives with similar potency profiles. A carbon–fluorine bond is often used as a bioisosteric replacement for a corresponding carbon–hydrogen bond, due to its similar size and lipophilicity. More importantly, due to the high electronegativity of fluorine, carbon–fluorine bonds are much stronger and exhibit a differential dipole-moment compared to the corresponding carbon–hydrogen bond. As such, the strategic introduction of a carbon–fluorine bond into a bioactive molecule can often have positive effects on overall metabolic stability, while maintaining the desired potency profile at the target of interest.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> With this in mind, we prepared a number of fluoroalkyl substituted isoxazole derivatives (compounds <b>31</b>–<b>36</b> and <b>38</b>–<b>45</b>). Direct replacement of the <i>tert</i>-butyl of <b>18</b> with the likely more metabolically stable trifluoromethyl group (<b>31</b>) resulted in loss of cellular potency, even though binding affinity remained comparable to that observed with <b>18</b>. Replacement of one (<b>32</b>) or two (<b>33</b>) fluoro groups (of <b>31</b>) with methyl, thereby increasing both the size and lipophilicity of this motif, resulted in the restoration of cellular activity, with the 2-fluoropropyl-containing derivative (<b>33</b>) proving equipotent to <b>18</b>. The 2-(trifluoromethyl)propyl derivative (<b>35</b>) also proved potent in both binding and cellular assays. However, incorporation of the slightly larger (trifluoromethyl)cyclobutyl group (<b>36</b>) led to a reduction in activity in the A375 proliferation assay, again suggesting that the size of the isoxazole substituent is important for optimal activity. On the basis of earlier observations, wherein differences in activity were observed between corresponding isoxazole isomeric pairs, we also investigated replacement of the <i>tert</i>-butyl group of isoxazol-3-yl derivative <b>4</b> with select fluorine-containing alkyl motifs. Again, key differences between isoxazole regioisomers were observed. For instance, compared to <b>33</b>, the corresponding 5-(2-fluoropropan-2-yl)isoxazol-3-yl derivative <b>38</b> proved approximately 2- and 4-fold less potent in the A375 pMEK and proliferation assays, respectively. In contrast, both isoxazole-3-yl derivatives <b>39</b> and <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> proved significantly more potent in cells than the corresponding isoxazol-5-yl isomers <b>34</b> and <b>35</b>, respectively. In fact, the 5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl derivative <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> proved one of the most potent compounds in this series, exhibiting potent binding (BRAF<sup>V600E</sup><i>K</i><sub>d</sub> = 14 nM) and cellular activity (pMEK IC<sub>50</sub> = 82 nM and A375 proliferation IC<sub>50</sub> = 78 nM), with activity in the proliferation assay being approximately 4-fold greater than that observed with the <i>tert</i>-butyl analogue <b>4</b>.</div><div class="NLM_p">The analogues described thus far contain an oxygen atom linking the quinazoline ring with the central phenyl moiety. We had previously observed that replacement of the oxygen linker of <b>4</b> with the slightly larger and more lipophilic sulfur atom not only yielded a derivative that proved equipotent in both the binding and pMEK cellular assays but also exhibited an improved <i>S</i>(10) score (0.18 vs 0.29).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> However, for some of the more potent derivatives described herein, replacement of oxygen with sulfur did not result in greatly improved selectivity profiles, and in certain cases, decreased activity was observed in the A375 proliferation assay (compare <b>43</b> with <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b>, and <b>45</b> with <b>33</b>). The complete loss of proliferation activity for <b>43</b> could not be readily explained. However, a similar drop-off in proliferation activity was observed for certain other closely related sulfur-linked analogues (data not shown).</div><div class="NLM_p">In addition to the described isoxazole urea-containing derivatives, we had earlier identified a related 3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl urea derivative <b>19</b> that displayed modest potency toward BRAF<sup>V600E</sup> (<i>K</i><sub>d</sub> = 87 nM, pMEK IC<sub>50</sub> = 336 nM). A number of additional pyrazole-containing analogues were prepared, represented by compounds <b>46</b>–<b>51</b>. Overall, SAR around the pyrazole <i>N</i>-1 substituent indicated that incorporation of larger alkyl moieties such as isopropyl (<b>46</b>), isobutyl (<b>47</b>), or cyclohexyl (<b>48</b>), although increasingly more selective as represented by decreasing <i>S</i>(10) scores, proved less potent in both the pMEK and proliferation cell assays. Only upon incorporation of a phenyl group (<b>49</b>) did we observe robust pMEK cell activity (IC<sub>50</sub> = 21 nM), although less than optimal activity was observed in the A375 proliferation assay. In addition, <b>49</b> exhibited decreased selectivity (<i>S</i>(10) = 0.40). Although significant effort was applied toward the optimization of the pyrazole series, a suitable balance between potency, selectivity, and PK profile ultimately proved elusive.</div><div class="NLM_p">The rat PK profile for selected analogues is illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Male Sprague–Dawley rats were dosed with compound either <i>via</i> intravenous (iv) or oral (po) administration (<i>n</i> = 2 and 3 animals for the iv and po arms, respectively), and PK parameters were calculated, including clearance (CL), volume of distribution (<i>V</i><sub>d</sub>), terminal half-life (<i>t</i><sub>1/2</sub>), AUC (iv and po), and absolute oral bioavailability (%<i>F</i>). As predicted, replacement of the isoxazole <i>tert</i>-butyl substituent with an appropriate fluoro-containing alkyl motif led to improved metabolic stability, as reflected by decreased <i>in vivo</i> clearance rates. This trend was further supported by rat liver microsome stability data. For example, in a rat liver microsome stability assay, the fluorinated derivatives <b>33</b>, <b>38</b>, and <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> exhibit approximately 2-fold improvement in metabolic stability when compared with <b>4</b>, as reflected by measured percent remaining of parent at 60 min (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). A second observation from the data in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> is that while their clearance rates and volumes of distribution remain equal, the isoxazol-3-yl-containing urea isomers typically exhibited significantly improved absorption profiles compared to the corresponding isoxazol-5-yl-containing urea isomers. For instance, the 5-<i>tert</i>-butyl-isoxazol-3-yl isomer <b>4</b> exhibited significantly improved oral exposure (AUC<sub>0-α</sub> = 17 μM·h; %<i>F</i> = 49) compared to the 3-<i>tert</i>-butyl-isoxazol-5-yl isomer <b>18</b> (AUC<sub>0-α</sub> = 1.9 μM·h; %<i>F</i> = 6). A similar trend was observed between the 2-fluoropropyl-isoxazole isomeric pairs <b>33</b> and <b>38</b> and the 2-(trifluoromethyl)propyl-isoxazole isomeric pairs <b>35</b> and <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b>, with the isoxazol-3-yl isomer exhibiting the greatest exposure after oral dosing in each case.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Rat Pharmacokinetic<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> and Rat Liver Microsomal Stability Data<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> for Select Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">CL [(mL/min)/kg]<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>d</sub>(L/kg)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–∞</sub>(po) (μM·h)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub>(po) (μM)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>max</sub>(po) (h)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">RLM % remaining (at 60 min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">(7.3, 17.6)</td><td class="colsep0 rowsep0" align="left">(0.5, 2.5)</td><td class="colsep0 rowsep0" align="left">19.2</td><td class="colsep0 rowsep0" align="char" char=".">17.0 ± 5.8</td><td class="colsep0 rowsep0" align="char" char=".">11.0 ± 2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.8 ± 0.3</td><td class="colsep0 rowsep0" align="left">49 ± 17</td><td class="colsep0 rowsep0" align="left">46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">(9.8, 11.9)</td><td class="colsep0 rowsep0" align="left">(1.0, 1.5)</td><td class="colsep0 rowsep0" align="left">8.2</td><td class="colsep0 rowsep0" align="char" char=".">1.9 ± 1.4</td><td class="colsep0 rowsep0" align="char" char=".">0.7 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">0.8 ± 0.3</td><td class="colsep0 rowsep0" align="left">6 ± 4</td><td class="colsep0 rowsep0" align="left">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">(4.0, 4.1)</td><td class="colsep0 rowsep0" align="left">(0.6, 0.6)</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="char" char=".">42.0 ± 19.2</td><td class="colsep0 rowsep0" align="char" char=".">7.9 ± 3.5</td><td class="colsep0 rowsep0" align="char" char=".">2.0 ± 0</td><td class="colsep0 rowsep0" align="left">48 ± 22</td><td class="colsep0 rowsep0" align="left">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b><a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">40.7 ± 12.2</td><td class="colsep0 rowsep0" align="char" char=".">4.7 ± 4.0</td><td class="colsep0 rowsep0" align="char" char=".">1.7 ± 0.6</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">(2.9, 3.1)</td><td class="colsep0 rowsep0" align="left">(0.5, 0.5)</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="char" char=".">127.0 ± 23.3</td><td class="colsep0 rowsep0" align="char" char=".">21.1 ± 4.0</td><td class="colsep0 rowsep0" align="char" char=".">2.0 ± 0</td><td class="colsep0 rowsep0" align="left">100 ± 20</td><td class="colsep0 rowsep0" align="left">92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b><a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">(3.4, 5.0)</td><td class="colsep0 rowsep0" align="left">(1.6, 2.0)</td><td class="colsep0 rowsep0" align="left">7.8</td><td class="colsep0 rowsep0" align="char" char=".">74.4 ± 9.7</td><td class="colsep0 rowsep0" align="char" char=".">6.5 ± 1.5</td><td class="colsep0 rowsep0" align="char" char=".">2.0 ± 0</td><td class="colsep0 rowsep0" align="left">94 ± 12</td><td class="colsep0 rowsep0" align="left">81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">(3.1, 5.2)</td><td class="colsep0 rowsep0" align="left">(0.3, 0.3)</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="char" char=".">25.9 ± 5.4</td><td class="colsep0 rowsep0" align="char" char=".">6.7 ± 4.6</td><td class="colsep0 rowsep0" align="char" char=".">1.3 ± 0.6</td><td class="colsep0 rowsep0" align="left">33 ± 7</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Dosed to Sprague–Dawley rats. The parameters were calculated using plasma concentration–time data for individual animals, <i>n</i> = 2 animals (iv arm) and 3 animals (po arm). Dosed iv at 1 mg/kg as a solution in 3:1 PEG400/water. Dosed po at 10 mg/kg as a solution in Pharmatek #6 (Hot Rod Chemistry vehicle series; Pharmatek Incorporated, San Diego, CA).</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Results are presented as mean values from experiments performed in duplicate. Compound concentration used was 1 μM. Compounds were incubated at 37 °C.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Data reported for both individual animals (<i>n</i> = 2).</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Mean values and standard deviation reported (<i>n</i> = 3).</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Dosed po (10 mg/kg) only.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last">ND = not determined.</p></div><div class="footnote" id="t3fn7"><sup>g</sup><p class="last">Dosed as a free base.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Selectivity and Further Pharmacokinetic Profiling of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b></h3><div class="NLM_p">Due to the combination of high potency for BRAF<sup>V600E</sup> in both binding and cellular assays coupled with excellent oral exposure in rat, <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> was chosen for further profiling. Compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> proved modestly selective when screened at 10 μM concentration across a KINOME<i>scan</i> panel of 290 diverse wild-type kinases, as indicated by the selectivity <i>S</i>(10) score of 0.245 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Corresponding <i>K</i><sub>d</sub> determinations versus select kinase targets are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. In addition to BRAF<sup>V600E</sup>, <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> exhibits high binding affinity for both wild-type BRAF and related CRAF, as well as certain receptor tyrosine kinases of known therapeutic utility, such as Abl-1, c-Kit, Ret, PDGFR-β, and VEGFR-2. However, <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> proved selective for the RAF members of the MAPK signal transduction pathway, as no significant affinity was observed for other key kinases of the MAPK pathway, including MEK-1, MEK-2, ERK-1, and ERK-2. This suggests that the observed cellular activity was driven primarily through inhibition of BRAF<sup>V600E</sup>, which is further supported by the observation that <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> exhibited selective cytotoxicity for tumor cell lines expressing mutant BRAF versus those expressing wild-type BRAF (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). When screened across a panel of tumor cell lines expressing BRAF<sup>V600E</sup> (A375, SK-MEL-28, Colo-205, Colo-679, and HT-144) versus a panel expressing only wild-type BRAF (HCT116, Hs578T, LNCaP, DU145, and PC-3), those cell lines harboring mutant BRAF<sup>V600E</sup> proved significantly more sensitive to treatment with <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b>. The only wild-type cell line in which <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> had appreciable activity was the HCT116 cell line, a colonic epithelial line with a known RAS mutation and wild-type p53, a combination previously shown to confer sensitivity to inhibition of the MAPK pathway.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> also exhibited good stability in mouse, dog, monkey, and human liver microsomal preparations (with measured intrinsic clearance values of <23 (μL/min)/mg and <i>t</i><sub>1/2</sub> > 60 min in all assays; data not shown), thus predicting low phase I hepatic clearance in these species. Metabolite profiling of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> in rat, dog, monkey, and human liver microsomes indicates that both mono O-demethylation (of the quinazoline methoxy groups) and oxidation of the (1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl moiety occur to some extent (data not shown). However, as indicated above, the measured <i>in vitro</i> clearance rates of such oxidative processes remain low across all species tested. In line with these observations, <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> exhibits an exceptional PK profile in mouse, dog, and cynomolgus monkey, as illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. For example, administration of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> to beagle dogs (single dose of 1 mg/kg iv and 10 mg/kg po) resulted in low clearance (CL = 5.0 (mL/min)/kg) and excellent bioavailability (%<i>F</i> = 100). Similarly, in cynomolgus monkey, the administration of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> (single dose of 1 mg/kg iv and 10 mg/kg po) led to high oral exposure due to low clearance (CL = 6.7 mL/min/kg) and excellent bioavailability (%<i>F</i> = 100). Compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> also exhibits a favorable CYP450 inhibition profile, with measured IC<sub>50</sub> values greater than 10 μM versus the CYP1A2, 2C9, 2D6, and 3A4 isoforms and an IC<sub>50</sub> = 3.4 μM versus 2C19 (data not shown). In addition, as a preliminary measure of potential cardiotoxicity, <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> was assessed for activity against the hERG potassium ion channel in a patch-clamp assay.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> does not significantly inhibit the hERG channel, exhibiting <10% inhibition at 10 μM concentration (data not shown).</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. KINOME<i>scan</i> tree spot graphic illustrating the selectivity profile for compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> versus a panel of 290 wild-type kinase targets (plotted as percent of control at 10 μM concentration, where 0 and 35% of control equals 100 and 65% competition, respectively). Images courtesy of KINOME<i>scan</i> (<a href="http://www.kinomescan.com" class="extLink">http://www.kinomescan.com</a>) and used with permission from KINOME<i>scan</i>, a division of DiscoveRx Corporation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Select Kinase <i>K</i><sub>d</sub> Determinations for Compound <a class="ref internalNav" href="#g1" aria-label="40">40</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>d</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>d</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRAF<sup>V600E</sup></td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">JAK-1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wt BRAF</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">JAK-2</td><td class="colsep0 rowsep0" align="left">4700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CRAF</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">JAK-3</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abl-1</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">c-Kit</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">LCK</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora A</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">MEK-1</td><td class="colsep0 rowsep0" align="left">7100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora B</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">MEK-2</td><td class="colsep0 rowsep0" align="left">8300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSF-1R</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">c-Met</td><td class="colsep0 rowsep0" align="left">513</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">PDGFR-β</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EPHA2</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">PIK3-CA</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK-1</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">PIK3-CB</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK-2</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">PLK-1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGFR-1</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">Ret</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INSR</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">VEGFR-2</td><td class="colsep0 rowsep0" align="left">8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Competition binding assays performed at rt for 1 h. <i>K</i><sub>d</sub> values were determined using eleven serial 3-fold dilutions. Results are presented as mean values from experiments performed in duplicate. Variability between individual values is less than 2-fold.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Cell Titer Blue Viability of Compound <a class="ref internalNav" href="#g1" aria-label="40">40</a> across Human Tumor Cell Lines Expressing BRAF<sup>V600E</sup> or Wild-Type BRAF<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line (BRAF<sup>V600E</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">cell line (wt BRAF)</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A375 (homozygous)</td><td class="colsep0 rowsep0" align="char" char=".">78</td><td class="colsep0 rowsep0" align="left">HCT116</td><td class="colsep0 rowsep0" align="char" char=".">669</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Colo-205 (heterozygous)</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="left">Hs578T</td><td class="colsep0 rowsep0" align="char" char=".">2736</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Colo-679 (homozygous)</td><td class="colsep0 rowsep0" align="char" char=".">211</td><td class="colsep0 rowsep0" align="left">LNCaP</td><td class="colsep0 rowsep0" align="char" char=".">6631</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-MEL-28 (homozygous)</td><td class="colsep0 rowsep0" align="char" char=".">454</td><td class="colsep0 rowsep0" align="left">DU145</td><td class="colsep0 rowsep0" align="char" char=".">2911</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT-144 (homozygous)</td><td class="colsep0 rowsep0" align="char" char=".">228</td><td class="colsep0 rowsep0" align="left">PC-3</td><td class="colsep0 rowsep0" align="char" char=".">6257</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Results are presented as mean values from experiments performed in duplicate. Cells were cultured in 0.5% serum overnight prior to incubation with test compound for 72 h. This was followed by addition of Cell Titer Blue (Promega, Madison, WI) to detect viable cells after 3 h incubation with reagent.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetics Profile of Compound <a class="ref internalNav" href="#g1" aria-label="40">40</a> in Mouse,<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> Dog,<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> and Monkey<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> Following Intravenous (iv) or Oral Dosing (po)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>d</sub>(L/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–∞</sub>(po) (μM·h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub>(po) (μM)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub>(po) (h)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">394 ± 131</td><td class="colsep0 rowsep0" align="left">35.6 ± 6.7</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.6</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">5.0 ± 1.0</td><td class="colsep0 rowsep0" align="left">4.5 ± 0.5</td><td class="colsep0 rowsep0" align="left">12 ± 2.8</td><td class="colsep0 rowsep0" align="left">55.1 ± 6.4<a class="ref internalNav" href="#t6fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">5.2 ± 0.6</td><td class="colsep0 rowsep0" align="left">2.0 ± 1.0</td><td class="colsep0 rowsep0" align="left">100 ± 14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">6.7 ± 3.3</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.6</td><td class="colsep0 rowsep0" align="left">4.9 ± 0.9</td><td class="colsep0 rowsep0" align="left">92.2 ± 15.4</td><td class="colsep0 rowsep0" align="left">4.3 ± 0.5</td><td class="colsep0 rowsep0" align="left">4.0 ± 2.3</td><td class="colsep0 rowsep0" align="left">100 ± 43</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Athymic nude mice (<i>n</i> = 3 animals), dosed at 100 mg/kg po only in Pharmatek #6 (Hot Rod Chemistry vehicle series; Pharmatek Incorporated, San Diego, CA).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Beagle dogs (<i>n</i> = 3 animals), dosed iv at 1 mg/kg as a solution in 22% HPβCD, and po at 10 mg/kg as a solution in 22% HPβCD.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Male Cynomolgus monkeys (<i>n</i> = 3 animals), dosed iv at 1 mg/kg as a solution in 22% HPβCD, and po at 10 mg/kg as a solution in 22% HPβCD.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">The parameters were calculated using plasma concentration–time data for individual animals, and mean values are reported with standard deviations.</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">ND = not determined.</p></div><div class="footnote" id="t6fn6"><sup>f</sup><p class="last">Reported as AUC<sub>0–24h</sub>.</p></div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vivo Efficacy and Pharmacodynamic Profiling of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b></h3><div class="NLM_p">Compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> was further evaluated for antitumor efficacy and tolerability in several BRAF<sup>V600E</sup>-driven human carcinoma xenograft mouse models, including both Colo-205 and A375.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Data from the Colo-205 xenograft study is presented here (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Athymic nude mice bearing established Colo-205 tumor xenografts were dosed orally with <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> at 10, 30, and 100 mg/kg twice daily (BID) over a 14-day period. All doses were well tolerated, with no mortality or significant body weight loss (<5% relative to vehicle matched controls) observed during treatment or up to 1 week post dosing. Dosing at 10 mg/kg BID had little effect on tumor growth compared to the control group. However, increasing the dose to either 30 or 100 mg/kg BID resulted in significant efficacy. The 30 mg/kg dose group exhibited tumor stasis and a 40% incidence of partial tumor regressions (PRs) (<i>p</i> < 0.008), whereas the 100 mg/kg BID dose group exhibited both tumor stasis and an 80% incidence of PRs (<i>p</i> < 0.0001). The observed efficacy is correlated with an <i>in vivo</i> pharmacodynamic–pharmacokinetic end point as illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>. Oral administration of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> to Colo-205 tumor xenograft-bearing mice resulted in significant inhibition of pMEK in tumor cell lysates. For instance, a single 30 mg/kg (po) dose of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> led to a 50 and 75% inhibition of normalized pMEK in tumor lysates at the 2 and 6 h postdose time point, respectively (<i>p</i> < 0.03), while a 55 mg/kg (po) dose resulted in a 75% to 57% (<i>p</i> < 0.03) inhibition of pMEK at 2 through 10 h post administration, with normalization to baseline by 24 h (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a). In general, the magnitude and duration of normalized pMEK inhibition by <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> was consistent with plasma and tumor levels over the dose range and time course of the pharmacodynamic study (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>b).</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy results upon oral dosing of compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> at 10, 30, and 100 mg/kg BID (dosed in 22% HPβCD) for 14 days to athymic nu/nu nude mice bearing established Colo-205 human colon tumor subcutaneous xenografts with the BRAF<sup>V600E</sup> genotype (10 animals per treatment group). A dose response relationship (left panel) for complete Colo-205 tumor growth inhibition and incidence of tumor regressions (right panel) was observed. Mice were monitored for signs of morbidity (behavior and body weight loss), and tumors were measured 3 times per week. Statistical significance (<i>p</i> < 0.05) for antitumor efficacy, based upon tumor growth inhibition relative to vehicle-treated controls, for both the 30 and 100 mg/kg groups was reached by day 5 of administration and extended to the termination of the study, with a final significance for tumor growth inhibition of <i>p</i> < 0.008 (30 mg/kg group) and <i>p</i> < 0.0001 (100 mg/kg group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) In vivo inhibition of normalized MEK phosphorylation in Colo-205 tumor xenograft-bearing mice over a 24 h period following a single oral dose of either vehicle (22% HPβCD) or compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> (10, 30, and 55 mg/kg, dosed in 22% HPβCD), and (b) corresponding compound levels in both plasma and tumor samples. At appropriate time points over a 24 h period, animals were sacrificed and plasma and tumor samples were collected and lysates prepared. Amounts of total MEK and pMEK in tumor lysates were measured by immunoblotting and ELISA methods. Compound levels in plasma and tumor tissue samples were analyzed and quantitated by LC-MS/MS. Values shown are mean + SEM from two studies; <i>n</i> = 3 tumor-bearing mice per time point per study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Molecular Modeling Studies of Compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> with BRAF<sup>V600E</sup></h3><div class="NLM_p">In order to gain a better understanding of how the described quinazoline-derived inhibitors might bind to BRAF<sup>V600E</sup>, we carried out docking experiments into the ligand binding site of the previously reported cocrystal structures of sorafenib (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>d) bound to a DFG-out form of BRAF<sup>V600E</sup> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1uwj">1uwj</a>) and a DFG-out form of wt-BRAF (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1uwh">1uwh</a>).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Select compounds, including <b>22</b>, <b>30</b>, and <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> docked to the DFG-out mode in a consistent manner, and all docking trials scored compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> the best. The predicted binding mode of these compounds to DFG-out BRAF<sup>V600E</sup> is illustrated with compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a). In this binding mode the quinazoline N-1 nitrogen participates in a hydrogen bonding interaction with the NH of Cys532 of the hinge domain. In addition, the quinazoline core is in close proximity to three aromatic residues, namely Trp531, Phe583, and Phe595 (of the DFG motif), which could participate in appropriate π–π or π–σ aromatic binding interactions with the quinazoline ring system. In a similar manner, Phe595 could also interact with the central phenyl ring of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b>. The urea moiety of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> participates in two key hydrogen bonding interactions with the protein: one between the urea oxygen and the NH of Asp594 (of the DFG motif); the other between one or both of the urea NH’s and the carboxylate of Glu501 (of the α-C Helix). Finally, the 5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol moiety sits in a hydrophobic pocket formed between the α-C and α-E helices and the N-terminal regions of the DFG motif and the catalytic loop, with the 1,1,1-trifluoro-2-methylpropan-2-yl group in close proximity to the residues Val504, Leu505, Thr508, Ile513, and Leu567. The model predicts that along with the expected hydrophobic interactions with the residues described, the CF<sub>3</sub> group can interact electrostatically with Thr508 via a hydrogen bonding interaction between a fluorine atom and the OH of Thr508 (F–Hdistance ∼2.97 Å). This interaction with Thr508 may contribute to the enhanced binding affinity observed with <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> relative to <b>4</b>. In an attempt to rationalize certain SAR observations, other compounds were docked into the BRAF<sup>V600E</sup> protein, including <b>22</b>, which contains an isoxazole bearing the much smaller methyl group at the 5-position of the isoxazol-3-yl ring. Compound <b>22</b> scored lower in these docking experiments, presumably due to less efficient hydrophobic interactions within the hydrophobic pocket (data not shown), which may explain the observed reduction in the binding affinity of <b>22</b> to BRAF<sup>V600E</sup>. Compounds such as <b>30</b>, which also exhibits reduced binding affinity compared to <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b>, has a methoxy group in place of the CF<sub>3</sub>. Compound <b>30</b> docked with this methoxy group pointing away from Thr508 and is therefore is unable to interact with this residue (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>c). Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b allows comparison between the binding mode of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> and sorafenib. As one might expect, overall, these ligands occupy similar space within the binding site, with similar positioning of the urea moieties and interaction of both quinazoline N-1 of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> and the pyridyl nitrogen of sorafenib with the same residue (the NH of Cys532) located on the hinge of the protein.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Binding mode of the isoxazol-3-yl urea compounds, based on docking experiments with DFG-out BRAF<sup>V600E</sup>, illustrated with compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> (carbon-magenta). The urea forms two hydrogen bonding interactions: one between the urea-O and the NH of Asp594 (DFG motif); the other between the urea NH’s and the carboxylate of Glu501 (α-C helix). A hydrogen bond (electrostatic interaction) between one of the fluorines of the CF<sub>3</sub> and the Thr508 OH may contribute a key binding interaction. (b) Comparison of the binding mode of sorafenib (carbon-light green) from the X-ray structure and compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> (carbon-magenta) from the docking studies. (c) Subtle changes in the binding mode of compound <b>30</b> (carbon-magenta). (d) Chemical structure of sorafenib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">An optimization campaign around the initial lead 5-<i>tert</i>-butyl-isoxazol-3-yl urea-containing quinazoline <b>4</b> was described. Targeted replacement of the metabolically sensitive <i>tert</i>-butyl moiety with a variety of alkyl fluoride motifs led to the identification of 5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl urea-containing quinazoline derivative <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b>. Compared to <b>4</b>, compound<b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> exhibited improved cellular potency against the BRAF<sup>V600E</sup>-dependent A375 cell line and much improved oral exposure in rat by virtue of reduced <i>in vivo</i> clearance. Compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> also exhibited excellent oral exposure in other preclinical species. In addition, <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> proved selective for the RAF kinase members of the MAPK signaling cascade and exhibited selective cytotoxicity for tumor cell lines expressing mutant BRAF<sup>V600E</sup> versus those containing wild-type BRAF. Compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> also demonstrated significant oral efficacy in a 14-day BRAF<sup>V600E</sup>-dependent human Colo-205 tumor xenograft mouse model, when dosed 30 and 100 mg/kg BID. These observations, coupled with excellent druglike properties and a favorable tolerability profile, led to the selection of <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> as a clinical candidate, which represents a new opportunity for the treatment of mutant BRAF<sup>V600E</sup>-driven human carcinomas.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemistry</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Methods</h4><div class="NLM_p">All commercially available solvents and reagents were used as received. Where appropriate, reactions were carried out under an argon atmosphere. Flash column chromatography was conducted under medium pressure either on silica (Merck silica gel 40–63 μM) or on prepacked silica gel cartridges (Biotage), and eluents were monitored by UV light (λ = 254 nm). <sup>1</sup>H NMR spectra were recorded using a Bruker Avance 300 MHz NMR spectrometer unless stated otherwise. Chemical shifts (δ) are reported as parts per million (ppm) relative to tetramethylsilane (internal standard), and coupling constants (<i>J</i>) are reported in Hz. The following abbreviations are used for multiplicities: s = singlet; br s = broad singlet; d = doublet; t = triplet; q = quartet; m = multiplet. Low resolution mass spectra (MS) were obtained as electrospray ionization (ESI) mass spectra, which were recorded on a Shimadzu HPLC/MS instrument using reverse-phase conditions (acetonitrile/water, containing 0.05% acetic acid). Preparative reverse-phase HPLC was performed using Varian HPLC systems with either a Varian Pursuit XRs 10 μm Diphenyl 250 mm × 50.0 mm column (eluent flow rate 95 mL/min) or a Phenomenex Luna 10 μm C18(2) 100 Å 250 × 21.20 mm column (eluent flow rate 30 mL/min), eluting with acetonitrile/water, containing 0.05% acetic acid. The purity of all final compounds was determined to be ≥95% by reverse-phase LC-MS, which was performed on a Shimadzu LC-MS 2010 EV (ESI probe) using a Phenomenex Luna 5 μm C18(2) 100 Å 250 mm × 4.60 mm column, eluting with a gradient of 10–95% acetonitrile in water (containing 0.05% acetic acid) over 30 min (at rt), with a flow rate of 1 mL/min and visualized using a wavelength of 254 nm.</div><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> 1-(5-<i>tert</i>-Butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea Hydrochloride (<b>4</b>)</h5><div class="NLM_p last">A stirred mixture of 3-aminophenol (4.36 g, 40 mmol) and 5-<i>tert</i>-butyl-3-isocyanatoisoxazole (6.64 g, 40 mmol) in degassed THF (300 mL) was heated at 50 °C for 15 h. After cooling to rt, the reaction was concentrated under reduced pressure and the resulting foam purified by silica gel flash chromatography (eluting with 25% to 75% EtOAc in hexanes) to afford 1-(5-<i>tert</i>-butylisoxazol-3-yl)-3-(3-hydroxyphenyl)urea as a solid (8.81 g, 80%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.39 (s, 1H), 9.37 (s, 1H), 8.69 (s, 1H), 7.01–7.06 (m, 2H), 6.78 (d, <i>J</i> = 6.0 Hz, 1H), 6.49 (s, 1H), 6.41 (d, <i>J</i> = 6.0 Hz, 1H), 1.29 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 275 [M + H]<sup>+</sup>.To a slurry of potassium <i>tert</i>-butoxide (6.73 g, 60 mmol) in THF(300 mL) was added 1-(5-<i>tert</i>-butylisoxazol-3-yl)-3-(3-hydroxyphenyl)urea (8.25 g, 30 mmol), and the solution was stirred at rt for 1 h, at which point 4-chloro-6,7-dimethoxyquinazoline (6.74 g, 30 mmol) was added, followed by potassium carbonate (4.1 g, 30 mmol). After stirring at rt for 72 h, the reaction was concentrated under reduced pressure and the resulting solid was partitioned between EtOAc and water. The organic layer was separated, dried over MgSO<sub>4</sub>, filtered, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 15% to 100% EtOAc in hexanes) to give 1-(5-<i>tert</i>-butylisoxazol-3-yl)-3-(3-(2-chloro-6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea as a white solid. The solid was dissolved in EtOAc (50 mL), and 4 M HCl in 1,4-dioxane (5 mL, 20 mmol) was added and stirred at rt for 30 min. The mixture was concentrated under reduced pressure to afford the title compound as a solid (6.29 g, 42%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.72 (s, 1H), 9.44 (s, 1H), 8.73 (s, 1H), 7.60–7.65 (m, 2H), 7.38–7.45 (m, 2H), 7.29 (d, <i>J</i> = 9.0 Hz, 1H), 6.98 (d, <i>J</i> = 9.0 Hz, 1H), 6.48 (s, 1H), 4.02 (s, 3H), 4.00 (s, 3H), 1.28 (s, 9H). LC-MS (ESI) <i>m</i>/z 464 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Preparation of Substituted 3-Oxopropanenitriles. General Procedure A</h4><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 4-Methyl-3-oxopentanenitrile (<b>5a</b>)</h5><div class="NLM_p last">A stirred suspension of sodium hydride (1.95 g, 60% dispersion in mineral oil, 48.75 mmol) in THF (25 mL) was heated to 75 °C. To this was added a mixture of methyl isobutyrate (3.19 g, 31.25 mmol) and acetonitrile (2.56 mL, 48.75 mmol) dropwise over the course of 45 min. The resulting pale yellow suspension was heated at 70 °C for a further 15 h. After cooling to rt, the reaction mixture was poured into water (150 mL) and the resulting solution was extracted with diethyl ether (2 × 100 mL). The aqueous layer was separated, acidified to pH 2 with aqueous 2 M HCl, and extracted with diethyl ether (2 × 100 mL). The combined ether layers were dried over MgSO<sub>4</sub> and then concentrated under reduced pressure to afford the title compound as a yellow oil, which did not require further purification (2.71 g, 78%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.53 (s, 2H), 2.81 (septet, <i>J</i> = 6 Hz, 1H), 1.21 (d, <i>J</i> = 6 Hz, 6H).</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 3-Cyclopentyl-3-oxopropanenitrile (<b>5b</b>)</h5><div class="NLM_p last">Prepared from methyl cyclopentanecarboxylate (4.0 g, 31.25 mmol) according to General Procedure A to afford the title compound as a yellow oil (3.97 g, 93%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.5 (s, 2H), 3.02–3.13 (m, 1H), 1.62–1.95 (m, 8H).</div></div><div id="sec5_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 4-Fluoro-4-methyl-3-oxopentanenitrile (<b>5c</b>)</h5><div class="NLM_p last">Prepared from ethyl 2-fluoroisobutyrate (10 g, 74.62 mmol) according to General Procedure A to afford the title compound as a yellow oil (8 g, 83%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.82 (s, 2H), 1.54 (d, <i>J</i> = 21 Hz, 6H).</div></div><div id="sec5_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 4,4-Difluoro-3-oxopentanenitrile (<b>5d</b>)</h5><div class="NLM_p last">Prepared from ethyl 2,2-difluoropropionate (3 g, 22 mmol) according to General Procedure A. The crude product was purified by silica gel flash chromatography (eluting with 10%–40% EtOAc in hexanes) to afford the title compound as a yellow oil (1 g, 31%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.95 (s, 2H), 1.86 (t, <i>J</i> = 19 Hz, 3H).</div></div><div id="sec5_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 4,4,4-Trifluoro-3-oxobutanenitrile (<b>5e</b>)</h5><div class="NLM_p last">Prepared from methyl 2,2,2-trifluoroacetate (10.24 g, 80 mmol) according to General Procedure A to afford the title compound as an oil (9.08 g, 83%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 2.93 (s, 2H).</div></div><div id="sec5_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 5,5,5-Trifluoro-4,4-dimethyl-3-oxopentanenitrile (<b>5f</b>)</h5><div class="NLM_p last">The reaction was carried out in two separate batches, employing 5 g (32 mmol) of 3,3,3-trifluoro-2,2-dimethylpropionic acid in each batch. To a stirred solution of 3,3,3-trifluoro-2,2-dimethylpropionic acid (5 g, 32 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at 0 °C was added dropwise a solution of (trimethylsilyl)diazomethane (18 mL of a 2 M solution in diethyl ether, 35 mmol) (gas evolution observed). The resulting yellow solution was allowed to warm to rt and stirred for a further 48 h. Additional (trimethylsilyl)diazomethane (5 mL of a 2 M solution in diethyl ether, 10 mmol) was added, and stirring was continued for a further 5 h, whereupon a further amount of (trimethylsilyl)diazomethane (6 mL of a 2 M solution in diethyl ether, 12 mmol) was added. After stirring for a further 15 h, the reaction mixture was concentrated under reduced pressure (keeping bath temperature below 30 °C). The resulting oil was redissolved in diethyl ether (200 mL), washed with saturated aqueous NaHCO<sub>3</sub> solution (100 mL), separated, and dried over MgSO<sub>4</sub>. Filtration followed by concentration under reduced pressure (keeping bath temperature below 30 °C) afforded methyl 3,3,3-trifluoro-2,2-dimethylpropanoate as an oil. Product from both batches was combined to afford methyl 3,3,3-trifluoro-2,2-dimethylpropanoate as a yellow oil (7.69 g, 71%), which was used in the next step without further purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.86 (s, 3H), 1.40 (s, 6H). Methyl 3,3,3-trifluoro-2,2-dimethylpropanoate (7.69 g, 45 mmol) was treated according to General Procedure A to afford the title compound as a yellow oil (4.27 g, 37%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.77 (s, 2H), 1.43 (s, 6H).</div></div><div id="sec5_1_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 2,2-Dimethyl-3-oxopentanedinitrile (<b>5g</b>)</h5><div class="NLM_p last">Prepared from ethyl 2-cyano-2-methylpropanoate (3.0 g, 21.25 mmol) according to General Procedure A to afford the title compound as a yellow oil (1.40 g, 48%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.98 (s, 2H), 1.60 (s, 6H).</div></div><div id="sec5_1_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 3-Oxo-3-(1-(trifluoromethyl)cyclopropyl)propanenitrile (<b>5h</b>)</h5><div class="NLM_p last">Prepared from methyl 1-(trifluoromethyl)cyclopropane carboxylate (2.0 g, 11.9 mmol) according to General Procedure A. The crude product was purified by silica gel flash chromatography (eluting with 5%–40% EtOAc in hexanes) to afford the title compound as an oil (1.03 g, 49%). LC-MS (ESI) <i>m</i>/<i>z</i> 178 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 3-Oxo-3-(1-(trifluoromethyl)cyclobutyl)propanenitrile (<b>5i</b>)</h5><div class="NLM_p last">To a stirred solution of 1-trifluoromethylcyclobutane-1-carboxylic acid (10 g, 59.5 mmol) in MeOH (50 mL) was added concentrated sulfuric acid (3 mL), and the resulting mixture was heated at 75 °C for 15 h. After cooling to rt, the solvent was removed under reduced pressure and the residue was partitioned between EtOAc and water. The organic phase was separated and the aqueous solution was further extracted with EtOAc. The combined organic layers were dried over MgSO<sub>4</sub> and then concentrated under reduced pressure (water bath at 20 °C) to afford methyl 1-(trifluoromethyl)cyclobutanecarboxylate as an oil, which did not require further purification (4.5 g, 42%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 3.76 (s, 3H), 2.50–2.60 (m, 2H), 2.35–2.45 (m, 2H), 1.91–2.04 (m, 2H). Methyl 1-(trifluoromethyl)cyclobutanecarboxylate (2 g, 11 mmol) was treated according to General Procedure A to afford the title compound as a yellow oil (1.68 g, 80%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.76 (s, 2H), 2.39–2.65 (m, 4H), 1.95–2.15 (m, 2H).</div></div><div id="sec5_1_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 5-Fluoro-4-(fluoromethyl)-4-methyl-3-oxopentanenitrile (<b>5j</b>)</h5><div class="NLM_p last">To a stirred suspension of 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoic acid (10.06 g, 75 mmol) in MeOH at rt was added dropwise (trimethylsilyl)diazomethane (50 mL of a 2 M solution in diethyl ether, 100 mmol). The reaction mixture was stirred at rt for 15 h. The mixture was concentrated under reduced pressure, and the residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated aqueous NaHCO<sub>3</sub> solution. The organic layer was separated, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure to afford methyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate as an oil, which did not require further purification (3.79 g, 34%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.81 (d, <i>J</i> = 13.8 Hz, 2H), 3.67 (s, 3H), 3.60 (d, <i>J</i> = 13.8 Hz, 2H), 2.89 (br s, 2H), 0.96 (s, 3H). To a solution of methyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate (13.0 g, 88 mmol) and 2,6-lutidine (26.79 g, 250 mmol) in CH<sub>2</sub>Cl<sub>2</sub> at −78 °C was added dropwise trifluoroacetic anhydride (50.0 g, 177 mmol). The reaction mixture was stirred for 2 h at −78 °C, after which the reaction was allowed to warm slowly to rt and was stirred for an additional 2 h. The mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (200 mL) and 3% aqueous HCl solution (200 mL). The organic layer was separated, washed with 3% aqueous HCl solution (200 mL), dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure to give an oil. The oil was dissolved in THF (50 mL) and cooled to 0 °C. Tetrabutylammonum fluoride (200 mL of a 1 M solution in THF, 200 mmol) was added dropwise, and the reaction mixture was stirred at rt for 15 h. The mixture was concentrated under reduced pressure and the residue dissolved in CH<sub>2</sub>Cl<sub>2</sub> (400 mL), which was washed with brine (2 × 200 mL), dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by vacuum distillation to afford methyl 3-fluoro-2-(fluoromethyl)-2-methylpropanoate as an oil (2.89 g, 22%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 4.33–4.66 (m, 4H), 3.67 (s, 3H), 1.14 (s, 3H). Methyl 3-fluoro-2-(fluoromethyl)-2-methylpropanoate (5.21 g, 34.2 mmol) was treated according to General Procedure A to afford the title compound as an oil (4.41 g, 80%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 4.67–4.72 (m, 2H), 4.45–4.52 (m, 2H), 3.80 (s, 2H), 1.27 (s, 3H).</div></div><div id="sec5_1_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 5-Hydroxy-4,4-dimethyl-3-oxopentanenitrile (<b>5k</b>)</h5><div class="NLM_p last">A solution of methyl 3-hydroxy-2,2-dimethylpropanoate (5.00 g, 38 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (7.30 g, 57 mmol), and <i>tert</i>-butyldimethylchlorosilane (6.80 g, 45 mmol) in DMF (70 mL) was stirred at rt for 12 h. The reaction solution was partitioned between water and diethyl ether. The combined organic layers were washed with water and then brine and then dried over MgSO<sub>4</sub>. Concentration under reduced pressure afforded methyl 3-(<i>tert</i>-butyldimethylsilyloxy)-2,2-dimethylpropanoate as a colorless oil, which did not require further purification (9.34 g, 100%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.64 (s, 3H), 3.55 (s, 2H), 1.13 (s, 6H), 0.85 (s, 9H), 0.00 (s, 6H). Methyl 3-(<i>tert</i>-butyldimethylsilyloxy)-2,2-dimethylpropanoate (6.0 g, 24.39 mmol) was treated according to General Procedure A and then purified by silica gel flash chromatography (eluting with 33% EtOAc in petroleum ether) to afford the title compound as a yellow oil (1 g, 29%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz,): δ 3.76 (s, 2H), 3.61 (s, 2H), 1.19 (s, 6H).</div></div><div id="sec5_1_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 5-Methoxy-4,4-dimethyl-3-oxopentanenitrile (<b>5l</b>)</h5><div class="NLM_p last">Prepared from methyl 3-methoxy-2,2-dimethylpropanoate<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a> (8 g, 54.7 mmol) according to General Procedure A to afford the title compound as a yellow oil (2.5 g, 29%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.72 (s, 2H), 3.32–3.33 (m, 5H), 1.18 (s, 6H).</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Preparation of Substituted Aminoisoxazoles. General Procedure B</h4><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 3-Isopropylisoxazol-5-amine (<b>6a</b>)</h5><div class="NLM_p last">To a stirred solution of sodium hydroxide (238 mg, 5.95 mmol) and compound <b>5a</b> (600 mg, 5.41 mmol) in a mixture of water (5 mL) and EtOH (5 mL) was added hydroxylamine sulfate (977 mg, 5.95 mmol). The reaction mixture was adjusted to pH 7.5 with aqueous 1 M sodium hydroxide solution and then heated at 80 °C for 15 h. After cooling to rt, the solvent was removed under reduced pressure. The resulting solid was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and water (50 mL), and the organic layer was separated, washed with brine (50 mL), dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure to afford the title compound as a cream solid, which did not require further purification (530 mg, 78%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.00 (s, 1H), 4.39 (br s, 2H), 2.89 (septet, <i>J</i> = 6 Hz, 1H), 1.23 (d, <i>J</i> = 6 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 127 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Preparation of Substituted Aminoisoxazoles. General Procedure C</h4><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-Cyclopentylisoxazol-5-amine (<b>6b</b>)</h5><div class="NLM_p last">To a stirred solution of compound <b>5b</b> (645 mg, 4.7 mmol) and sodium hydroxide (386 mg, 9.65 mmol) in water (4.7 mL) was added hydroxylamine hydrochloride (343 mg, 4.94 mmol), and the resulting mixture was heated at 100 °C for 2.5 h. After cooling to rt, the mixture was diluted with CHCl<sub>3</sub> and the organic layer was separated. The aqueous layer was further extracted with CHCl<sub>3</sub>, and the combined organic layers were dried over MgSO<sub>4</sub> and then concentrated under reduced pressure to afford the title compound as a colorless solid, which did not require further purification (680 mg, 95%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.09 (br s, 2H), 4.93 (s, 1H), 2.94–3.02 (m, 1H), 1.73–2.00 (m, 2H), 1.62–1.73 (m, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 153 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 3-(2-Fluoropropan-2-yl)isoxazol-5-amine (<b>6c</b>)</h5><div class="NLM_p last">Prepared from compound <b>5c</b> (6.0 g, 47 mmol) according to General Procedure B to afford the title compound as a light yellow solid (4.83 g, 71%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.19 (s, 1H), 4.48 (br s, 2H), 1.68 (d, <i>J</i> = 21 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 145 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 3-(1,1-Difluoroethyl)isoxazol-5-ylamine (<b>6d</b>)</h5><div class="NLM_p last">Prepared from compound <b>5d</b> (100 mg, 0.75 mmol) according to General Procedure B to afford the title compound as a colorless solid (100 mg, 90%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.30 (s, 1H), 4.70 (s, 2H), 2.00 (t, <i>J</i> = 19 Hz, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 149 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 3-(Trifluoromethyl)isoxazol-5-amine (<b>6e</b>)</h5><div class="NLM_p last">(Trimethylsilyl)diazomethane (21 mL of a 2 M solution in diethyl ether, 42 mmol) was added dropwise to a stirred solution of compound <b>5e</b> (3.79 g, 26 mmol) in diethyl ether (25 mL) at 0 °C. The resulting mixture was allowed to slowly warm to rt and was stirred for 15 h. The mixture was concentrated under reduced pressure to afford 4,4,4-trifluoro-3-methoxybut-2-enenitrile as an oil, which did not require further purification (3.93 g, 100%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.00 (s, 1H), 4.16 (s, 3H). To a stirred solution of hydroxylamine hydrochloride (2.88 g, 41.5 mmol) in MeOH (20 mL) at 0 °C was added solid sodium methoxide (2.24 g, 41.5 mmol), and the resulting suspension was stirred at rt for 15 min. The suspension was cooled to 0 °C, and then 4,4,4-trifluoro-3-methoxybut-2-enenitrile (3.93 g, 26 mmol) was added dropwise and the mixture was allowed to slowly warm to rt. The mixture was then heated to 60 °C for 15 h. The colorless precipitate was removed by filtration, and the filtrate was concentrated under reduced pressure to afford a solid. The solid was redissolved in EtOH (25 mL) and the solution acidified to pH = 1 with 37% aqueous HCl and then stirred at 60 °C for 2 h. After cooling to rt, the mixture was concentrated under reduced pressure and the residue partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated aqueous NaHCO<sub>3</sub> solution. The organic layer was separated, and the aqueous layer was further extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over MgSO<sub>4</sub> and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 5% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a solid (446 mg, 11%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.31 (s, 1H), 5.03 (br s, 2H). LC-MS (ESI) <i>m</i>/<i>z</i> 153 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 3-(1,1,1-Trifluoro-2-methylpropan-2-yl)isoxazol-5-amine (<b>6f</b>)</h5><div class="NLM_p last">Prepared from compound <b>5f</b> (524 mg, 2.9 mmol) according to General Procedure C to afford the title compound as a solid (150 mg, 27%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.19 (s, 1H), 4.50 (br s, 2H), 1.54 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 195 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 2-(5-Aminoisoxazol-3-yl)-2-methylpropanenitrile (<b>6g</b>)</h5><div class="NLM_p last">Prepared from compound <b>5g</b> (500 mg, 3.68 mmol) according to General Procedure B to afford the title compound as a colorless solid (130 mg, 23%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.22 (s, 1H), 4.58 (br s, 2H), 1.72 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 152 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 3-(1-(Trifluoromethyl)cyclobutyl)isoxazol-5-amine (<b>6h</b>)</h5><div class="NLM_p last">Prepared from compound <b>5i</b> (500 mg, 2.6 mmol) according to General Procedure B to afford the title compound as a colorless solid (210 mg, 39%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.04 (s, 1H), 4.55 (br s, 2H), 2.40–2.59 (m, 4H), 1.90–2.09 (m, 2H). LC-MS (ESI) <i>m</i>/<i>z</i> 207 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 3-(1,3-Difluoro-2-methylpropan-2-yl)isoxazol-5-amine (<b>6i</b>)</h5><div class="NLM_p last">To a stirred solution of compound <b>5j</b> (1.00 g, 6.2 mmol) and sodium hydroxide (0.27 g, 6.8 mmol) in EtOH (5 mL) and water (5 mL) at rt was added a solution of hydroxylamine sulfate (1.12 g, 6.8 mmol) in water (5 mL). To the mixture was added additional sodium hydroxide until the pH was 8–9, and the mixture was heated at 100 °C for 2 h. After cooling to rt, the mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub>and water. The organic layer was separated and the aqueous layer re-extracted with additional CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with water, separated, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 100% hexanes to 50% EtOAc in hexanes) to afford the title compound as a solid (191 mg, 17%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.16 (s, 1H), 4.54–4.68 (m, 2H), 4.32–4.50 (m, 4H), 1.37 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 177 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 3-<i>tert</i>-Butylisoxazol-5-amine (<b>6j</b>)</h5><div class="NLM_p last">Prepared from pivaloylacetonitrile (1 g, 7.90 mmol) according to General Procedure C to afford the title compound as a colorless solid (1.07 g, 97%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.00 (s, 1H), 4.79 (br s, 2H), 1.33 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 141 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 3-Phenylisoxazole-5-amine (<b>6k</b>)</h5><div class="NLM_p last">Prepared from benzoylacetonitrile (707 mg, 4.9 mmol) according to General Procedure C. The crude product was purified by silica gel flash chromatography (eluting with 20–40% EtOAc in hexanes) to afford the title compound as a solid (456 mg, 58%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.70–7.76 (m, 2H), 7.40–7.47 (m, 3H), 5.49 (s, 1H), 4.52 (s, 2H). LC-MS (ESI) <i>m</i>/<i>z</i> 161 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Preparation of Substituted Isoxazole Carbamates. General Procedure D</h4><div id="sec5_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> Phenyl 3-Isopropylisoxazol-5-ylcarbamate (<b>7a</b>)</h5><div class="NLM_p last">To a stirred mixture of compound <b>6a</b> (250 mg, 1.98 mmol) and potassium carbonate (634 mg, 4.59 mmol) in THF (6 mL) was added phenyl chloroformate (341 mg, 2.18 mmol). The reaction mixture was stirred at rt for 3.5 h, and then additional phenyl chloroformate (341 mg, 2.18 mmol) was added and stirring was continued for a further 15 h. The resulting mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and water (50 mL), and the organic layer was separated, washed with brine (50 mL), dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 4–40% EtOAc in hexanes) to afford the title compound as a colorless solid (330 mg, 68%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.76 (br s, 1H), 7.40–7.45 (m, 2H), 7.18–7.31 (m, 3H), 6.07 (s, 1H), 3.02 (septet, <i>J</i> = 6 Hz, 1H), 1.28 (d, <i>J</i> = 6 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 247 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> Phenyl 3-Cyclopentylisoxazol-5-ylcarbamate (<b>7b</b>)</h5><div class="NLM_p last">Prepared from compound <b>6b</b> (675 mg, 4.44 mmol) according to General Procedure D to afford the title compound as a colorless solid (528 mg, 50%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.21 (br s, 1H), 7.39–7.44 (m, 2H), 7.26–7.30 (m, 1H), 7.21 (d, <i>J</i> = 9 Hz, 2H), 6.06 (s, 1H), 3.12 (m,1H), 1.99–2.06 (m, 2H), 1.63–1.76 (m, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 273 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Phenyl 3-(2-Fluoropropan-2-yl)isoxazol-5-ylcarbamate (<b>7c</b>)</h5><div class="NLM_p last">Prepared from compound <b>6c</b> (4.83 g, 33.54 mmol) according to General Procedure D to afford the title compound as a colorless solid (6.04 g, 68%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.80 (br s, 1H), 7.39–7.45 (m, 2H), 7.18–7.32 (m, 3H), 6.27 (s, 1H), 1.74 (d, <i>J</i> = 21 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 265 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> Phenyl 3-(1,1-Difluoroethyl)isoxazol-5-ylcarbamate (<b>7d</b>)</h5><div class="NLM_p last">Prepared from compound <b>6d</b> (100 mg, 0.68 mmol) according to General Procedure D to afford the title compound as an oil (141 mg, 77%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.02 (s, 1H), 7.40–7.45 (m, 2H), 7.18–7.32 (m, 3H), 6.38 (s, 1H), 2.03 (t, <i>J</i> = 19 Hz, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 269 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Phenyl 3-(Trifluoromethyl)isoxazol-5-ylcarbamate (<b>7e</b>)</h5><div class="NLM_p last">To a stirred solution of compound <b>6e</b> (446 mg, 2.93 mmol) in THF (6 mL) at rt were added triethylamine (1.1 mL, 8.2 mmol), phenyl chloroformate (0.88 mL, 7.03 mmol), and 4-(dimethylamino)pyridine (357 mg, 2.93 mmol). The reaction mixture was stirred at rt for 3 h. The mixture was filtered through a pad of Celite, and then the filtrate was concentrated under reduced pressure. The residue was redissolved in CH<sub>2</sub>Cl<sub>2</sub>, washed with brine, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 20% EtOAc in hexanes) to afford the title compound as a colorless solid (269 mg, 33%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.99 (br s, 1H), 7.39–7.42 (m, 2H), 7.02–7.35 (m, 3H), 6.70 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i> 273 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 4-Chlorophenyl 3-(1,1,1-Trifluoro-2-methylpropan-2-yl)isoxazol-5-ylcarbamate (<b>7f</b>)</h5><div class="NLM_p last">Prepared from compound <b>6f</b> (150 mg, 0.77 mmol) and 4-chlorophenyl choloroformate (412 mg, 2.15 mmol) according to General Procedure D to afford the title compound as a colorless solid (210 mg, 78%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.72 (br s, 1H), 7.39 (d, <i>J</i> = 12 Hz, 2H), 7.16 (d, <i>J</i> = 12 Hz, 2H), 6.27 (s, 1H), 1.57 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 349 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Phenyl 3-(2-Cyanopropan-2-yl)isoxazol-5-ylcarbamate (<b>7g</b>)</h5><div class="NLM_p last">Prepared from compound <b>6g</b> (130 mg, 0.861 mmol) according to General Procedure D to afford the title compound as a colorless solid (93 mg, 40%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.82 (br s, 1H), 7.41–7.46 (m, 2H), 7.32 (m, 1H), 7.18–7.21 (m, 2H), 6.29 (s, 1H), 1.83 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 272 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Phenyl 3-(1-(Trifluoromethyl)cyclobutyl)isoxazol-5-ylcarbamate (<b>7h</b>)</h5><div class="NLM_p last">Prepared from compound <b>6h</b> (210 mg, 1 mmol) according to General Procedure D to afford the title compound as a colorless solid (320 mg, 98%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 12.17 (br s, 1H), 7.10–7.54 (m, 5H), 6.08 (s, 1H), 2.50–2.70 (m, 4H), 1.90–2.10 (m, 2H). LC-MS (ESI) <i>m</i>/<i>z</i> 327 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> Phenyl 3-(1,3-Difluoro-2-methylpropan-2-yl)isoxazol-5-ylcarbamate (<b>7i</b>)</h5><div class="NLM_p last">Prepared from compound <b>6i</b> (190 mg, 1.08 mmol) according to General Procedure D to afford the title compound as a solid (0.319 g, 100%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.83 (s, 1H), 7.17–7.45 (m, 5H), 6.23 (s, 1H), 4.68–4.74 (m, 2H), 4.49–4.58 (m, 2H), 1.40 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 297 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Phenyl 3-<i>tert</i>-Butylisoxazol-5-ylcarbamate (<b>7j</b>)</h5><div class="NLM_p last">Prepared from compound <b>6j</b> (620 mg, 4.43 mmol) according to General Procedure D to afford the title compound as a colorless solid (1.02 g, 89%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 11.81 (br s, 1H), 7.42–7.47 (m, 2H), 7.23–7.32 (m, 3H), 6.05 (s, 1H), 1.27 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 261 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Phenyl 3-Phenylisoxazol-5-ylcarbamate (<b>7k</b>)</h5><div class="NLM_p last">Prepared from compound <b>6k</b> (456 mg, 2.85 mmol) according to General Procedure D to afford the title compound as a colorless solid (675 mg, 84%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.77–7.81 (m, 3H), 7.40–7.47 (m, 5H), 7.19–7.32 (m, 3H), 6.54 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i> 281 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> 5-(1,1,1-Trifluoro-2-methylpropan-2-yl)isoxazol-3-amine (<b>8a</b>)</h5><div class="NLM_p last">Compound <b>5f</b> (3 g, 16.76 mmol), hydroxylamine sulfate (3.30 g, 20.11 mmol), and NaHCO<sub>3</sub> (3.52 g, 41.90 mmol) in a mixture of 10% MeOH in water (60 mL) were heated at 65 °C for 15 h. After cooling to rt, an additional 30 mL of 10% MeOH in water was added and the mixture was divided into 9 × 10 mL batches. Each batch was adjusted to pH 1 with concentrated HCl and placed into a 20 mL volume microwave vial fitted with a stirrer bar. After sealing, each batch was placed in a Biotage Microwave Synthesizer and heated (with stirring) at 140 °C for 5 min (maximum internal pressure attained was 7 bar). Each batch was cooled and neutralized with saturated aqueous NaHCO<sub>3</sub> solution. All processed batches were combined and then concentrated under reduced pressure, and the aqueous solution was extracted with 10% isopropanol in CHCl<sub>3</sub> (3 × 150 mL). The combined organic layers were washed with brine (200 mL), dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure to afford the title compound as a pale yellow solid, which did not require further purification (2.34 g, 71%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.80 (s, 1H), 3.98 (br s, 2H), 1.53 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 195 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 5-(1,3-Difluoro-2-methylpropan-2-yl)isoxazol-3-amine (<b>8b</b>)</h5><div class="NLM_p last">A stirred mixture of compound <b>5j</b> (483 mg, 3 mmol), hydroxylamine sulfate (590 mg, 3.6 mmol), and NaHCO<sub>3</sub> (700 mg, 8.3 mmol) in MeOH (1 mL) and water (10 mL) was heated at 60 °C for 8 h. The reaction was adjusted to pH =1 with 10% aqueous HCl, and the resulting mixture was heated at 60 °C for a further 3 h. After cooling to rt, the mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated aqueous NaHCO<sub>3</sub> solution. The organic layer was separated, and the aqueous layer was further extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over MgSO<sub>4</sub> and then concentrated under reduced pressure to afford the title compound as a solid, which did not require further purification (289 mg, 55%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.76 (s, 1H), 4.58–4.60 (m, 2H), 4.48–4.51 (m, 4H), 1.37 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 177 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 5-(1-(Trifluoromethyl)cyclopropyl)isoxazol-3-amine (<b>8c</b>)</h5><div class="NLM_p last">Prepared from compound <b>5h</b> (1 g, 5.65 mmol) according to the procedure described for <b>8a</b> to afford the title compound as a pale yellow solid (687 mg, 64%). LC-MS (ESI) <i>m</i>/<i>z</i> 193 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 2-(3-Aminoisoxazol-5-yl)-2-methylpropan-1-ol (<b>8d</b>)</h5><div class="NLM_p last">A stirred solution of compound <b>5k</b> (1 g, 7.90 mmol), 96% sodium hydroxide (374 mg, 9.35 mmol), and hydroxylamine hydrochloride (650 mg, 9.35 mmol) in a mixture of EtOH (100 mL) and water (100 mL) was heated at 60 °C for 22 h. Concentrated HCl (3 mL) was added, and the mixture was heated at 80 °C for 1 h. The reaction mixture was cooled to rt and then concentrated under reduced pressure. The residue was partitioned between CHCl<sub>3</sub> and 7 M aqueous sodium hydroxide solution, and the organic layer was separated, washed with water, and then dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated under reduced pressure. The residue was purified by recrystallization from diethyl ether to afford the title compound as a colorless solid (600 mg, 49%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.64 (s, 1H), 3.65 (s, 2H), 2.30 (br s, 2H), 1.31 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 157 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 5-(1-Methoxy-2-methylpropan-2-yl)isoxazol-3-amine (<b>8e</b>)</h5><div class="NLM_p last">Prepared from compound <b>5l</b> (1 g, 6.5 mmol) according to the procedure described for <b>8d</b>. Purified by silica gel flash chromatography (eluting with a mixture of petroleum ether and EtOAc) to afford the title compound as a colorless solid (350 mg, 32%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.60 (s, 1H), 3.39 (s, 2H), 3.32 (s, 3H), 2.94 (br s, 2H), 1.28 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 171 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 5-Phenylisoxazol-3-amine (<b>8f</b>)</h5><div class="NLM_p last">Prepared from benzoylacetonitrile (1.45 g, 10 mmol) according to the procedure described for <b>8d</b>. Purified by silica gel flash chromatography (eluting with 20–40% EtOAc in hexanes) to afford the title compound as a colorless solid (420 mg, 26%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.72 (d, <i>J</i> = 9 Hz, 2H), 7.39–7.69 (m, 3H), 6.20 (s, 1H), 4.01 (br s, 2H). LC-MS (ESI) <i>m</i>/<i>z</i> 161 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 5-Isopropylisoxazol-3-amine (<b>8h</b>)</h5><div class="NLM_p last">To a stirred solution of hydroxylamine hydrochloride (6.3 g, 91.7 mmol) in MeOH (2.5 mL) was added ammonia (15.7 mL of a 7 M solution in MeOH, 110 mmol), and the resulting suspension was stirred at rt for 30 min. 8-Hydroxyquinoline (290 mg, 2 mmol) was added, followed by a solution of compound <b>10a</b> (3.38 g, 22 mmol) in MeOH (2.5 mL). The mixture was heated at 70 °C for 15 h. After cooling to rt, the mixture was filtered and the filtrate concentrated under reduced pressure and reconcentrated three times from toluene to afford <i>N</i>′-hydroxy-2-(2-isopropyl-1,3-dioxolan-2-yl)acetimidamide as a yellow solid, which did not require further purification (3.9 g, 94%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.01 (br s, 2H), 3.94–4.05 (m, 4H), 2.44 (s, 2H), 1.99 (m, 1H), 0.95 (d, <i>J</i> = 12 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 189 [M + H]<sup>+</sup>. <i>N</i>′-Hydroxy-2-(2-isopropyl-1,3-dioxolan-2-yl)acetimidamide (1.8 g, 9.57 mmol) was dissolved in EtOH (12 mL) and acidified to pH 1 with 37% aqueous HCl. The mixture was placed into a 20 mL microwave vial fitted with a stirrer bar. After sealing, the reaction mixture was placed in a Biotage Microwave Synthesizer and heated (with stirring) at 120 °C for 30 min. After cooling to rt, the mixture was concentrated under reduced pressure and the residue diluted with CH<sub>2</sub>Cl<sub>2</sub>. Saturated aqueous NaHCO<sub>3</sub> solution was added until the mixture became basic (pH = 11) and the organic layer separated. The aqueous layer was further extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic layers were combined, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 20–100% EtOAc in hexanes) to afford the title compound as a solid (819 mg, 68%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.52 (s, 1H), 3.89 (br s, 2H), 2.94 (m, 1H), 1.27 (d, <i>J</i> = 12 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 127 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 5-Cyclopentylisoxazol-3-amine (<b>8i</b>)</h5><div class="NLM_p last">Prepared from compound <b>10b</b> (1.5 g, 8.3 mmol) according to the procedure described for compound <b>8h</b>, to afford the title compound as a colorless solid (875 mg, 69%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.52 (s, 1H), 3.86 (br s, 2H), 3.06 (m, 1H), 2.04 (m, 2H), 1.62–1.75 (m, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 153 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 5-(2-Fluoropropan-2-yl)isoxazol-3-amine (<b>8j</b>)</h5><div class="NLM_p last">To MeOH (10 mL) at rt was added portionwise sodium metal (145 mg, 6.30 mmol). After all of the metal had dissolved, the reaction mixture was cooled to 0 °C and hydroxylamine hydrochloride (438 mg, 6.30 mmol) was added in one portion. The reaction mixture was stirred for 15 min. A solution of compound <b>11</b> (500 mg, 3.50 mmol) in MeOH (3 mL) was added, and the mixture was heated at 70 °C for 16 h. Concentrated HCl (0.8 mL, 9.6 mmol) was added and the reaction mixture stirred at 80 °C for 30 min. After cooling to rt, the mixture was concentrated under reduced pressure to give an orange foam which was dissolved in water (50 mL) and the solution adjusted to pH 10 using aqueous 1 M sodium hydroxide solution. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>(3 × 50 mL), and the combined organic layers were washed with brine (50 mL), dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 12–100% EtOAc in hexanes) to afford the title compound as a cream solid (64 mg, 13%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 5.82 (s, 1H), 4.08 (br s, 2H), 1.71 (d, <i>J</i> = 21 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 145 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 4-Chlorophenyl 5-(1,1,1-Trifluoro-2-methylpropan-2-yl)isoxazol-3-ylcarbamate (<b>9a</b>)</h5><div class="NLM_p last">Prepared from compound <b>8a</b> (123 mg, 0.63 mmol) and 4-chlorophenyl chloroformate (180 mg, 0.95 mmol) according to General Procedure D to afford the title compound as a colorless solid (85 mg, 39%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.83 (br s, 1H), 7.38 (d, <i>J</i> = 9 Hz, 2H), 7.15 (d, <i>J</i> = 9 Hz, 2H), 6.82 (s, 1H), 1.59 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 349 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Phenyl 5-(1,3-Difluoro-2-methylpropan-2-yl)isoxazol-3-ylcarbamate (<b>9b</b>)</h5><div class="NLM_p last">Prepared from compound <b>8b</b> (287 mg, 1.6 mmol) according to General Procedure D to afford the title compound as a solid (358 mg, 76%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.17 (br s, 1H), 7.39–7.44 (m, 2H), 7.26 (m, 1H), 7.17–7.20 (m, 2H), 6.81 (s, 1H), 4.63–4.71 (m, 2H), 4.47–4.55 (m, 2H), 1.42 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 297 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Phenyl 5-(1-(Trifluoromethyl)cyclopropyl)isoxazol-3-ylcarbamate (<b>9c</b>)</h5><div class="NLM_p last">Prepared from compound <b>8c</b> (687 mg, 3.58 mmol) according to General Procedure D to afford the title compound as a colorless solid (727 mg, 65%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.34 (br s, 1H), 7.40–7.47 (m, 2H), 7.20–7.31 (m, 3H), 6.80 (s, 1H), 1.45–1.56 (m, 4H). LC-MS (ESI) <i>m</i>/<i>z</i> 313 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Phenyl 5-(1-Hydroxy-2-methylpropan-2-yl)isoxazol-3-ylcarbamate (<b>9d</b>)</h5><div class="NLM_p last">Prepared from compound <b>8d</b> (100 mg, 0.64 mmol) according to General Procedure D to afford the title compound as a colorless solid (120 mg, 68%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.30 (br s, 1H), 7.42–7.43 (m, 2H), 7.26 (m, 1H), 7.18–7.21 (m, 2H), 6.65 (s, 1H), 3.67 (s, 2H), 1.98 (br s, 1H), 1.32 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 277 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Phenyl 5-(1-Methoxy-2-methylpropan-2-yl)isoxazol-3-ylcarbamate (<b>9e</b>)</h5><div class="NLM_p last">Prepared from compound <b>8e</b> (30 mg, 0.176 mmol) according to General Procedure D to afford the title compound as an oil (50 mg, 98%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.04 (br s, 1H), 7.42–7.43 (m, 2H), 7.31 (m, 1H), 7.18–7.21 (m, 2H), 6.63 (s, 1H), 3.45 (s, 2H), 3.33 (s, 3H), 1.35 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 291 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Phenyl 5-Phenylisoxazol-3-ylcarbamate (<b>9f</b>)</h5><div class="NLM_p last">Prepared from compound <b>8f</b> (428 mg, 2.67 mmol) according to General Procedure D to afford the title compound as a colorless solid (599 mg, 80%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.92 (br s, 1H), 7.77–7.80 (m, 2H), 7.40–7.51 (m, 6H), 7.20–7.32 (m, 2H), 7.12 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i> 281 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Phenyl 5-Methylisoxazol-3-ylcarbamate (<b>9g</b>)</h5><div class="NLM_p last">Prepared from 5-methylisoxazol-3-amine <b>8g</b> (490 mg, 5.0 mmol) according to General Procedure D to afford the title compound as a solid (425 mg, 39%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.14 (s, 1H), 7.41–7.46 (m, 2H), 7.29 (d, <i>J</i> = 6 Hz, 1H), 7.21 (m, 2H), 6.47 (s, 1H), 2.38 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 219 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Phenyl 5-Isopropylisoxazol-3-ylcarbamate (<b>9h</b>)</h5><div class="NLM_p last">Prepared from compound <b>8h</b> (816 mg, 6.5 mmol) according to General Procedure D to afford the title compound as a solid (1.24 g, 77%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.05 (br s, 1H), 7.38–7.45 (m, 2H), 7.18–7.30 (m, 3H), 6.55 (s, 1H), 3.06 (m, 1H), 1.30 (d, <i>J</i> = 12 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 247 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> Phenyl 5-Cyclopentylisoxazol-3-ylcarbamate (<b>9i</b>)</h5><div class="NLM_p last">Prepared from compound <b>8i</b> (875 mg, 5.75 mmol) according to General Procedure D to afford the title compound as a colorless solid (1.4 g, 89%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.97 (br s, 1H), 7.39–7.44 (m, 2H), 7.18–7.29 (m, 3H), 6.54 (s, 1H), 3.16 (m, 1H), 2.04–2.10 (m, 2H), 1.58–1.78 (m, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 273 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 4-Chlorophenyl 5-(2-Fluoropropan-2-yl)isoxazol-3-ylcarbamate (<b>9j</b>)</h5><div class="NLM_p last">Prepared from compound <b>8j</b> (40 mg, 0.278 mmol) and 4-chlorophenyl chloroformate (54 mg, 0.28 mmol) according to General Procedure D to afford the title compound as a colorless solid (83 mg, 100%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.11 (br s, 1H), 7.36–7.40 (m, 2H), 7.12–7.17 (m, 2H), 6.83 (s, 1H), 1.76 (d, <i>J</i> = 21 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 299 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 2-(2-Isopropyl-1,3-dioxolan-2-yl)acetonitrile (<b>10a</b>)</h5><div class="NLM_p last">A stirred mixture of compound <b>5a</b> (3.12 g, 28 mmol), ethylene glycol (4.7 mL, 84 mmol), and chlorotrimethylsilane (10.6 mL, 84 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was heated at 40 °C for 15 h. After cooling to rt, aqueous 5% NaHCO<sub>3</sub> (50 mL) was added. The organic layer was separated and the aqueous phase further extracted with diethyl ether. The combined organic layers were dried over MgSO<sub>4</sub> and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 20–40% EtOAc in hexanes) to afford the title compound as a colorless oil (3.38 g, 78%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 4.16–4.21 (m, 2H), 3.99–4.07 (m, 2H), 2.69 (s, 2H), 2.07 (m, 1H), 0.96 (d, <i>J</i> = 12 Hz, 6H).</div></div><div id="sec5_1_5_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> 2-(2-Cyclopentyl-1,3-dioxolan-2-yl)acetonitrile (<b>10b</b>)</h5><div class="NLM_p last">Prepared from compound <b>5b</b> (2 g, 14.6 mmol) according to the procedure described for compound <b>10a</b> to afford the title compound as an oil (1.5 g, 57%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 4.15–4.23 (m, 2H), 4.01–4.12 (m, 2H), 2.72 (s, 2H), 2.36 (m, 1H), 1.45–1.81 (m, 8H).</div></div><div id="sec5_1_5_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 4-Fluoro-3-methoxy-4-methylpent-2-enenitrile (<b>11</b>)</h5><div class="NLM_p last">To a stirred solution of compound <b>5c</b> (1 g, 7.75 mmol) in diethyl ether (150 mL) at 0 °C was added dropwise (trimethylsilyl)diazomethane (4.65 mL of a 2.0 M solution in diethyl ether, 9.30 mmol). After warming to rt, the reaction mixture was stirred for a further 15 h. The reaction mixture was concentrated under reduced pressure to afford the title compound as a yellow oil, which did not require further purification (1 g, 90%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 4.89 (s, 1H), 4.23 (s, 3H), 1.47 (d, <i>J</i> = 21 Hz, 6H).</div></div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Preparation of Substituted Aminopyrazoles. General Procedure E</h4><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> 3-<i>tert</i>-Butyl-1-isopropyl-1<i>H</i>-pyrazol-5-amine Hydrochloride (<b>12a</b>)</h5><div class="NLM_p last">A stirred solution of isopropylhydrazine hydrochloride (500 mg, 4.54 mmol) and 4,4-dimethyl-3-oxopentanenitrile (679 mg, 5.44 mmol) in EtOH (5 mL) was heated under reflux for 15 h. After cooling to rt, the reaction mixture was concentrated under reduced pressure and the solid residue was recrystallized from a mixture of diethyl ether and petroleum ether to afford the title compound as a colorless solid (500 mg, 51%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 5.55 (s, 1H), 5.05 (br s, 2H), 3.62 (m, 1H), 1.68 (d, <i>J</i> = 6.4 Hz, 6H), 1.43 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 182 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> 3-<i>tert</i>-Butyl-1-isobutyl-1<i>H</i>-pyrazol-5-amine Hydrochloride (<b>12b</b>)</h5><div class="NLM_p last">Prepared from isobutylhydrazine hydrochloride (1 g, 8 mmol) according to General Procedure E to afford the title compound as a colorless solid (800 mg, 43%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 14.06 (br s, 1H), 6.93 (br s, 2H), 5.52 (s, 1H), 3.92 (m, 2H), 2.16 (m, 1H), 1.26 (s, 9H), 0.83 (m, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 196 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> 3-<i>tert</i>-Butyl-1-cyclohexyl-1<i>H</i>-pyrazol-5-amine Hydrochloride (<b>12c</b>)</h5><div class="NLM_p last">Prepared from cyclohexylhydrazine hydrochloride (1.5 g, 9.96 mmol) according to General Procedure E to afford the title compound as a colorless solid (1.0 g, 39%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 13.24 (br s, 1H), 7.02 (br s, 2H), 5.52 (s, 1H), 4.30 (m, 1H), 1.63–1.98 (m, 7H), 1.10–1.40 (m, 12H). LC-MS (ESI) <i>m</i>/<i>z</i> 222 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 1-Benzyl-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-amine (<b>12d</b>)</h5><div class="NLM_p last">Prepared from benzylhydrazine (977 mg, 8.0 mmol) according to General Procedure E. The crude product was purified by silica gel flash chromatography (eluting with 5% to 25% EtOAc in hexanes) to afford the title compound as a solid (666 mg, 36%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.21–7.32 (m, 3H), 7.09 (d, <i>J</i> = 9 Hz, 2H), 5.17 (s, 1H), 5.07 (s, 2H), 5.04 (s, 2H), 1.15 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 230 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 1-Phenyl-3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1<i>H</i>-pyrazol-5-amine (<b>12e</b>)</h5><div class="NLM_p last">To a stirred solution of compound <b>5f</b> (1 g, 5.58 mmol) in 50% aqueous EtOH (25 mL) was added phenylhydrazine sulfate (1.15 g, 5.58 mmol), and the reaction mixture was heated at 80 °C for 15 h. After cooling to rt, the reaction mixture was concentrated under reduced pressure and the residue was partitioned between EtOAc and aqueous 1 M sodium hydroxide. The organic layer was separated and the aqueous layer was further extracted multiple times with EtOAc. The combined organic layers were dried over MgSO<sub>4</sub> and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 7–60% EtOAc in hexanes) to afford the title compound as a yellow solid (590 mg, 40%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.30–7.59 (m, 5H), 5.53 (s, 1H), 5.37 (br s, 2 H), 1.45 (s, 6 H). LC-MS (ESI) <i>m</i>/<i>z</i> 270 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Preparation of Substituted Pyrazole Carbamates. General Procedure F</h4><div id="sec5_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> Phenyl 3-<i>tert</i>-Butyl-1-isopropyl-1<i>H</i>-pyrazol-5-ylcarbamate (<b>13a</b>)</h5><div class="NLM_p last">To a stirred mixture of phenyl chloroformate (170 mg, 1.1 mmol) and potassium carbonate (210 mg, 1.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub>(3 mL) at 0 °C was added dropwise a solution of compound <b>12a</b>(220 mg, 1 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (130 mg, 1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL), and the reaction mixture was stirred at 0 °C for 3 h. The mixture was filtered, and the filtrate was washed with water and brine and then dried over MgSO<sub>4</sub>. Concentration under reduced pressure gave a solid, which was recrystallized from diethyl ether to afford the title compound as a colorless solid (300 mg, 100%). LC-MS (ESI) <i>m</i>/<i>z</i> 302 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> Phenyl 3-<i>tert</i>-Butyl-1-isobutyl-1<i>H</i>-pyrazol-5-ylcarbamate (<b>13b</b>)</h5><div class="NLM_p last">Prepared from compound <b>12b</b> according to General Procedure F to afford the title compound as a solid. LC-MS (ESI) <i>m</i>/<i>z</i> 316 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> Phenyl 3-<i>tert</i>-Butyl-1-cyclohexyl-1<i>H</i>-pyrazol-5-ylcarbamate (<b>13c</b>)</h5><div class="NLM_p last">Prepared from compound <b>12c</b> (260 mg, 1 mmol) according to General Procedure F to afford the title compound as a solid (300 mg, 88%). LC-MS (ESI) <i>m</i>/<i>z</i> 342 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Preparation of Substituted Pyrazole Carbamates. General Procedure G</h4><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> Phenyl 3-<i>tert</i>-Butyl-1-benzyl-1<i>H</i>-pyrazol-5-ylcarbamate (<b>13d</b>)</h5><div class="NLM_p last">To a stirred mixture of compound <b>12d</b> (666 mg, 2.91 mmol) and potassium carbonate (522 mg, 3.78 mmol) in THF (10 mL) at rt was added dropwise a solution of phenyl chloroformate (499 mg, 3.2 mmol) in THF (5 mL). The reaction mixture was stirred at rt for 15 h. The mixture was partitioned between water and CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was separated, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 100% hexanes to 50% EtOAc in hexanes) to afford the title compound as a solid (565 mg, 56%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.20 (br s, 1H), 7.10–7.43 (m, 10H), 6.14 (s, 1H), 5.29 (s, 2H), 1.22 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 350 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> Phenyl 1-Phenyl-3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1<i>H</i>-pyrazol-5-ylcarbamate (<b>13e</b>)</h5><div class="NLM_p last">Prepared from compound <b>12e</b> (590 mg, 2.2 mmol) according to General Procedure G to afford the title compound as a solid (748 mg, 87%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.02–7.55 (m, 11H), 6.65 (br s, 1H), 1.60 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 390 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> Phenyl 3-<i>tert</i>-Butyl-1-methyl-1<i>H</i>-pyrazol-5-ylcarbamate (<b>13f</b>)</h5><div class="NLM_p last">Prepared from 3-<i>tert</i>-butyl-1-methyl-1<i>H</i>-pyrazol-5-amine <b>12f</b> (1.0 g, 6.5 mmol) according to General Procedure G to afford the title compound as a solid (530 mg, 30%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.20 (s, 1H), 7.40–7.49 (m, 2H), 721–7.30 (m, 3H), 6.06 (s, 1H), 3.66 (s, 3H), 1.25 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 274 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> Phenyl 3-<i>tert</i>-Butyl-1-phenyl-1<i>H</i>-pyrazol-5-ylcarbamate (<b>13g</b>)</h5><div class="NLM_p last">Prepared from 3-<i>tert</i>-butyl-1-phenyl-1<i>H</i>-pyrazol-5-amine <b>12g</b> (2.00 g, 9.3 mmol) according to General Procedure G to afford the title compound as a solid (1.3 g, 42%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.00 (s, 1H), 7.42–7.57 (m, 4H), 7.33–7.44 (m, 3H), 7.08–7.23 (m, 3H), 6.37 (s, 1H), 1.30 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 336 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> 3-(6,7-Dimethoxyquinazolin-4-yloxy)aniline (<b>16</b>)</h5><div class="NLM_p last">To a stirred slurry of cesium carbonate (28.20 g, 86 mmol) in THF (300 mL) at rt was added 3-aminophenol (4.83 g, 43 mmol). After stirring for 30 min at rt, 4-chloro-6,7-dimethoxyquinazoline (10 g, 43 mmol) was added and the reaction mixture was heated at 50 °C for 24 h. After cooling to rt, the mixture was partitioned between EtOAc and 1 M aqueous sodium hydroxide. The organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 1% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a solid (12.7 g, 100%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.55 (s, 1H), 7.51 (s, 1H), 7.37 (s, 1H), 7.09 (m, 1H), 6.38–6.49 (m, 3H), 5.30 (br s, 2H), 3.99 (s, 3H), 3.97 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 298 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> 3-(6,7-Dimethoxyquinazolin-4-ylthio)aniline (<b>17</b>)</h5><div class="NLM_p last">To a stirred slurry of sodium hydride (3.52 g of a 60% dispersion in mineral oil, 88 mmol) in THF (500 mL) at rt was added portionwise 3-aminobenzenethiol (10 g, 80 mmol). After stirring for 30 min at rt, 4-chloro-6,7-dimethoxyquinazoline (18 g, 80 mmol) was added and the reaction mixture was stirred at rt for 15 h. The mixture was partitioned between EtOAc and water, and the organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by trituration with diethyl ether to afford the title compound as a solid (21.3 g, 85%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.70 (s, 1H), 7.33 (s, 1H), 7.31 (s, 1H), 7.13 (t, <i>J</i> = 7.6 Hz, 1H), 6.81 (s, 1H), 6.67–6.74 (m, 2H), 5.35 (br s, 2H), 3.98 (s, 3H), 3.97 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 314 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Preparation of Quinazolin-4-yloxy Phenylurea Derivatives. General Procedure H</h4><div id="sec5_1_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> 1-(3-<i>tert</i>-Butylisoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>18</b>)</h5><div class="NLM_p last">To a stirred solution of compound <b>16</b> (90 mg, 0.3 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (78 μL, 0.45 mmol), and 4-(dimethylamino)pyridine (1.8 mg, 0.015 mmol) in THF (1.5 mL) was added compound <b>7j</b> (118 mg, 0.45 mmol). The reaction mixture was heated at 50 °C for 2.5 h. After cooling to rt, the mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated aqueous NaHCO<sub>3</sub>. The organic layer was separated and the aqueous layer was further extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over MgSO<sub>4</sub> and then concentrated under reduced pressure. The residue was purified by preparative reverse-phase HPLC, and the obtained solid was triturated with diethyl ether to afford the title compound as a colorless solid (41 mg, 29%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.19 (s, 1H), 9.04 (s, 1H), 8.57 (s, 1H), 7.56–7.59 (m, 2H), 7.39–7.44 (m, 2H), 7.30 (d, <i>J</i> = 9 Hz, 1H), 6.98 (d, <i>J</i> = 9 Hz, 1H),6.04 (s, 1H), 3.99 (s, 6H), 1.25 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 464 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> 1-(3-<i>tert</i>-Butyl-1-methyl-1<i>H</i>-pyrazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>19</b>)</h5><div class="NLM_p last">Prepared from compound <b>13f</b> (123 mg, 0.45 mmol) and compound <b>16</b> (89 mg, 0.30 mmol) according to General Procedure H. The crude product was purified by silica gel flash chromatography (eluting with 100% hexanes to 100% EtOAc in hexanes) to afford the title compound as a solid (102 mg, 71%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.20 (s, 1H), 8.56–8.58 (m, 2H), 7.53 (m, 2H), 7.50 (m, 2H), 7.30 (m, 1H), 6.95 (m, 1H), 6.08 (s, 1H), 3.99 (s, 6H), 3.54 (s, 3H), 1.25 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 477 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> 1-(4-<i>tert</i>-Butylphenyl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>20</b>)</h5><div class="NLM_p last">To a stirred solution of compound <b>16</b> (89 mg, 0.3 mmol) in DMF (3 mL) at rt was added 4-<i>tert</i>-butylphenyl isocyanate (54 μL, 0.3 mmol), and the mixture was heated at 50 °C for 4 h. After cooling to rt, the mixture was partitioned between EtOAc and water. The organic layer was separated and further washed with brine. The organic layer was separated, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 25% to 100% EtOAc in hexanes) to afford the title compound as a solid (54 mg, 38%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.83 (s, 1H), 8.65 (s, 1H), 8.57 (s, 1H), 7.60 (s, 1H), 7.56 (s, 1H), 7.21–7.40 (m, 7H), 6.91 (d, <i>J</i> = 6 Hz, 1H), 3.99 (s, 6H), 1.25 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 473 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> 1-(3-<i>tert</i>-Butylphenyl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>21</b>)</h5><div class="NLM_p last">A mixture of 3-<i>tert</i>-butylaniline (447 mg, 3 mmol), potassium carbonate (828 mg, 6 mmol), phenyl chloroformate (1.13 mL,9 mmol), and 4-(dimethylamino)pyridine (36 mg, 0.30 mmol) in THF (15 mL) was stirred at rt for 15 h. The reaction mixture was diluted with EtOAc, filtered, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 5–15% EtOAc in hexanes) to afford phenyl 3-<i>tert</i>-butylphenylcarbamate as a solid (458 mg, 57%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.14 (s, 1H), 7.59 (s, 1H), 7.10–7.49 (m, 7H), 7.08 (d, <i>J</i> = 9 Hz, 1H), 1.25 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 270 [M + H]<sup>+</sup>. Phenyl 3-<i>tert</i>-butylphenylcarbamate (114 mg, 0.42 mmol) and compound <b>16</b> (90 mg, 0.3 mmol) were allowed to react according to General Procedure H. The crude product was purified by silica gel flash chromatography (eluting with 25–100% EtOAc in hexanes) to afford the title compound as a solid (83 mg, 59%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.83 (s, 1H), 8.70 (s, 1H), 8.57 (s, 1H), 7.61 (s, 1H), 7.57 (s, 1H), 7.36–7.50 (m, 3H), 7.14–7.31 (m, 3H), 6.86–7.05 (m, 2H), 4.00 (s, 6H), 1.28 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 473 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea (<b>22</b>)</h5><div class="NLM_p last">Prepared from compound <b>9g</b> (98 mg, 0.42 mmol) and compound <b>16</b> (89 mg, 0.3 mmol) according to General Procedure H to afford the title compound as a solid (31 mg, 25%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.53 (s, 1H), 9.01 (s, 1H), 8.56 (s, 1H), 7.57 (s, 1H), 7.55 (s, 1H), 7.35–7.45 (m, 2H), 7.26 (d, <i>J</i> = 9 Hz, 1H), 6.97 (d, <i>J</i> = 6 Hz, 1H), 6.51 (s, 1H), 3.99 (s, 6H), 2.35 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 422 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-isopropylisoxazol-3-yl)urea (<b>23</b>)</h5><div class="NLM_p last">Prepared from compound <b>9h</b> (110 mg, 0.45 mmol) and compound <b>16</b> (90 mg, 0.3 mmol) according to General Procedure H to afford the title compound as a colorless solid (79 mg, 59%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.57 (s, 1H), 9.01 (s, 1H), 8.56 (s, 1H), 7.57 (s, 2H), 7.38–7.43 (m, 2H), 7.27 (d, <i>J =</i> 9 Hz, 1H), 6.99 (d, <i>J =</i> 9 Hz, 1H), 6.49 (s, 1H), 4.00 (s, 6H), 3.00 (m, 1H), 1.22 (d, <i>J</i> = 12 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 450 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> 1-(5-Cyclopentylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>24</b>)</h5><div class="NLM_p last">Prepared from compound <b>9i</b> (130 mg, 0.48 mmol) and compound <b>16</b> (95 mg, 0.32 mmol) according to General Procedure H to afford the title compound as a colorless solid (81 mg, 53%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.58 (s, 1H), 9.03 (s, 1H), 8.56 (s, 1H), 7.57 (s, 2H), 7.38–7.43 (m, 2H), 7.26 (d, <i>J</i> = 9 Hz, 1H), 6.97 (d, <i>J</i> = 9 Hz, 1H), 6.50 (s, 1H), 4.00 (s, 6H), 3.11 (m, 1H), 1.64–1.66 (m, 2H), 1.18–1.20 (m, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 476 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-phenylisoxazol-3-yl)urea (<b>25</b>)</h5><div class="NLM_p last">Prepared from compound <b>9f</b> (126 mg, 0.45 mmol) and compound <b>16</b> (90 mg, 0.3 mmol) according to General Procedure H to afford the title compound as a colorless solid (47 mg, 32%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.75 (s, 1H), 9.08 (s, 1H), 8.58 (s, 1H), 7.86 (d, <i>J</i> = 6 Hz, 2H), 7.51–7.87 (m, 4H), 7.40–7.51 (m, 2H), 7.21–7.31 (m, 3H), 7.00 (d, <i>J</i> = 6 Hz, 1H), 4.00 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 484 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-isopropylisoxazol-5-yl)urea (<b>26</b>)</h5><div class="NLM_p last">Prepared from compound <b>7a</b> (89 mg, 0.36 mmol) and compound <b>16</b> (89 mg, 0.30 mmol) according to General Procedure H to afford the title compound as a colorless solid (25 mg, 19%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.30 (br s, 1H), 9.14 (s, 1H), 8.56 (s, 1H), 7.57 (s, 2H), 7.39–7.44 (m, 2H), 7.31 (m, 1H), 6.99 (m, 1H), 5.99 (s, 1H), 4.00 (s, 6H), 2.90 (septet, <i>J</i> = 6 Hz, 1H), 1.19 (d, <i>J</i> = 6 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 450 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> 1-(3-Cyclopentylisoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>27</b>)</h5><div class="NLM_p last">Prepared from compound <b>7b</b> (124 mg, 0.45 mmol) and compound <b>16</b> (104 mg, 0.35 mmol) according to General Procedure H to afford the title compound as a colorless solid (75 mg, 45%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.18 (s, 1H), 9.05 (s, 1H), 8.56 (s, 1H) 7.57 (s, 2H), 7.39–7.56 (m, 2H), 7.29 (d, <i>J</i> = 9 Hz, 1H), 6.98 (d, <i>J</i> = 9 Hz, 1H), 5.95 (s, 1H), 4.00 (s, 6H), 3.03 (m, 1H), 1.93–1.99 (m, 2H), 1.61–1.69 (m, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 476 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-phenylisoxazol-5-yl)urea (<b>28</b>)</h5><div class="NLM_p last">Prepared from compound <b>7k</b> (126 mg, 0.45 mmol) and compound <b>16</b> (90 mg, 0.3 mmol) according to General Procedure H to afford the title compound as a colorless solid (63 mg, 43%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.40 (s, 1H), 9.14 (s, 1H), 8.50 (s, 1H), 7.74–7.83 (m, 2H), 7.48–7.83 (m, 7H), 7.42 (d, <i>J</i> = 9 Hz, 1H), 7.00 (d, <i>J</i> = 9 Hz, 1H), 6.56 (s, 1H), 4.00 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 484 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-hydroxy-2-methylpropan-2-yl)isoxazol-3-yl)urea (<b>29</b>)</h5><div class="NLM_p last">Prepared from compound <b>9d</b> (41 mg, 0.15 mmol) and compound <b>16</b> (30 mg, 0.10 mmol) according to General Procedure H. The crude product was purified by preparative silica gel TLC (eluting with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a colorless solid (30 mg, 63%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.57 (br s, 1H), 8.99 (br s, 1H), 8.56 (s, 1H), 7.56–7.58 (m, 2H), 7.38–7.42 (m, 2H), 7.25 (m, 1H), 6.97 (m, 1H), 6.49 (s, 1H), 4.95 (br s, 1H), 3.99 (s, 3H), 3.98 (s, 3H), 3.43 (s, 2H), 1.20 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 480 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-methoxy-2-methylpropan-2-yl)isoxazol-3-yl)urea (<b>30</b>)</h5><div class="NLM_p last">Prepared from compound <b>9e</b> (50 mg, 0.17 mmol) and compound <b>16</b> (50 mg, 0.16 mmol) according to General Procedure H. The crude product was purified by preparative silica gel TLC (eluting with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a colorless solid (38 mg, 49%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.57 (br s, 1H), 9.01 (br s, 1H), 8.56 (s, 1H), 7.57–7.58 (m, 2H), 7.38–7.42 (m, 2H), 7.25 (m, 1H), 6.97 (m, 1H), 6.50 (s, 1H), 3.99 (s, 6H), 3.38 (s, 2H), 3.23 (s, 3H), 1.24 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 494 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(trifluoromethyl)isoxazol-5-yl)urea (<b>31</b>)</h5><div class="NLM_p last">Prepared from compound <b>7e</b>(124 mg, 0.45 mmol) and compound <b>16</b> (104 mg, 0.35 mmol) according to General Procedure H to afford the title compound as a colorless solid (9 mg, 5%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.90 (br s, 1H), 9.30 (br s, 1H), 8.59 (br s, 1H), 7.20–7.80 (m, 5H), 7.06 (br s, 1H), 6.50 (s, 1H), 4.09 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 476 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> 1-(3-(1,1-Difluoroethyl)isoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>32</b>)</h5><div class="NLM_p last">Prepared from compound <b>7d</b>(141 mg, 0.52 mmol) and compound <b>16</b> (156 mg, 0.52 mmol) according to General Procedure H to afford the title compound as a colorless solid (66 mg, 27%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.70 (s, 1H), 9.17 (s, 1H), 8.56 (s, 1H), 7.56–7.57 (m, 2H), 7.39–7.45 (m, 2H), 7.33 (m, 1H), 7.00 (m, 1H), 6.27 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H), 2.00 (t, <i>J</i> = 19 Hz, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 472 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea (<b>33</b>)</h5><div class="NLM_p last">Prepared from compound <b>7c</b> (95 mg, 0.36 mmol) and compound <b>16</b> (89 mg, 0.3 mmol) according to General Procedure H, to afford the title compound as a colorless solid (63 mg, 45%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.50 (br s, 1H), 9.15 (s, 1H), 8.56 (s, 1H), 7.57–7.58 (m, 2H), 7.40–7.45 (m, 2H), 7.32 (m, 1H), 7.00 (m, 1H), 6.14 (s, 1H), 4.00 (s, 3H), 3.99 (s, 3H), 1.67 (d, <i>J</i> = 21 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 468 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> 1-[3-(1,3-Difluoro-2-methylpropan-2-yl)isoxazol-5-yl]-3-[3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl]urea (<b>34</b>)</h5><div class="NLM_p last">Prepared from compound <b>7i</b> (158 mg, 0.5 mmol) and compound <b>16</b> (119 mg, 0.4 mmol) according to General Procedure H. The crude product was purified by silica gel flash chromatography (eluting with 40–50% EtOAc in hexanes) to afford the title compound as a solid (115 mg, 58%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.33 (s, 1H), 9.00 (s, 1H), 8.55 (s, 1H), 7.55–7.58 (m, 3H), 7.39 (s, 1H), 7.26 (d, <i>J</i> = 6 Hz, 2H), 6.24 (s, 1H), 4.72–4.76 (m, 2H), 4.56–4.57 (m, 2H), 3.98 (s, 6H), 1.30 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 500 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-5-yl)urea (<b>35</b>)</h5><div class="NLM_p last">Prepared from compound <b>7f</b> (104 mg, 0.3 mmol) and compound <b>16</b> (89 mg, 0.3 mmol) according to General Procedure H. The crude product was purified by silica gel flash chromatography (eluting with 100% CH<sub>2</sub>Cl<sub>2</sub> to 50% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a colorless solid (80 mg, 52%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.44 (s, 1H), 9.11 (s, 1H), 8.56 (s, 1H), 7.56–7.58 (m, 2H), 7.40–7.45 (m, 2H), 7.31 (m, 1H), 7.01 (m, 1H), 6.18 (s, 1H), 4.00 (s, 6H), 1.24 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 518 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(1-(trifluoromethyl)cyclobutyl)isoxazol-5-yl)urea (<b>36</b>)</h5><div class="NLM_p last">Prepared from compound <b>7h</b> (147 mg, 0.45 mmol) and compound <b>16</b> (89 mg, 0.30 mmol) according to General Procedure H. The crude product was purified by silica gel flash chromatography (eluting with 100% CH<sub>2</sub>Cl<sub>2</sub> to 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a colorless solid (81 mg, 51%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.50 (br s, 1H), 9.11 (s, 1H), 8.56 (s, 1H), 7.56 (d, <i>J</i> = 2.3 Hz, 2H), 7.29–7.44 (m, 3H), 7.00 (d, <i>J</i> = 7.9 Hz, 1H), 6.08 (s, 1H), 3.99 (s, 6H), 2.50–2.56 (m, 4H), 2.02 (m, 2H). LC-MS (ESI) <i>m</i>/<i>z</i> 530 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> 1-(3-(2-Cyanopropan-2-yl)isoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>37</b>)</h5><div class="NLM_p last">Prepared from compound <b>7g</b>(90 mg, 0.332 mmol) and compound <b>16</b> (89 mg, 0.30 mmol) according to General Procedure H. The crude product was purified by silica gel flash chromatography (eluting with 100% CH<sub>2</sub>Cl<sub>2</sub> to 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a colorless solid (55 mg, 39%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.51 (br s, 1H), 9.12 (br s, 1H), 8.57 (s, 1H), 7.56–7.57 (m, 2H), 7.31–7.45 (m, 3H), 7.01 (m, 1H), 6.27 (s, 1H), 4.00 (s, 6H), 1.68 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 475 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(2-fluoropropan-2-yl)isoxazol-3-yl)urea (<b>38</b>)</h5><div class="NLM_p last">Prepared from compound <b>9j</b>(90 mg, 0.302 mmol) and compound <b>16</b> (90 mg, 0.302 mmol) according to General Procedure H. The crude product was purified by silica gel flash chromatography (eluting with 100% CH<sub>2</sub>Cl<sub>2</sub> to 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a colorless solid (37 mg, 26%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.75 (br s, 1H), 9.04 (br s, 1H), 8.56 (s, 1H), 7.56–7.58 (m, 2H), 7.40–7.41 (m, 2H), 7.29 (m, 1H), 7.00 (m, 1H), 6.86 (s, 1H), 4.00 (s, 6H), 1.72 (d, <i>J</i> = 21 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 468 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> 1-[5-(1,3-Difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-[3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl]urea (<b>39</b>)</h5><div class="NLM_p last">A mixture of compound <b>9b</b> (89 mg, 0.3 mmol), compound <b>16</b> (89 mg, 0.3 mmol), and 4-(dimethylamino)pyridine (30 mg, 0.25 mmol) in THF (6 mL) was stirred at rt for 15 h. The reaction mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and water, and the organic layer was separated, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 70–95% EtOAc in hexanes) to afford the title compound as a solid (55 mg, 31%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.70 (s, 1H), 9.02 (s, 1H), 8.57 (s, 1H), 7.57–7.58 (m, 2H), 7.38–7.43 (m, 2H), 7.27 (d, <i>J</i> = 9 Hz, 1H), 6.98 (d, <i>J</i> = 9 Hz, 1H), 6.77 (s, 1H), 4.71 (m, 2H), 4.56 (m, 2H), 4.00 (s, 3H), 3.98 (s, 3H), 1.28 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 500 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (<b>40</b>)</h5><div class="NLM_p last">To a solution of compound <b>16</b> (3.52 g, 11.9 mmol) in THF (140 mL) were added compound <b>9a</b> (4.1 g, 11.8 mmol) and 4-dimethylaminopyridine (100 mg, 0.8 mmol), and the solution was stirred at rt for 15 h before heating at 45 °C for a further 24 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 20–100% EtOAc in hexanes) to afford 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea as a colorless solid (4.55 g, 75%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.74 (s, 1H), 9.01 (s, 1H), 8.56 (s, 1H), 7.56–7.59 (m, 2H), 7.38–7.41 (m, 2H), 7.26 (m, 1H), 6.98 (m, 1H), 6.87 (s, 1H), 3.99 (s, 6H), 1.54 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 518 [M + H]<sup>+</sup>. To a stirred solution of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea (3.49 g, 6.75 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) at 0 °C was added slowly a 1 M solution of HCl in diethyl ether (13.50 mL, 13.50 mmol). A colorless precipitate was observed. After stirring for a further 5 min, the mixture was concentrated under reduced pressure. The resulting solid was triturated with diethyl ether,then filtered and dried, to afford the title compound as a colorless solid (3.25 g, 87%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.00 (br s, 1H), 9.73 (br s, 1H), 8.83 (s, 1H), 7.66 (s, 1H), 7.62 (dd, <i>J</i> = 2.1, 2.1 Hz, 1H), 7.48 (s, 1H), 7.43 (dd, <i>J</i> = 8.1, 8.1 Hz, 1H), 7.31 (m, 1H), 7.00 (m, 1H), 6.87 (s, 1H), 4.03 (s, 3H), 4.02 (s, 3H), 1.54 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 518 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-(trifluoromethyl)-cyclopropyl)isoxazol-3-yl)urea (<b>41</b>)</h5><div class="NLM_p last">Prepared from compound <b>9c</b> (112 mg, 0.36 mmol) and compound <b>16</b> (90 mg, 0.3 mmol) according to General Procedure H to afford the title compound as a solid (107 mg, 69%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.73 (s, 1H), 9.10 (s, 1H), 8.56 (s, 1H), 7.58 (s, 1H), 7.57 (s, 1H), 7.41 (t, <i>J</i> = 8.1 Hz, 1H), 7.39 (s, 1H), 7.26 (d, <i>J</i> = 6 Hz, 1H), 6.98 (d, <i>J</i> = 6 Hz, 1H), 6.85 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H), 1.56–1.41 (m, 4H). LC-MS (ESI) <i>m</i>/<i>z</i> 516 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> Preparation of Quinazolin-4-ylthio Phenylurea Derivatives. General Procedure I</h4><div id="sec5_1_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> 1-[5-(1,3-Difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-[3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl]urea (<b>42</b>)</h5><div class="NLM_p last">A mixture of compound <b>9b</b> (89 mg, 0.3 mmol), compound <b>17</b>(94 mg, 0.3 mmol), and 4-(dimethylamino)pyridine (30 mg, 0.25 mmol) in THF (6 mL) was stirred at rt for 15 h. The reaction mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and water, and the organic layer was separated, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 70–95% EtOAc in hexanes) to afford the title compound as a solid (48 mg, 31%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.71 (s, 1H), 9.02 (s, 1H), 8.70 (s, 1H), 7.85 (s, 1H), 7.45–7.54 (m, 2H), 7.28–7.36 (m, 3H), 6.78 (s, 1H), 4.72 (m, 2H), 4.56 (m, 2H), 3.99 (s, 6H), 1.29 (s, 3H). LC-MS (ESI) <i>m</i>/<i>z</i> 516 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> 1-(3-(6,7-Dimethoxyquinazolin-4-ylthio)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea (<b>43</b>)</h5><div class="NLM_p last">Prepared from compound <b>9a</b> (161 mg, 0.46 mmol) and compound <b>17</b> (144 mg,0.46 mmol) according to General Procedure I to afford the title compound as a colorless solid (134 mg, 55%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.77 (s, 1H), 9.04 (s, 1H), 8.70 (s, 1H), 7.86 (s, 1H), 7.28–7.54 (m, 5H), 6.89 (s, 1H), 3.99 (s, 6H), 1.54 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 534 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> 1-(3-(6,7-Dimethoxyquinazolin-4-ylthio)phenyl)-3-(5-(1-(trifluoromethyl)cyclopropyl)isoxazol-3-yl)urea (<b>44</b>)</h5><div class="NLM_p last">Prepared from compound <b>9c</b> (112 mg, 0.36 mmol) and compound <b>17</b> (95 mg, 0.3 mmol) according to General Procedure I to afford the title compound as a solid (108 mg, 68%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.73 (s, 1H), 9.01 (s, 1H), 8.69 (s, 1H), 7.84 (s, 1H), 7.52 (m, 1H), 7.45 (t, <i>J</i> = 9 Hz, 1H), 7.35 (s, 1H), 7.34 (s, 1H), 7.29 (d, <i>J</i> = 6 Hz, 1H), 6.86 (s, 1H), 3.99 (s, 6H), 1.45–1.56 (m, 4H). LC-MS (ESI) <i>m</i>/<i>z</i> 532 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> 1-(3-(6,7-Dimethoxyquinazolin-4-ylthio)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea (<b>45</b>)</h5><div class="NLM_p last">Prepared from compound <b>7c</b> (253 mg, 0.96 mmol) and compound <b>17</b> (200 mg, 0.64 mmol) according to General Procedure I. The crude product was purified by trituration with MeOH to afford the title compound as a colorless solid (142 mg, 46%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.43 (br s, 1H), 9.13 (br s, 1H), 8.70 (s, 1H), 7.84 (s, 1H), 7.57 (m, 1H), 7.46 (m, 1H), 7.30–7.35 (m, 3H), 6.16 (s, 1H), 3.99 (s, 6H), 1.67 (d, <i>J</i> = 21 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 484 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> 1-(3-<i>tert</i>-Butyl-1-isopropyl-1<i>H</i>-pyrazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>46</b>)</h5><div class="NLM_p last">A stirred solution of compound <b>13a</b> (150 mg, 0.50 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (80 mg, 0.62 mmol), and compound <b>16</b> (92 mg, 0.31 mmol) in THF (1 mL) was heated at 60 °C for 15 h. After cooling to rt, the reaction mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated aqueous Na<sub>2</sub>CO<sub>3</sub>. The organic phase was separated, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 2–4% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) followed by preparative reverse-phase HPLC to afford the title compound as a colorless solid (62 mg, 40%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.08 (s, 1H), 8.57 (s, 1H), 8.43 (s, 1H), 7.55–7.59 (m, 2H), 7.37–7.40 (m, 2H), 7.24 (m, 1H), 6.93 (m, 1H), 6.00 (s, 1H), 4.35 (m, 1H), 4.00 (s, 3H), 3.99 (s, 3H), 1.34 (d, <i>J</i> = 6.4 Hz, 6H), 1.24 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 505 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> 1-(3-<i>tert</i>-Butyl-1-isobutyl-1<i>H</i>-pyrazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>47</b>)</h5><div class="NLM_p last">Prepared from compound <b>13b</b> (150 mg, 0.47 mmol) and compound <b>16</b> (92 mg, 0.31 mmol) according to the procedure described for compound <b>46</b> to afford the title compound as a pale yellow solid (60 mg, 38%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.09 (s, 1H), 8.57 (s, 1H), 8.49 (s, 1H), 7.61 (m, 1H), 7.57 (m, 1H), 7.37–7.41 (m, 2H), 7.24 (m, 1H), 6.94 (m, 1H), 6.01 (s, 1H), 4.00 (s, 3H), 3.99 (s, 3H), 3.71 (d, <i>J</i> = 7.6 Hz, 2H), 2.07 (m, 1H), 1.20 (s, 9H), 0.83 (d, <i>J</i> = 6.4 Hz, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 519 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> 1-(3-<i>tert</i>-Butyl-1-cyclohexyl-1<i>H</i>-pyrazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>48</b>)</h5><div class="NLM_p last">Prepared from compound <b>13c</b> (200 mg, 0.58 mmol) and compound <b>16</b> (80 mg, 0.26 mmol) according to the procedure described for compound <b>46</b> to afford the title compound as a pale yellow solid (55 mg, 39%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.10 (s, 1H), 8.57 (s, 1H), 8.47 (s, 1H), 7.57–7.60 (m, 2H), 7.37–7.41 (m, 2H), 7.24 (m, 1H), 6.93 (m, 1H), 6.01 (s, 1H), 4.00 (s, 3H), 3.99 (s, 3H), 3.94 (m, 1H), 1.62–1.82 (m, 8H), 1.24–1.35 (m, 2H), 1.24 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 545 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> 1-(3-<i>tert</i>-Butyl-1-phenyl-<i>1H-</i>pyrazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>49</b>)</h5><div class="NLM_p last">Prepared from compound <b>13g</b> (151 mg, 0.45 mmol) and compound <b>16</b> (89 mg, 0.30 mmol) according to General Procedure H. The crude product was purified by silica gel flash chromatography (eluting with 100% hexanes to 85% EtOAc in hexanes) to afford the title compound as a solid (68 mg, 42% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.13 (s, 1H), 8.55 (s, 1H), 8.47 (s, 1H), 7.52–7.55 (m, 6H), 7.36–7.40 (m, 3H), 7.15 (s, 1H), 6.92 (d, <i>J</i> = 7.9 Hz, 1H), 6.36 (s, 1H), 4.00 (s, 6H), 1.25 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 539 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135"> 1-(1-Benzyl-3-<i>tert</i>-butyl-1<i>H</i>-pyrazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea (<b>50</b>)</h5><div class="NLM_p last">Prepared from compound <b>13d</b> (105 mg, 0.30 mmol) and compound <b>16</b> (90 mg, 0.30 mmol) according to General Procedure H to afford the title compound as a solid (50 mg, 30%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.00 (s, 1H), 8.59 (br s, 2H), 7.58–6.93 (m, 11H), 6.16 (s, 1H), 5.20 (br s, 2H), 3.98 (s, 6H), 1.21 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 553 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(1-phenyl-3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1<i>H</i>-pyrazol-5-yl)urea (<b>51</b>)</h5><div class="NLM_p last">Prepared from compound <b>13e</b> (104 mg, 0.27 mmol) and compound <b>16</b> (89 mg, 0.3 mmol) according to the procedure described for compound <b>46</b> to afford the title compound as a solid (103 mg, 64%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.28 (s, 1H), 8.55–8.59 (m, 2H), 7.34–7.57 (m, 9H), 7.17 (d, <i>J</i> = 9 Hz, 1H), 6.94 (d, <i>J</i> = 9 Hz, 1H), 6.55 (s, 1H), 4.02 (s, 6H), 1.56 (s, 6H). LC-MS (ESI) <i>m</i>/<i>z</i> 593 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> 1-(1-<i>tert</i>-Butyl-1<i>H</i>-pyrazol-4-yl)-3-(3-hydroxyphenyl)urea (<b>53</b>)</h5><div class="NLM_p last">To a stirred solution of 1-<i>tert</i>-butyl-1<i>H</i>-pyrazol-4-amine (995 mg, 7.16 mmol) in THF (20 mL) were added phenyl chloroformate (1.25 g, 8.02 mmol) and potassium carbonate (1.32 g, 9.52 mmol), and the reaction mixture was stirred at rt for 15 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with brine. The organic layer was separated, dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure to afford phenyl 1-<i>tert</i>-butyl-1<i>H</i>-pyrazol-4-ylcarbamate as a solid which did not require further purification (1.65 g, 89%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.85 (1H, s), 7.37–7.45 (m, 5H), 7.16–7.19 (m, 2H), 1.60 (s, 9H). To a solution of phenyl 1-<i>tert</i>-butyl-1<i>H</i>-pyrazol-4-ylcarbamate (782 mg, 3.02 mmol) in THF (10 mL) was added 3-aminophenol (329 mg, 3.02 mmol), and the mixture was heated in a sealed vial at 120 °C for 2 h. After cooling to rt, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc, and the solution was washed with water and brine. The organic layer was dried over MgSO<sub>4</sub> and then concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (eluting with 2–20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound as a solid (169 mg, 20%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.25 (s, 1H), 8.48 (s, 1H), 8.20 (s, 1H), 7.80 (s, 1H), 7.39 (s, 1H), 6.98–7.03 (m, 2H), 6.77 (d, <i>J</i> = 7.9 Hz, 1H), 6.35 (d, <i>J</i> = 7.9 Hz, 1H), 1.49 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 275 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> 1-(1-<i>tert</i>-Butyl-1<i>H</i>-pyrazol-4-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl) Urea (<b>54</b>)</h5><div class="NLM_p last">A mixture of compound <b>53</b> (169 mg, 0.62 mmol) and cesium carbonate (403 mg, 1.24 mmol) in THF (8 mL) was stirred at rt for 1 h. 4-Chloro-6,7-dimethoxyquinazoline (138 mg, 0.62 mmol) was added, and the mixture was heated at 55 °C for 15 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative reverse-phase HPLC to afford the title compound as a colorless solid (122 mg, 43%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.86 (s, 1H), 8.55 (s, 1H), 8.40 (s, 1H), 7.80 (s, 1H), 7.59 (s, 1H), 7.54 (s, 1H), 7.35–7.40 (m, 3H), 7.23 (d, <i>J</i> = 9 Hz, 1H), 6.88 (d, <i>J</i> = 6 Hz, 1H), 3.98 (s, 6H), 1.50 (s, 9H). LC-MS (ESI) <i>m</i>/<i>z</i> 463 [M + H]<sup>+</sup>.</div></div></div></div><div id="sec10" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> Biology</h3><div id="sec5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> Kinase Competition Binding Assays</h4><div class="NLM_p last">KINOME<i>scan</i> competition binding assays (<a href="http://www.kinomescan.com" class="extLink">www.kinomescan.com</a>) were performed as described previously.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Kinases were produced displayed on T7 phage or by expression in HEK-293 cells and tagged with DNA. Binding reactions were performed at rt for 1 h, and the fraction of kinase not bound to test compound was determined by capture with an immobilized affinity ligand and quantitation by quantitative PCR. Each kinase was tested individually against each compound. <i>K</i><sub>d</sub> values were determined using eleven serial 3-fold dilutions and presented as mean values from experiments performed in duplicate. Variability between individual values was less than 2-fold.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> A375 Cell Phospho-MEK Inhibition Assay</h4><div class="NLM_p last">In order to quantify cellular inhibition of BRAF<sup>V600E</sup>, the A375 human melanoma cell line which carries this activating mutation was acquired from the American Type Culture Collection. The cells were seeded at 50,000 per well in a 96-well plate in DMEM (Dulbecco’s Modification of Eagle’s Medium) (Mediatech) with 10% of Fetal Calf Serum (Omega Scientific) and allowed to attach for at least 6 h. The cells were then washed once with PBS (phosphate buffered saline) and incubated overnight in DMEM with 0.5% of serum. Compounds of interest were added at various concentrations to the cells, and the final DMSO concentration was maintained at 0.5%. The cells were incubated with compounds for 2 h before being washed and lysed using cell extraction buffer (Invitrogen, # FNN0011). Phosphor-MEK Elisa assays were carried out per manufacture’s specifications (Biosources, KHO0321). Total MEK Elisa assays from the same lysates were also run in parallel and used for normalization of the phosphor- signal (Biosource, KHO0291). IC<sub>50</sub> values were derived using a 9-point curve fitted with Igor Pro (WaveMetrics, Inc.) and are presented as mean values from experiments performed in duplicate. Variability between individual values was less than 2-fold.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> A375 Cell Proliferation Assay</h4><div class="NLM_p last">A375 cells were seeded at 10,000 cells per well in DMEM with 10% fetal calf serum and allowed to attach. The cells were washed with PBS and switched to DMEM with 0.5% of serum and incubated overnight. The test compounds were then added at various concentrations with a final DMSO concentration of 0.5% and incubated for 72 h. At the end of incubation, a Cell Titer Blue (Promega, Madison, WI) was added per instructions, and incubation was continued for 3 h. Remaining viable cells were quantified by measuring the strength of the fluorescence signal using SoftMax Pro (excitation at 560 nm and emission at 590 nm). IC<sub>50</sub> values were derived using a 9-point curve fitted with Igor Pro (WaveMetrics, Inc.) and are presented as mean values from experiments performed in duplicate. Variability between individual values was less than 2-fold.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> Cellular Cytotoxicity Assays</h4><div class="NLM_p last">For a comparison of activity in mutated versus wild-type BRAF cell lines, A375, Colo-679, SK-MEL-28, HT-144, Colo-205, HCT 116, Hs578T, LNCaP, DU 145, and PC-3 cell lines were obtained from and cultured in media recommended by ATCC (Manassas, VA). All cell lines were MAP (Mouse Antibody Production) and mycoplasma-tested and deemed contaminant-free prior to <i>in vitro</i> and <i>in vivo</i> studies. Cells were cultured in 0.5% serum overnight prior to incubation with test compound for 72 h, followed by addition of Cell Titer Blue (Promega, Madison, WI) to detect viable cells after3 h incubation with reagent. Concentration–response curves were generated from the fluorometric product, and EC<sub>50</sub> values were determined. Each experiment was conducted in duplicate and repeated at least once.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> Microsomal Stability Determinations</h4><div class="NLM_p last">Pooled liver microsomes for rat, dog, cynomolgus monkey (In Vitro Technologies, Baltimore, MD), and human (CellzDirect, Dallas, TX) (0.5 mg/mL), 0.1 M phosphate buffer pH 7.4, 6.5 mM MgCl<sub>2</sub>, and test compound (1 μM; 0.2% final DMSO concentration) were premixed prior to the addition of NADPH (1 mM) to initiate the reaction. A minus NADPH control and testosterone positive control were included. All incubations were carried out at 37 °C. All incubations were performed in duplicate. Aliquots (50 μL) were taken at 0, 5, 15, 30, and 60 min and added to 200 μL acetonitrile containing an internal standard to quench the reaction. Samples were diluted with 100 μL 50/50 acetonitrile/water, vortexed, and centrifuged at 36,000 rpm for 10 min at 4 °C to precipitate the protein. The sample supernatants were analyzed by LC-MS/MS. The <i>t</i> = 0 time point normalized peak area was set to 100%, and the natural log of the percent compound remaining was plotted versus time. The elimination rate constant (<i>k</i><sub>el</sub>) was determined by linear regression. Half-life (<i>t</i><sub>1/2</sub>) and intrinsic clearance (Cl<sub>int</sub>) were calculated using the following equations: <i>t</i><sub>1/2</sub> = 0.693/<i>k</i><sub>el</sub> and CL<sub>int</sub> (μL/min/mg protein) = 0.693<i>V</i>/<i>t</i><sub>1/2</sub>, where <i>V</i> is expressed as μL/mg protein. All microsomes were stored at −80 °C before use.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> CYP450 Inhibition Assays</h4><div class="NLM_p last">Pooled human liver microsomes (male and female) were purchased from CellzDirect, Dallas, TX (lot HMMC-PL020). The CYP450 inhibition assay was multiplexed, such that individual CYP substrates at 5-fold stock concentration were used, including testosterone (375 μM), diclofenac (80 μM), dextromethorphan (40 μM), mephenytoin (255 μM), and phenacetin (390 μM). Equivolume amounts of the five substrates were mixed to prepare the pooled substrate stock solution. Individual control CYP inhibitors at 5-fold stock concentration were used, including ketoconazole (2.5 μM), sulfaphenazole (10 μM), quinidine (1 μM), ticlopidine (1 μM), and furafylline (0.6 μM). Equivolume amounts of the five control inhibitors were mixed to prepare the pooled inhibitor stock solution. Eight test inhibitor concentrations (0.31, 0.62, 1.25, 2.5, 5, 10, 20, and 40 μM in DMSO; 0.2% final DMSO concentration) were incubated with human liver microsomes (0.25 mg/mL) and NADPH (1 mM) in the presence of the five pooled CYP probe substrates for 20 min at 37 °C. The five pooled CYP inhibitors were screened as positive controls in parallel with test compounds. Reactions were terminated by the addition of 3:1 acetonitrile/water containing 0.05% formic acid and an internal standard and centrifuged, and the formation of the five CYP isoform-specific metabolites was monitored by LC-MS/MS.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> hERG Inhibition Assay</h4><div class="NLM_p last">Assays were performed at Aviva Biosciences (San Diego, CA). Aviva’s CHO cell line, which stably expresses hERG channels, was employed. Cells were cultured in DMEM/F12 containing 10% FBS (fetal bovine serum), 1% penicillin/streptomycin, and 500 μg/mL Geneticin. Before testing, cells were harvested using Accumax (Innovative Cell Technologies). For electrophysiology experiments, whole cell recordings were performed using PX7000A (Molecular Devices) with Aviva’s SealChip technology. An external solution containing 0.1% DMSO (vehicle) was applied to the cells to establish a baseline. After allowing the current to stabilize for 3–10 min, the test article was applied. Test article solutions and cells were kept in test solution until the effect of the test article reached steady state, to a maximum of 12 min. Next, 1 μM of cisapride (positive control) was added. Finally, washout with external solution was performed until the recovery current reached steady state. Data analysis was performed using DataXpress (Molecular Devices), Clampfit (Molecular Devices), and Origin (OriginLab) software.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> Rodent Pharmacokinetic Studies</h4><div class="NLM_p last">Pharmacokinetic (PK) studies were conducted in accordance with the ILAR Guide for the Care and Use of Laboratory Animals and the USDA Animal Welfare Act and Cephalon Inc. IACUC guidelines. In pharmacokinetic assays, precatheterized (jugular vein) male Sprague–Dawley rats (Charles River, Hollister, CA, 250–350 g, <i>n</i> = 2 (iv) and 3 (po) animals) or female athymic nude mice (Charles River; San Diego, CA, 20–25 g, <i>n</i> = 3 animals) were administered a single dose of compound either iv or po formulated in either a screening vehicle (Pharmatek #6 of the Hot Rod Chemistry vehicle series; Pharmatek, Inc., San Diego, CA) or a safety vehicle, 3:1 PEG400/water or 22–50% HPβCD, at various doses (calculated as free base equivalents), following a minimum of 2 days acclimation to the vivarium. Blood samples were collected at 5 (iv only), 15, and 30 min and 1, 2, 4, 6, and 24 h into K3EDTA tubes and kept on ice until centrifugation. Following centrifugation, plasma was pipetted into 96 well plates and stored at −20 °C for LC-MS analysis. Compound levels in plasma were quantitatively analyzed by LC-MS/MS (API 4000-Qtrap, Applied Biosystems) following protein precipitation with acetonitrile containing an internal standard, and PK parameters were calculated from the normalized LC-MS/MS peak areas using a noncompartmental model with WinNonlin version 5.2, using the linear trapezoidal estimation method. The mean parameters were calculated using plasma concentration–time data for individual animals.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> Dog and Monkey Pharmacokinetic Studies</h4><div class="NLM_p last">Compound <b>40</b> was administered to nondrug-naive male cynomolgus monkeys weighing between 2.6 and 3.4 kg and to beagle dogs weighing between 10.3 and 11.9 kg. Animals received a single 10 mg/kg po dose and a single 1 mg/kg IV dose (<i>n</i> = 3 animals) in a crossover design with a minimum 7 day washout period separating successive phases of dosing. All oral doses were free base equivalents formulated in 22% HPβCD administered <i>via</i> nasogastric gavage at a fixed volume of 3 mL/kg (monkeys) and 1 mL/kg (dogs). Intravenous doses were prepared in the same vehicle and administered as bolus injection <i>via</i> saphenous vein at a fixed volume of 0.5 mL/kg. Animals were fasted overnight prior to dosing and through approximately 4 h post dose for a total fasting time of 18–23 h. During all phases of dosing, blood samples for pharmacokinetic profiling were collected <i>via</i> a femoral vein immediately prior to dosing and at preselected time points through 24 h post dose. Concentrations of compound <b>40</b> in plasma samples were determined by LC-MS/MS following acetonitrile precipitation of proteins. PK parameters were calculated from the normalized LC-MS/MS peak areas using a noncompartmental model with WinNonlin version 5.2, using the linear trapezoidal estimation method. The mean parameters were calculated using plasma concentration–time data for individual animals.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> Mouse Tumor Xenograft Efficacy Studies</h4><div class="NLM_p last">All efficacy studies were conducted in accordance with the ILAR Guide for the Care and Use of Laboratory Animals and the USDA Animal Welfare Act and Cephalon Inc. IACUC guidelines. The Colo-205 cell line was obtained from ATCC (Manassas, VA). Six to eight week old athymic nu/nu nude mice (Charles River; San Diego, CA, 20–25 g) were inoculated subcutaneously with Colo-205 tumor cells (1 × 10<sup>6</sup>/mouse) in the right flank. Upon reaching an average tumor volume of 150–200 mm<sup>3</sup> (10–12 days post implantation), animals were randomized into treatment groups (<i>n</i> = 10 mice/group). Each group was dosed orally for 14 days with either vehicle only (22% HPβCD) or with compound <b>40</b> at 10, 30, or 100 mg/kg twice daily (BID), and each dose of drug was given in a volume of 0.1 mL per 20 g of body weight, adjusted for the body weight of the animal. Tumor volumes were measured three times weekly using vernier calipers, and volumes were calculated using the following formula: tumor volume (mm<sup>3</sup>) = <i>W</i><sup>2</sup>(<i>L</i>/2), where <i>W</i> = width and <i>L</i> = length in mm. The reported incidence of partial tumor regressions refers to the percent of tumor bearing mice showing a reduction in tumor volume (from initial tumor volume) in 3 or more successive tumor measurements, culminating in tumors whose final volume is smaller than the starting tumor volume but that are still palpable, measurable tumors. Mice were monitored for signs of morbidity (behavioral abnormalities and body weight loss). Upon discontinuation of dosing, animals were evaluated for a period of 7–10 days to assess any potential residual side effects of treatment.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> Mouse Tumor Pharmacodynamic–Pharmacokinetic Studies</h4><div class="NLM_p last">Studies were conducted in accordance with the ILAR Guide for the Care and Use of Laboratory Animals and the USDA Animal Welfare Act and Cephalon Inc. IACUC guidelines. Athymic nude mice bearing Colo-205 subcutaneous tumors were treated with a single oral dose of vehicle (22% HPβCD) or compound <b>40</b> (10, 30, and 55 mg/kg, dosed in 22% HPβCD). At appropriate time points over a 24 h period, animals were sacrificed and plasma and tumor samples were collected and lysates prepared. Amounts of total MEK and pMEK in tumor lysates were measured by immunoblotting and ELISA methods. Compound levels in plasma and tumor tissue samples were analyzed and quantitated by LC-MS/MS. Values given are mean ± SEM from two studies, <i>n</i> = 3 tumor-bearing mice per time point per study.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> Computational Chemistry: Ligand Docking Studies</h4><div class="NLM_p last">The computational work was carried out using the Schrödinger/Maestro molecular modeling package (Maestro Version 9.1.107, Schrödinger, LLC, New York, NY). The essential steps in the current docking experiment were (1) preparation of two DFG-out BRAF structures from the Protein Data Bank (PDB) (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1uwh">1uwh</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1uwj">1uwj</a>),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> using the Maestro protein preparation workflow, (2) creation of a grid around the ligand, (3) preparation of ligands <b>4</b>, <b>22</b>, <b>25</b>, <b>30</b>, and <b>40</b> using the LigPrep module, (4) use of Glide/XP docking to keep the top 10 binding poses for each compound, and (5) selection of the binding mode using our previously described knowledge based approach.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(22)</a></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i152"><a href="/doi/suppl/10.1021/jm2009925">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74173" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74173" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The complete list of the 290 individual wild-type kinase targets used for the KINOME<i>scan</i> selectivity profiling of the compounds. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm2009925/suppl_file/jm2009925_si_001.pdf">jm2009925_si_001.pdf (119.67 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm2009925" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04607" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04607" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin W. Rowbottom</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6c011e031b0e03181803012c0d010e05180e0503420f030142"><span class="__cf_email__" data-cfemail="4429362b33262b30302b29042529262d30262d2b6a272b296a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raffaella Faraoni</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi Chao</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian T. Campbell</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andiliy G. Lai</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eduardo Setti</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maiko Ezawa</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kelly G. Sprankle</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sunny Abraham</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lan Tran</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Struss</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Gibney</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert C. Armstrong</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ruwanthi N. Gunawardane</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ronald R. Nepomuceno</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ianina Valenta</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen Hua</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael F. Gardner</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Merryl D. Cramer</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dana Gitnick</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darren E. Insko</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julius L. Apuy</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Jones-Bolin</span> - <span class="hlFld-Affiliation affiliation">Cephalon,
Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arup K. Ghose</span> - <span class="hlFld-Affiliation affiliation">Cephalon,
Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Torsten Herbertz</span> - <span class="hlFld-Affiliation affiliation">Cephalon,
Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Ator</span> - <span class="hlFld-Affiliation affiliation">Cephalon,
Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce D. Dorsey</span> - <span class="hlFld-Affiliation affiliation">Cephalon,
Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce Ruggeri</span> - <span class="hlFld-Affiliation affiliation">Cephalon,
Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Williams</span> - <span class="hlFld-Affiliation affiliation">Cephalon,
Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shripad Bhagwat</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joyce James</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark W. Holladay</span> - <span class="hlFld-Affiliation affiliation">Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack" id="ACK-d155e7208-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i153">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78863" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78863" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Paul Gallant, Mazen W. Karaman, Antonio Torres, Gabriel Pallares, and the KINOME<i>scan</i> team for the generation of <i>K</i><sub>d</sub> and kinome selectivity data. We also thank Dan Treiber (of KINOME<i>scan</i>), Patrick P. Zarrinkar, Wendell Wierenga, and John P. Mallamo for their valued insight and support. KINOME<i>scan</i> is a division of DiscoveRx Corporation.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i154" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i154"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i155" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i155"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absoption–distribution–metabolism–excretion</p></td></tr><tr><td class="NLM_term">BRAF</td><td class="NLM_def"><p class="first last">V-RAF murine sarcoma viral oncogene homologue B1</p></td></tr><tr><td class="NLM_term">CYP450</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular regulated kinase</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-à-go-go related gene</p></td></tr><tr><td class="NLM_term">HPβCD</td><td class="NLM_def"><p class="first last">2-hydroxypropyl-beta-cyclodextrin</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase/extracellular regulated kinase kinase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">RAF</td><td class="NLM_def"><p class="first last">rapidly growing fibrosarcoma</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i156">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 22 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Peyssonnaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eychéne, A.</span><span> </span><span class="NLM_article-title">The Raf/MEK/ERK pathway: New concepts of activation</span> <span class="citation_source-journal">Biol. Cell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1016%2FS0248-4900%2801%2901125-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=11730323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=53-62&author=C.+Peyssonnauxauthor=A.+Eych%C3%A9ne&title=The+Raf%2FMEK%2FERK+pathway%3A+New+concepts+of+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Raf/MEK/ERK pathway: New concepts of activation</span></div><div class="casAuthors">Peyssonnaux, Carole; Eychene, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  The Raf/MEK/ERK signaling was the first MAP kinase cascade to be characterized.  It is probably one of the most well known signal transduction pathways among biologists because of its implication in a wide variety of cellular functions as diverse -and occasionally contradictory- as cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis.  Discovery and understanding of this pathway have benefited from the combination of both genetic studies in worms and flies and biochem. studies in mammalian cells.  However, ten years after, this field is still under debate and new mol. partners in the cascade continue to increase the complexity of its regulation.  This review deals with the emergence of new concepts in the activation and regulation of the Raf/MEK/ERK module.  In particular, the preponderant role of B-Raf is underlined, and the role of novel regulators such as KSR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyjiXSFlBQ6rVg90H21EOLACvtfcHk0ljdNPJDBXD0Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D&md5=cde3db5b205a1305dc2e6262deea65ec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0248-4900%2801%2901125-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0248-4900%252801%252901125-X%26sid%3Dliteratum%253Aachs%26aulast%3DPeyssonnaux%26aufirst%3DC.%26aulast%3DEych%25C3%25A9ne%26aufirst%3DA.%26atitle%3DThe%2520Raf%252FMEK%252FERK%2520pathway%253A%2520New%2520concepts%2520of%2520activation%26jtitle%3DBiol.%2520Cell.%26date%3D2001%26volume%3D93%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the <i>BRAF</i> gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0ljdNPJDBXD0Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.-S.</span><span> </span><span class="NLM_article-title">Clinicopathologic significance of <i>BRAF</i> V600E mutation in papillary carcinomas of the thyroid: A meta-analysis</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=38-46&author=J.+H.+Leeauthor=E.-S.+Leeauthor=Y.-S.+Kim&title=Clinicopathologic+significance+of+BRAF+V600E+mutation+in+papillary+carcinomas+of+the+thyroid%3A+A+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DE.-S.%26aulast%3DKim%26aufirst%3DY.-S.%26atitle%3DClinicopathologic%2520significance%2520of%2520BRAF%2520V600E%2520mutation%2520in%2520papillary%2520carcinomas%2520of%2520the%2520thyroid%253A%2520A%2520meta-analysis%26jtitle%3DCancer%26date%3D2007%26volume%3D110%26spage%3D38%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Samowitz, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertsen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtaugh, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slattery, M. L.</span><span> </span><span class="NLM_article-title">Poor survival associated with the <i>BRAF</i> V600E mutation in microsatellite-stable colon cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">6063</span><span class="NLM_x">–</span> <span class="NLM_lpage">6069</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=6063-6069&author=W.+S.+Samowitzauthor=C.+Sweeneyauthor=J.+Herrickauthor=H.+Albertsenauthor=T.+R.+Levinauthor=M.+A.+Murtaughauthor=R.+K.+Wolffauthor=M.+L.+Slattery&title=Poor+survival+associated+with+the+BRAF+V600E+mutation+in+microsatellite-stable+colon+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamowitz%26aufirst%3DW.%2BS.%26aulast%3DSweeney%26aufirst%3DC.%26aulast%3DHerrick%26aufirst%3DJ.%26aulast%3DAlbertsen%26aufirst%3DH.%26aulast%3DLevin%26aufirst%3DT.%2BR.%26aulast%3DMurtaugh%26aufirst%3DM.%2BA.%26aulast%3DWolff%26aufirst%3DR.%2BK.%26aulast%3DSlattery%26aufirst%3DM.%2BL.%26atitle%3DPoor%2520survival%2520associated%2520with%2520the%2520BRAF%2520V600E%2520mutation%2520in%2520microsatellite-stable%2520colon%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D6063%26epage%3D6069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Houben, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terheyden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bröcker, E.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, U. R.</span><span> </span><span class="NLM_article-title">Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis</span> <span class="citation_source-journal">J. Carcinog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1186%2F1477-3163-3-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=15046639" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=6-18&author=R.+Houbenauthor=J.+C.+Beckerauthor=A.+Kappelauthor=P.+Terheydenauthor=E.-B.+Br%C3%B6ckerauthor=R.+Goetzauthor=U.+R.+Rapp&title=Constitutive+activation+of+the+Ras-Raf+signaling+pathway+in+metastatic+melanoma+is+associated+with+poor+prognosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1186%2F1477-3163-3-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1477-3163-3-6%26sid%3Dliteratum%253Aachs%26aulast%3DHouben%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DKappel%26aufirst%3DA.%26aulast%3DTerheyden%26aufirst%3DP.%26aulast%3DBr%25C3%25B6cker%26aufirst%3DE.-B.%26aulast%3DGoetz%26aufirst%3DR.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26atitle%3DConstitutive%2520activation%2520of%2520the%2520Ras-Raf%2520signaling%2520pathway%2520in%2520metastatic%2520melanoma%2520is%2520associated%2520with%2520poor%2520prognosis%26jtitle%3DJ.%2520Carcinog.%26date%3D2004%26volume%3D3%26spage%3D6%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Cantwell-Dorris, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Leary, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheils, O. M.</span><span> </span><span class="NLM_article-title">BRAF<sup>V600E</sup>: Implications for carcinogenesis and molecular therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1158%2F1535-7163.MCT-10-0799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=21388974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVCku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=385-394&author=E.+R.+Cantwell-Dorrisauthor=J.+J.+O%E2%80%99Learyauthor=O.+M.+Sheils&title=BRAFV600E%3A+Implications+for+carcinogenesis+and+molecular+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">BRAFV600E: Implications for Carcinogenesis and Molecular Therapy</span></div><div class="casAuthors">Cantwell-Dorris, Emma R.; O'Leary, John J.; Sheils, Orla M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-394</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is frequently mutated in human cancer.  This pathway consists of a small GTP protein of the RAS family that is activated in response to extracellular signaling to recruit a member of the RAF kinase family to the cell membrane.  Active RAF signals through MAP/ERK kinase to activate ERK and its downstream effectors to regulate a wide range of biol. activities including cell differentiation, proliferation, senescence, and survival.  Mutations in the v-raf murine sarcoma viral oncogenes homolog B1 (BRAF) isoform of the RAF kinase or KRAS isoform of the RAS protein are found as activating mutations in approx. 30% of all human cancers.  The BRAF pathway has become a target of interest for mol. therapy, with promising results emerging from clin. trials.  Here, the role of the most common BRAF mutation BRAFV600E in human carcinogenesis is investigated through a review of the literature, with specific focus on its role in melanoma, colorectal, and thyroid cancers and its potential as a therapeutic target.  Mol Cancer Ther; 10(3); 385-94.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcfrh5aNWzwbVg90H21EOLACvtfcHk0lg8nOvve15TMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVCku7o%253D&md5=dbe88681162d6cc363205028606ccba5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0799%26sid%3Dliteratum%253Aachs%26aulast%3DCantwell-Dorris%26aufirst%3DE.%2BR.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BJ.%26aulast%3DSheils%26aufirst%3DO.%2BM.%26atitle%3DBRAFV600E%253A%2520Implications%2520for%2520carcinogenesis%2520and%2520molecular%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D385%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="note"><p class="first last">Select examples include the following:</p></div><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ramurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costales, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashash, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renhowe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhagen, J.</span><span> </span><span class="NLM_article-title">Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3286</span><span class="NLM_x">–</span> <span class="NLM_lpage">3289</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3286-3289&author=S.+Ramurthyauthor=M.+Aikawaauthor=P.+Amiriauthor=A.+Costalesauthor=A.+Hashashauthor=J.+M.+Jansenauthor=S.+Linauthor=S.+Maauthor=P.+A.+Renhoweauthor=C.+M.+Shaferauthor=S.+Subramanianauthor=L.+Sungauthor=J.+Verhagen&title=Design+and+synthesis+of+5%2C6-fused+heterocyclic+amides+as+Raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DAikawa%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DCostales%26aufirst%3DA.%26aulast%3DHashash%26aufirst%3DA.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DSung%26aufirst%3DL.%26aulast%3DVerhagen%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%25205%252C6-fused%2520heterocyclic%2520amides%2520as%2520Raf%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3286%26epage%3D3289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrendt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malesky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newhouse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddatz, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturgis, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span> </span><span class="NLM_article-title">Pyrazolopyridine inhibitors of B-Raf<sup>V600E</sup>. Part 1: The development of selective, orally available, and efficacious inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml200025q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=342-347&author=S.+Wenglowskyauthor=L.+Renauthor=K.+A.+Arrendtauthor=E.+R.+Lairdauthor=I.+Aliagasauthor=B.+Alickeauthor=A.+J.+Buckmelterauthor=E.+F.+Chooauthor=V.+Dinkelauthor=B.+Fengauthor=S.+L.+Gloorauthor=S.+E.+Gouldauthor=S.+Grossauthor=J.+Gunzner-Tosteauthor=J.+D.+Hansenauthor=G.+Hatzivassiliouauthor=B.+Liuauthor=K.+Maleskyauthor=S.+Mathieuauthor=B.+Newhouseauthor=N.+J.+Raddatzauthor=Y.+Ranauthor=S.+Ranaauthor=N.+Randolphauthor=T.+Risomauthor=J.+Rudolphauthor=S.+Savageauthor=L.+T.+Selbyauthor=M.+Shragauthor=K.+Songauthor=H.+L.+Sturgisauthor=W.+C.+Voegtliauthor=Z.+Wenauthor=B.+S.+Willisauthor=R.+D.+Woessnerauthor=W.-I.+Wuauthor=W.+B.+Youngauthor=J.+Grina&title=Pyrazolopyridine+inhibitors+of+B-RafV600E.+Part+1%3A+The+development+of+selective%2C+orally+available%2C+and+efficacious+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1021%2Fml200025q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200025q%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DArrendt%26aufirst%3DK.%2BA.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DMalesky%26aufirst%3DK.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNewhouse%26aufirst%3DB.%26aulast%3DRaddatz%26aufirst%3DN.%2BJ.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DRandolph%26aufirst%3DN.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DSelby%26aufirst%3DL.%2BT.%26aulast%3DShrag%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DWillis%26aufirst%3DB.%2BS.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DGrina%26aufirst%3DJ.%26atitle%3DPyrazolopyridine%2520inhibitors%2520of%2520B-RafV600E.%2520Part%25201%253A%2520The%2520development%2520of%2520selective%252C%2520orally%2520available%252C%2520and%2520efficacious%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D342%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miknis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rast, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlachter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callejo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbraith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span> </span><span class="NLM_article-title">Non-oxime inhibitors of B-Raf<sup>V600E</sup> kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1243</span><span class="NLM_x">–</span> <span class="NLM_lpage">1247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1243-1247&author=L.+Renauthor=S.+Wenglowskyauthor=G.+Miknisauthor=B.+Rastauthor=A.+J.+Buckmelterauthor=R.+J.+Elyauthor=S.+Schlachterauthor=E.+R.+Lairdauthor=N.+Randolphauthor=M.+Callejoauthor=M.+Martinsonauthor=S.+Galbraithauthor=B.+J.+Brandhuberauthor=G.+Vigersauthor=T.+Moralesauthor=W.+C.+Voegtliauthor=J.+Lyssikatos&title=Non-oxime+inhibitors+of+B-RafV600E+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMiknis%26aufirst%3DG.%26aulast%3DRast%26aufirst%3DB.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DEly%26aufirst%3DR.%2BJ.%26aulast%3DSchlachter%26aufirst%3DS.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DRandolph%26aufirst%3DN.%26aulast%3DCallejo%26aufirst%3DM.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DGalbraith%26aufirst%3DS.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DLyssikatos%26aufirst%3DJ.%26atitle%3DNon-oxime%2520inhibitors%2520of%2520B-RafV600E%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1243%26epage%3D1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gould, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adhikari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afroze, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calderwood, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chouitar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffey, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsyth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaulin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenspan, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iartchouk, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janowick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulkarni, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langston, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizutani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paske, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezaei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowland, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sintchak, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tregay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veiby, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vos, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyskocil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, K. M.</span><span> </span><span class="NLM_article-title">Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1836</span><span class="NLM_x">–</span> <span class="NLM_lpage">1846</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101479y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1836-1846&author=A.+E.+Gouldauthor=R.+Adamsauthor=S.+Adhikariauthor=K.+Aertgeertsauthor=R.+Afrozeauthor=C.+Blackburnauthor=E.+F.+Calderwoodauthor=R.+Chauauthor=J.+Chouitarauthor=M.+O.+Duffeyauthor=D.+B.+Englandauthor=C.+Farrerauthor=N.+Forsythauthor=K.+Garciaauthor=J.+Gaulinauthor=P.+D.+Greenspanauthor=R.+Guoauthor=S.+J.+Harrisonauthor=S.-C.+Huangauthor=N.+Iartchoukauthor=D.+Janowickauthor=M.-S.+Kimauthor=B.+Kulkarniauthor=S.+P.+Langstonauthor=J.+X.+Liuauthor=L.-T.+Maauthor=S.+Menonauthor=H.+Mizutaniauthor=E.+Paskeauthor=C.+C.+Renouauthor=M.+Rezaeiauthor=R.+S.+Rowlandauthor=M.+D.+Sintchakauthor=M.+D.+Smithauthor=S.+G.+Stroudauthor=M.+Tregayauthor=Y.+Tianauthor=O.+P.+Veibyauthor=T.+J.+Vosauthor=S.+Vyskocilauthor=J.+Williamsauthor=T.+Xuauthor=J.+J.+Yangauthor=J.+Yanoauthor=H.+Zengauthor=D.+M.+Zhangauthor=Q.+Zhangauthor=K.+M.+Galvin&title=Design+and+optimization+of+potent+and+orally+bioavailable+tetrahydronaphthalene+Raf+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors</span></div><div class="casAuthors">Gould, Alexandra E.; Adams, Ruth; Adhikari, Sharmila; Aertgeerts, Kathleen; Afroze, Roushan; Blackburn, Christopher; Calderwood, Emily F.; Chau, Ryan; Chouitar, Jouhara; Duffey, Matthew O.; England, Dylan B.; Farrer, Cheryl; Forsyth, Nancy; Garcia, Khristofer; Gaulin, Jeffery; Greenspan, Paul D.; Guo, Ribo; Harrison, Sean J.; Huang, Shih-Chung; Iartchouk, Natalia; Janowick, Dave; Kim, Mi-Sook; Kulkarni, Bheemashankar; Langston, Steven P.; Liu, Jane X.; Ma, Li-Ting; Menon, Saurabh; Mizutani, Hirotake; Paske, Erin; Renou, Christelle C.; Rezaei, Mansoureh; Rowland, R. Scott; Sintchak, Michael D.; Smith, Michael D.; Stroud, Stephen G.; Tregay, Ming; Tian, Yuan; Veiby, Ole P.; Vos, Tricia J.; Vyskocil, Stepan; Williams, Juliet; Xu, Tianlin; Yang, Johnny J.; Yano, Jason; Zeng, Hongbo; Zhang, Dong Mei; Zhang, Qin; Galvin, Katherine M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1836-1846</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth.  Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity.  This article describes the design and optimization of tetrahydronaphthalene-derived compds. as potent inhibitors of the Raf pathway in vitro and in vivo.  These compds. possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNulHRlb4oULVg90H21EOLACvtfcHk0ljbgXnCNXuq7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWls7g%253D&md5=568fb1b26a6685df082ac0337494a9c5</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1021%2Fjm101479y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101479y%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DA.%2BE.%26aulast%3DAdams%26aufirst%3DR.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DAfroze%26aufirst%3DR.%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DCalderwood%26aufirst%3DE.%2BF.%26aulast%3DChau%26aufirst%3DR.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DDuffey%26aufirst%3DM.%2BO.%26aulast%3DEngland%26aufirst%3DD.%2BB.%26aulast%3DFarrer%26aufirst%3DC.%26aulast%3DForsyth%26aufirst%3DN.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DGaulin%26aufirst%3DJ.%26aulast%3DGreenspan%26aufirst%3DP.%2BD.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DHarrison%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DS.-C.%26aulast%3DIartchouk%26aufirst%3DN.%26aulast%3DJanowick%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DM.-S.%26aulast%3DKulkarni%26aufirst%3DB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DMa%26aufirst%3DL.-T.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DPaske%26aufirst%3DE.%26aulast%3DRenou%26aufirst%3DC.%2BC.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DRowland%26aufirst%3DR.%2BS.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DStroud%26aufirst%3DS.%2BG.%26aulast%3DTregay%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DVeiby%26aufirst%3DO.%2BP.%26aulast%3DVos%26aufirst%3DT.%2BJ.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%2BM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGalvin%26aufirst%3DK.%2BM.%26atitle%3DDesign%2520and%2520optimization%2520of%2520potent%2520and%2520orally%2520bioavailable%2520tetrahydronaphthalene%2520Raf%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1836%26epage%3D1846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preece, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span> </span><span class="NLM_article-title">A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of <sup>V600E</sup>BRAF</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">8036</span><span class="NLM_x">–</span> <span class="NLM_lpage">8044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=8036-8044&author=S.+Whittakerauthor=D.+M%C3%A9nardauthor=R.+Kirkauthor=L.+Ogilvieauthor=D.+Hedleyauthor=A.+Zambonauthor=F.+Lopesauthor=N.+Preeceauthor=H.+Manneauthor=S.+Ranaauthor=M.+Lambrosauthor=J.+S.+Reis-Filhoauthor=R.+Maraisauthor=C.+J.+Springer&title=A+novel%2C+selective%2C+and+efficacious+nanomolar+pyridopyrazinone+inhibitor+of+V600EBRAF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DM%25C3%25A9nard%26aufirst%3DD.%26aulast%3DKirk%26aufirst%3DR.%26aulast%3DOgilvie%26aufirst%3DL.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DManne%26aufirst%3DH.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%252C%2520and%2520efficacious%2520nanomolar%2520pyridopyrazinone%2520inhibitor%2520of%2520V600EBRAF%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D8036%26epage%3D8044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zambon, A.; Ménard, D.; Suijkerbuijk, B. M. J. M.; Niculescu-Duvaz, I.; Whittaker, S.; Niculescu-Duvaz, D.; Nourry, A.; Davies, L.; Manne, H. A.; Lopes, F.; Preece, N.; Hedley, D.; Ogilvie, L. M.; Kirk, R.; Marais, R.; Springer, C. J.</span><span> </span><span class="NLM_article-title">Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors</span>.  <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5639</span><span class="NLM_x">–</span> <span class="NLM_lpage">5655</span> (and references contained therein).</span><div class="citationLinks">[<a href="/doi/10.1021/jm100383b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5639-5655&author=A.+Zambon&author=D.+M%C3%A9nard&author=B.+M.+J.+M.+Suijkerbuijk&author=I.+Niculescu-Duvaz&author=S.+Whittaker&author=D.+Niculescu-Duvaz&author=A.+Nourry&author=L.+Davies&author=H.+A.+Manne&author=F.+Lopes&author=N.+Preece&author=D.+Hedley&author=L.+M.+Ogilvie&author=R.+Kirk&author=R.+Marais&author=C.+J.+Springer&title=Novel+hinge+binder+improves+activity+and+pharmacokinetic+properties+of+BRAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5f&amp;dbid=16384&amp;doi=10.1021%2Fjm100383b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100383b%26sid%3Dliteratum%253Aachs%26aulast%3DZambon%26aufirst%3DA.%26atitle%3DNovel%2520hinge%2520binder%2520improves%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520BRAF%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5639%26epage%3D5655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salaski, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojciechowicz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frommer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span> </span><span class="NLM_article-title">Indazolylpyrazolopyrimidines as highly potent B-Raf inhibitors with in vivo activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7878</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1007566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7874-7878&author=X.+Wangauthor=D.+M.+Bergerauthor=E.+J.+Salaskiauthor=N.+Torresauthor=M.+Dutiaauthor=C.+Hannaauthor=Y.+Huauthor=J.+L.+Levinauthor=D.+Powellauthor=D.+Wojciechowiczauthor=K.+Collinsauthor=E.+Frommerauthor=J.+Lucas&title=Indazolylpyrazolopyrimidines+as+highly+potent+B-Raf+inhibitors+with+in+vivo+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5g&amp;dbid=16384&amp;doi=10.1021%2Fjm1007566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1007566%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DSalaski%26aufirst%3DE.%2BJ.%26aulast%3DTorres%26aufirst%3DN.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLevin%26aufirst%3DJ.%2BL.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DWojciechowicz%26aufirst%3DD.%26aulast%3DCollins%26aufirst%3DK.%26aulast%3DFrommer%26aufirst%3DE.%26aulast%3DLucas%26aufirst%3DJ.%26atitle%3DIndazolylpyrazolopyrimidines%2520as%2520highly%2520potent%2520B-Raf%2520inhibitors%2520with%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7874%26epage%3D7878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF<sup>V600E</sup> mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3042</span><span class="NLM_x">–</span> <span class="NLM_lpage">3051</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3042-3051&author=K.+P.+Hoeflichauthor=S.+Herterauthor=J.+Tienauthor=L.+Wongauthor=L.+Berryauthor=J.+Chanauthor=C.+O%E2%80%99Brienauthor=Z.+Modrusanauthor=S.+Seshagiriauthor=M.+Lacknerauthor=H.+Sternauthor=E.+Chooauthor=L.+Murrayauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Antitumor+efficacy+of+the+novel+RAF+inhibitor+GDC-0879+is+predicted+by+BRAFV600E+mutational+status+and+sustained+extracellular+signal-regulated+kinase%2Fmitogen-activated+protein+kinase+pathway+suppression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DHerter%26aufirst%3DS.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DLackner%26aufirst%3DM.%26aulast%3DStern%26aufirst%3DH.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DAntitumor%2520efficacy%2520of%2520the%2520novel%2520RAF%2520inhibitor%2520GDC-0879%2520is%2520predicted%2520by%2520BRAFV600E%2520mutational%2520status%2520and%2520sustained%2520extracellular%2520signal-regulated%2520kinase%252Fmitogen-activated%2520protein%2520kinase%2520pathway%2520suppression%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D3042%26epage%3D3051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMorin, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paras, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petkus, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nixey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnahan, J.</span><span> </span><span class="NLM_article-title">Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6189</span><span class="NLM_x">–</span> <span class="NLM_lpage">6192</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901081g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6189-6192&author=A.+L.+Smithauthor=F.+F.+DeMorinauthor=N.+A.+Parasauthor=Q.+Huangauthor=J.+K.+Petkusauthor=E.+M.+Dohertyauthor=T.+Nixeyauthor=J.+L.+Kimauthor=D.+A.+Whittingtonauthor=L.+F.+Epsteinauthor=M.+R.+Leeauthor=M.+J.+Roseauthor=C.+Babijauthor=M.+Fernandoauthor=K.+Hessauthor=Q.+Leauthor=P.+Beltranauthor=J.+Carnahan&title=Selective+inhibitors+of+the+mutant+B-Raf+pathway%3A+discovery+of+a+potent+and+orally+bioavailable+aminoisoquinoline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5i&amp;dbid=16384&amp;doi=10.1021%2Fjm901081g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901081g%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DDeMorin%26aufirst%3DF.%2BF.%26aulast%3DParas%26aufirst%3DN.%2BA.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DPetkus%26aufirst%3DJ.%2BK.%26aulast%3DDoherty%26aufirst%3DE.%2BM.%26aulast%3DNixey%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DK.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DBeltran%26aufirst%3DP.%26aulast%3DCarnahan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibitors%2520of%2520the%2520mutant%2520B-Raf%2520pathway%253A%2520discovery%2520of%2520a%2520potent%2520and%2520orally%2520bioavailable%2520aminoisoquinoline%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6189%26epage%3D6192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Ramurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costales, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dove, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pick, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renhowe, P. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7049</span><span class="NLM_x">–</span> <span class="NLM_lpage">7052</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801050k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7049-7052&author=S.+Ramurthyauthor=S.+Subramanianauthor=M.+Aikawaauthor=P.+Amiriauthor=A.+Costalesauthor=J.+Doveauthor=S.+Fongauthor=J.+M.+Jansenauthor=B.+Levineauthor=S.+Maauthor=C.+M.+McBrideauthor=J.+Michaelianauthor=T.+Pickauthor=D.+J.+Poonauthor=S.+Girishauthor=C.+M.+Shaferauthor=D.+Stuartauthor=L.+Sungauthor=P.+A.+Renhowe&title=Design+and+synthesis+of+orally+bioavailable+benzimidazoles+as+Raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5j&amp;dbid=16384&amp;doi=10.1021%2Fjm801050k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801050k%26sid%3Dliteratum%253Aachs%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DAikawa%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DCostales%26aufirst%3DA.%26aulast%3DDove%26aufirst%3DJ.%26aulast%3DFong%26aufirst%3DS.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DLevine%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DMichaelian%26aufirst%3DJ.%26aulast%3DPick%26aufirst%3DT.%26aulast%3DPoon%26aufirst%3DD.%2BJ.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DSung%26aufirst%3DL.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520orally%2520bioavailable%2520benzimidazoles%2520as%2520Raf%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7049%26epage%3D7052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span>See the Novartis website (<a href="http://www.novartisoncology.com/research-innovation/pipeline/raf265" class="extLink">http://www.novartisoncology.com/research-innovation/pipeline/raf265</a>) (accessed April 10, 2011) and the ClinicalTrials.gov website (<a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>) (NCT00304525, accessed on April 10, 2011). Also see: <span class="NLM_contrib-group">Stuart, D.; Aardalen, K.; Venetsanakos, E.; Lorenzana, E.; Salangsang, F.; Nagel, T.; Wallroth, M.; Batt, D.; Ramurthy, S.; Poon, D.; Faure, M.; Aikawa, M.; Dove, J.; Garrett, L.; Kaplan, A.; Amiri, P.; Pryer, N.; Renhowe, P.</span><span> </span><span class="NLM_article-title">RAF265 is a potent Raf inhibitor with selective anti-proliferative activity in vitro and in vivo</span>. AACR Annu. Meet.<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">, </span>Abstract  <span class="NLM_fpage">4876</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+Stuart&author=K.+Aardalen&author=E.+Venetsanakos&author=E.+Lorenzana&author=F.+Salangsang&author=T.+Nagel&author=M.+Wallroth&author=D.+Batt&author=S.+Ramurthy&author=D.+Poon&author=M.+Faure&author=M.+Aikawa&author=J.+Dove&author=L.+Garrett&author=A.+Kaplan&author=P.+Amiri&author=N.+Pryer&author=P.+Renhowe&title=RAF265+is+a+potent+Raf+inhibitor+with+selective+anti-proliferative+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DStuart%26aufirst%3DD.%26atitle%3DRAF265%2520is%2520a%2520potent%2520Raf%2520inhibitor%2520with%2520selective%2520anti-proliferative%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAACR%2520Annu.%2520Meet.%26date%3D2008%26spage%3D4876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span>See the Exelixis website (<a href="http://www.exelixis.com/pipeline" class="extLink">http://www.exelixis.com/pipeline</a>) (accessed April 10, 2011) and the ClinicalTrials.gov website (<a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>) (NCT01086267, accessed on April 10, 2011). See also: <span class="NLM_contrib-group">Schwartz, G. L.; Robertson, S.; Shen, A.; Wang, E.; Pace, L.; Dials, H.; Mendelson, D.; Shannon, P.; Gordon, M.</span><span> </span><span class="NLM_article-title">A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span>, 15sAbstr.  <span class="NLM_fpage">3513</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1200%2FJCO.2008.20.3745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3513&author=G.+L.+Schwartz&author=S.+Robertson&author=A.+Shen&author=E.+Wang&author=L.+Pace&author=H.+Dials&author=D.+Mendelson&author=P.+Shannon&author=M.+Gordon&title=A+phase+I+study+of+XL281%2C+a+selective+oral+RAF+kinase+inhibitor%2C+in+patients+%28Pts%29+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.20.3745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.20.3745%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BL.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520XL281%252C%2520a%2520selective%2520oral%2520RAF%2520kinase%2520inhibitor%252C%2520in%2520patients%2520%2528Pts%2529%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D3513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span>See the GlaxoSmithKline website (<a href="http://www.gsk.com/investors/pp-pipeline-standard" class="extLink">http://www.gsk.com/investors/pp-pipeline-standard</a>) (accessed April 10, 2011) and the ClinicalTrials.gov website (<a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>) (NCT01227889, accessed on April 10, 2011). See also: <span class="NLM_contrib-group">Kefford, R.; Arkenau, H.; Brown, M. P.; Millward, M.; Infante, J. R.; Long, G. V.; Ouellet, D.; Curtis, M.; Lebowitz, P. F.; Falchook, G. S.</span><span> </span><span class="NLM_article-title">Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span>, 15sAbstr.  <span class="NLM_fpage">8503</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=8503&author=R.+Kefford&author=H.+Arkenau&author=M.+P.+Brown&author=M.+Millward&author=J.+R.+Infante&author=G.+V.+Long&author=D.+Ouellet&author=M.+Curtis&author=P.+F.+Lebowitz&author=G.+S.+Falchook&title=Phase+I%2FII+study+of+GSK2118436%2C+a+selective+inhibitor+of+oncogenic+mutant+BRAF+kinase%2C+in+patients+with+metastatic+melanoma+and+other+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKefford%26aufirst%3DR.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520GSK2118436%252C%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520mutant%2520BRAF%2520kinase%252C%2520in%2520patients%2520with%2520metastatic%2520melanoma%2520and%2520other%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D8503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="note"><p class="first last">For the most current information, refer to the Plexxikon (<a href="http://www.plexxikon.com" class="extLink">http://www.plexxikon.com</a>), Daiichi-Sankyo (<a href="http://www.daiichisankyo.com" class="extLink">http://www.daiichisankyo.com</a>), and Roche Web sites (<a href="http://www.roche.com" class="extLink">http://www.roche.com</a>) and the following references:</p></div><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0li9OrHbWBTWdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vultur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">Targeting BRAF in advanced melanoma: A first step toward manageable disease</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1658</span><span class="NLM_x">–</span> <span class="NLM_lpage">1663</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1158%2F1078-0432.CCR-10-0174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=21447722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1658-1663&author=A.+Vulturauthor=J.+Villanuevaauthor=M.+Herlyn&title=Targeting+BRAF+in+advanced+melanoma%3A+A+first+step+toward+manageable+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease</span></div><div class="casAuthors">Vultur, Adina; Villanueva, Jessie; Herlyn, Meenhard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1658-1663</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Melanoma is the deadliest form of skin cancer and its incidence has been increasing worldwide.  The disease manifests itself as clin. and genetically distinct subgroups, indicating the need for patient-specific diagnostic and treatment tools.  The discovery of activating mutations (V600E) in the BRAF kinase in approx. 50% of patients spurred the development of compds. to inhibit aberrant BRAF activity, and the first drug candidate to show promising clin. activity is PLX4032 (also known as RG7204).  Most recent clin. data from a phase II trial indicate that PLX4032 causes tumor regression and stabilized disease in >50% of advanced melanoma patients harboring BRAF V600E tumors.  These data validate the effectiveness of oncogene-targeted therapy against advanced melanoma and offer hope that the disease can be overcome.  However, as melanoma is dynamic and heterogeneous, careful treatment strategies and combination therapies are warranted to obtain long-term clin. effects.  Clin Cancer Res; 17(7); 1658-63.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRWKQUyFvFObVg90H21EOLACvtfcHk0li9OrHbWBTWdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOisrw%253D&md5=eca5a7d0b4ab7c3dc5c0dc93ab264716</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0174%26sid%3Dliteratum%253Aachs%26aulast%3DVultur%26aufirst%3DA.%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DTargeting%2520BRAF%2520in%2520advanced%2520melanoma%253A%2520A%2520first%2520step%2520toward%2520manageable%2520disease%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D1658%26epage%3D1663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0li9OrHbWBTWdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lg7DnmWW0FI-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="note"><p class="first last">See <a href="http://www.kinomescan.com" class="extLink">http://www.kinomescan.com</a> and</p></div><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A qualitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+qualitative+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520qualitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lhsi0Ibpf85oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Posy, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermsmeir, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaccaro, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todderud, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughney, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span> </span><span class="NLM_article-title">Trends in kinase selectivity: Insights for target class-focused library screening</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101195a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFSms7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=54-66&author=S.+L.+Posyauthor=M.+A.+Hermsmeirauthor=W.+Vaccaroauthor=K.-H.+Ottauthor=G.+Todderudauthor=J.+S.+Lippyauthor=G.+L.+Trainorauthor=D.+A.+Loughneyauthor=S.+R.+Johnson&title=Trends+in+kinase+selectivity%3A+Insights+for+target+class-focused+library+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in Kinase Selectivity: Insights for Target Class-Focused Library Screening</span></div><div class="casAuthors">Posy, Shana L.; Hermsmeier, Mark A.; Vaccaro, Wayne; Ott, Karl-Heinz; Todderud, Gordon; Lippy, Jonathan S.; Trainor, George L.; Loughney, Deborah A.; Johnson, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-66</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A kinome-wide selectivity screen of >20000 compds. with a rich representation of many structural classes has been completed.  Anal. of the selectivity patterns for each class shows that a broad spectrum of structural scaffolds can achieve specificity for many kinase families.  Kinase selectivity and potency are inversely correlated, a trend that is also found in a large set of kinase functional data.  Although selective and nonselective compds. are mostly similar in their physicochem. characteristics, we identify specific features that are present more frequently in compds. that bind to many kinases.  Our results support a scaffold-oriented approach for building compd. collections to screen kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJlqg1ZszRmLVg90H21EOLACvtfcHk0lhsi0Ibpf85oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFSms7jJ&md5=f824b454904fb99d1ddd1ac6396cb784</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fjm101195a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101195a%26sid%3Dliteratum%253Aachs%26aulast%3DPosy%26aufirst%3DS.%2BL.%26aulast%3DHermsmeir%26aufirst%3DM.%2BA.%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DOtt%26aufirst%3DK.-H.%26aulast%3DTodderud%26aufirst%3DG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DLoughney%26aufirst%3DD.%2BA.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26atitle%3DTrends%2520in%2520kinase%2520selectivity%253A%2520Insights%2520for%2520target%2520class-focused%2520library%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D54%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">High-throughput kinase profiling as a platform for drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnrd2541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=18404149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=391-397&author=D.+M.+Goldsteinauthor=N.+S.+Grayauthor=P.+P.+Zarrinkar&title=High-throughput+kinase+profiling+as+a+platform+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput kinase profiling as a platform for drug discovery</span></div><div class="casAuthors">Goldstein, David M.; Gray, Nathanael S.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">391-397</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  High-throughput profiling of compd. libraries against large panels of kinases is becoming tech. feasible.  In contrast to the traditional linear, target-centric approach to discovery, this approach may provide a choice of targets to pursue that is guided by the quality of lead compds. available, rather than by target biol. alone, and could thereby significantly improve the productivity of kinase inhibitor discovery.  To fully exploit the potential of kinases as drug targets, novel strategies for the efficient discovery of inhibitors are required.  In contrast to the traditional, linear process of inhibitor discovery, high-throughput kinase profiling enables a parallel approach by interrogating compds. against hundreds of targets in a single screen.  Compd. potency and selectivity are detd. simultaneously, providing a choice of targets to pursue that is guided by the quality of lead compds. available, rather than by target biol. alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwnJ59cVxbJbVg90H21EOLACvtfcHk0lhkVDrS3_QCOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbs%253D&md5=eaa61fd2958ff04fecf86a993f91833d</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1038%2Fnrd2541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2541%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DHigh-throughput%2520kinase%2520profiling%2520as%2520a%2520platform%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D391%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Holladay, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowbottom, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitnick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span> </span><span class="NLM_article-title">4-Quinazolinyloxy-diaryl ureas as novel BRAF<sup>V600E</sup> inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5342</span><span class="NLM_x">–</span> <span class="NLM_lpage">5346</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5342-5346&author=M.+W.+Holladayauthor=B.+T.+Campbellauthor=M.+W.+Rowbottomauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=A.+G.+Laiauthor=S.+Abrahamauthor=E.+Settiauthor=R.+Faraoniauthor=L.+Tranauthor=R.+C.+Armstrongauthor=R.+N.+Gunawardaneauthor=M.+F.+Gardnerauthor=M.+D.+Cramerauthor=D.+Gitnickauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=B.+R.+Ruggeriauthor=M.+Williamsauthor=S.+S.+Bhagwatauthor=J.+James&title=4-Quinazolinyloxy-diaryl+ureas+as+novel+BRAFV600E+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DSetti%26aufirst%3DE.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DRuggeri%26aufirst%3DB.%2BR.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26aulast%3DJames%26aufirst%3DJ.%26atitle%3D4-Quinazolinyloxy-diaryl%2520ureas%2520as%2520novel%2520BRAFV600E%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5342%26epage%3D5346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Abraham, S.; Bhagwat, S.; Campbell, B. T.; Chao, Q.; Faraoni, R.; Holladay, M. W.; Lai, A. G.; Rowbottom, M. W.; Setti, E.; Sprankle, K. G.</span><span> </span><span class="NLM_article-title">Preparation of quinazoline derivatives as RAF kinase modulators for treating cancers, inflammations and immune diseases</span>. Patent Application WO 2009117080 A1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Abraham%2C+S.%3B+Bhagwat%2C+S.%3B+Campbell%2C+B.+T.%3B+Chao%2C+Q.%3B+Faraoni%2C+R.%3B+Holladay%2C+M.+W.%3B+Lai%2C+A.+G.%3B+Rowbottom%2C+M.+W.%3B+Setti%2C+E.%3B+Sprankle%2C+K.+G.+Preparation+of+quinazoline+derivatives+as+RAF+kinase+modulators+for+treating+cancers%2C+inflammations+and+immune+diseases.+Patent+Application+WO+2009117080+A1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520quinazoline%2520derivatives%2520as%2520RAF%2520kinase%2520modulators%2520for%2520treating%2520cancers%252C%2520inflammations%2520and%2520immune%2520diseases" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Takase, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murabayashi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumimoto, S.</span><span> </span><span class="NLM_article-title">Practical synthesis of 3-amino-5-<i>tert</i>-butylisoxazole from 4,4-dimethyl-3-oxopentanenitrile with hydroxylamine</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=1153-1158&author=A.+Takaseauthor=A.+Murabayashiauthor=S.+Sumimoto&title=Practical+synthesis+of+3-amino-5-tert-butylisoxazole+from+4%2C4-dimethyl-3-oxopentanenitrile+with+hydroxylamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakase%26aufirst%3DA.%26aulast%3DMurabayashi%26aufirst%3DA.%26aulast%3DSumimoto%26aufirst%3DS.%26atitle%3DPractical%2520synthesis%2520of%25203-amino-5-tert-butylisoxazole%2520from%25204%252C4-dimethyl-3-oxopentanenitrile%2520with%2520hydroxylamine%26jtitle%3DHeterocycles%26date%3D1991%26volume%3D32%26spage%3D1153%26epage%3D1158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="note"><p class="first last">The <i>tert</i>-butyl motif is often incorporated into drug candidates, and it is a component of numerous approved drugs. However, it is known that, with certain drugs containing a <i>tert</i>-butyl group, the <i>tert</i>-butyl itself may be subject to phase I oxidative processes <i>in vivo</i>, resulting in formation of the corresponding hydroxylated <i>tert</i>-butyl derivatives (which can be further oxidized to the corresponding carboxylates). For specific examples, see:</p></div><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Garteiz, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okerholm, R. A.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and biotransformation studies of terfenadine in man</span> <span class="citation_source-journal">Arzneim. Forsch. Drug Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1185</span><span class="NLM_x">–</span> <span class="NLM_lpage">1190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=6817765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADyaL3sXhsFA%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1982&pages=1185-1190&author=D.+A.+Garteizauthor=R.+H.+Hookauthor=B.+J.+Walkerauthor=R.+A.+Okerholm&title=Pharmacokinetics+and+biotransformation+studies+of+terfenadine+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and biotransformation studies of terfenadine in man</span></div><div class="casAuthors">Garteiz, D. A.; Hook, R. H.; Walker, B. J.; Okerholm, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9A</span>),
    <span class="NLM_cas:pages">1185-90</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    </div><div class="casAbstract">In normal human subjects, comparison of the plasma level data obtained from a dose-response study to that of a 14C-material balance study indicates that 99.48% of the terfenadine (I)  [50679-08-8]-related material absorbed undergoes biotransformation.  From the balance study, it has been detd. that fecal excretion accounts for ca. 60% of the dose administered.  Thin-layer chromatog. anal. of urine and feces revealed the presence of 2 major metabolic products.  These compds. have been isolated and their structures detd. by gas chromatog.-mass spectroscopy.  One of the metabolic products, a carboxylic acid analog of terfenadine  [83799-24-0] had antihistaminic activity and may play a role in the activity of the parent drug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqscH5aP4FNNrVg90H21EOLACvtfcHk0liEr47KcsLq8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhsFA%253D&md5=2a24c77c63188bc4b89bf8cab09b38e3</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarteiz%26aufirst%3DD.%2BA.%26aulast%3DHook%26aufirst%3DR.%2BH.%26aulast%3DWalker%26aufirst%3DB.%2BJ.%26aulast%3DOkerholm%26aufirst%3DR.%2BA.%26atitle%3DPharmacokinetics%2520and%2520biotransformation%2520studies%2520of%2520terfenadine%2520in%2520man%26jtitle%3DArzneim.%2520Forsch.%2520Drug%2520Res.%26date%3D1982%26volume%3D32%26spage%3D1185%26epage%3D1190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulford, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surber, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukulka, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrero, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shet, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estabrook, R. W.</span><span> </span><span class="NLM_article-title">In vitro metabolism of terfenadine by purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase: Comparison to human liver microsomes and precision-cut liver tissue slices</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=765-775&author=A.+D.+Rodriguesauthor=D.+J.+Mulfordauthor=R.+D.+Leeauthor=B.+W.+Surberauthor=M.+J.+Kukulkaauthor=J.+L.+Ferreroauthor=S.+B.+Thomasauthor=M.+S.+Shetauthor=R.+W.+Estabrook&title=In+vitro+metabolism+of+terfenadine+by+purified+recombinant+fusion+protein+containing+cytochrome+P4503A4+and+NADPH-P450+reductase%3A+Comparison+to+human+liver+microsomes+and+precision-cut+liver+tissue+slices"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DMulford%26aufirst%3DD.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BD.%26aulast%3DSurber%26aufirst%3DB.%2BW.%26aulast%3DKukulka%26aufirst%3DM.%2BJ.%26aulast%3DFerrero%26aufirst%3DJ.%2BL.%26aulast%3DThomas%26aufirst%3DS.%2BB.%26aulast%3DShet%26aufirst%3DM.%2BS.%26aulast%3DEstabrook%26aufirst%3DR.%2BW.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520terfenadine%2520by%2520purified%2520recombinant%2520fusion%2520protein%2520containing%2520cytochrome%2520P4503A4%2520and%2520NADPH-P450%2520reductase%253A%2520Comparison%2520to%2520human%2520liver%2520microsomes%2520and%2520precision-cut%2520liver%2520tissue%2520slices%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1995%26volume%3D23%26spage%3D765%26epage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Carlin, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christofalo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arison, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosegay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, S. H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenheuvel, W. J. A.</span><span> </span><span class="NLM_article-title">Disposition and metabolism of finasteride in dogs</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=100-109&author=J.+R.+Carlinauthor=P.+Christofaloauthor=B.+H.+Arisonauthor=R.+E.+Ellsworthauthor=A.+Rosegayauthor=R.+R.+Millerauthor=S.+H.+L.+Chiuauthor=W.+J.+A.+Vandenheuvel&title=Disposition+and+metabolism+of+finasteride+in+dogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlin%26aufirst%3DJ.%2BR.%26aulast%3DChristofalo%26aufirst%3DP.%26aulast%3DArison%26aufirst%3DB.%2BH.%26aulast%3DEllsworth%26aufirst%3DR.%2BE.%26aulast%3DRosegay%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DChiu%26aufirst%3DS.%2BH.%2BL.%26aulast%3DVandenheuvel%26aufirst%3DW.%2BJ.%2BA.%26atitle%3DDisposition%2520and%2520metabolism%2520of%2520finasteride%2520in%2520dogs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1997%26volume%3D25%26spage%3D100%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Prakash, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colizza, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span> </span><span class="NLM_article-title">Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2822</span><span class="NLM_x">–</span> <span class="NLM_lpage">2832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1002%2Frcm.3153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=17661339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSnsrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2822-2832&author=C.+Prakashauthor=J.+Linauthor=K.+Colizzaauthor=Z.+Miao&title=Characterization+of+metabolites+of+a+NK1+receptor+antagonist%2C+CJ-11%2C972%2C+in+human+liver+microsomes+and+recombinant+human+CYP+isoforms+by+liquid+chromatography%2Ftandem+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15dR"><div class="casContent"><span class="casTitleNuber">15d</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry</span></div><div class="casAuthors">Prakash, Chandra; Lin, Jinyan; Colizza, Kevin; Miao, Zhuang</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2822-2832</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The in vitro metab. of CJ-11,972, (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-tert-butyl-2-methoxybenzyl)amine, an NK1 receptor antagonist, was studied in human liver microsomes and recombinant human CYP isoforms.  Liq. chromatog./mass spectrometry (LC/MS) and tandem mass spectrometry (LC/MS/MS) coupled to radioactive detection were used to detect and identify the metabolites.  CJ-11,972 was extensively metabolized in human liver microsomes and recombinant human CYP3A4/3A5 isoforms.  A total of fourteen metabolites were identified by a combination of various MS techniques.  The major metabolic pathways were due to oxidn. of the tert-Bu moiety to form an alc. (M6) and/or O-demethylation of the anisole moiety.  The alc. metabolite M6 was further oxidized to the corresponding aldehyde (M7) and carboxylic acid (M4).  Two unusual metabolites (M13, M17), formed by C-demethylation of the tert-Bu group, were identified as 2-{3-[(2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-ylamino)methyl]-4-methoxyphenyl}propan-2-ol and (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-isopropenyl-2-methoxybenzyl)amine.  A plausible mechanism for C-demethylation may involve oxidn. of M6 to form an aldehyde metabolite (M7), followed by cytochrome P 450-mediated deformylation leaving an unstable carbon-centered radical, which would quickly form either the alc. metabolite M13 and the olefin metabolite M17.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_dgJ2mV5orLVg90H21EOLACvtfcHk0liEr47KcsLq8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSnsrzP&md5=85f43a40f501349655a92837f324799c</span></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1002%2Frcm.3153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.3153%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DColizza%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DZ.%26atitle%3DCharacterization%2520of%2520metabolites%2520of%2520a%2520NK1%2520receptor%2520antagonist%252C%2520CJ-11%252C972%252C%2520in%2520human%2520liver%2520microsomes%2520and%2520recombinant%2520human%2520CYP%2520isoforms%2520by%2520liquid%2520chromatography%252Ftandem%2520mass%2520spectrometry%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2007%26volume%3D21%26spage%3D2822%26epage%3D2832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Park, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitteringham, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neil, P. M.</span><span> </span><span class="NLM_article-title">Metabolism of fluorine-containing drugs</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1146%2Fannurev.pharmtox.41.1.443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=11264465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVaqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=443-470&author=K.+B.+Parkauthor=N.+R.+Kitteringhamauthor=P.+M.+O%E2%80%99Neil&title=Metabolism+of+fluorine-containing+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of fluorine-containing drugs</span></div><div class="casAuthors">Park, B. Kevin; Kitteringham, Neil R.; O'Neill, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">443-470</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 109 refs.  This article reviews current knowledge of the metab. of drugs that contain fluorine.  The strategic value of fluorine substitution in drug design is discussed in terms of chem. structure and basic concepts in drug metab. and drug toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAja3Ht70KbVg90H21EOLACvtfcHk0lhPnl69ICCtkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVaqtrc%253D&md5=0e2ee242da0f4cef8d203e92aee03180</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.41.1.443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.41.1.443%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DK.%2BB.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DP.%2BM.%26atitle%3DMetabolism%2520of%2520fluorine-containing%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2001%26volume%3D41%26spage%3D443%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hodgetts, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combs, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elder, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, G. C.</span><span> </span><span class="NLM_article-title">The role of fluorine in the discovery and optimization of CNS agents: Modulation of drug-like properties</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=429-448&author=K.+J.+Hodgettsauthor=K.+J.+Combsauthor=A.+M.+Elderauthor=G.+C.+Harriman&title=The+role+of+fluorine+in+the+discovery+and+optimization+of+CNS+agents%3A+Modulation+of+drug-like+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHodgetts%26aufirst%3DK.%2BJ.%26aulast%3DCombs%26aufirst%3DK.%2BJ.%26aulast%3DElder%26aufirst%3DA.%2BM.%26aulast%3DHarriman%26aufirst%3DG.%2BC.%26atitle%3DThe%2520role%2520of%2520fluorine%2520in%2520the%2520discovery%2520and%2520optimization%2520of%2520CNS%2520agents%253A%2520Modulation%2520of%2520drug-like%2520properties%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D429%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Q.</span><span> </span><span class="NLM_article-title">Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">613</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2004&pages=609-613&author=Z.+Wangauthor=Y.+Liauthor=E.+T.+Liuauthor=Q.+Yu&title=Susceptibility+to+cell+death+induced+by+blockade+of+MAPK+pathway+in+human+colorectal+cancer+cells+carrying+Ras+mutations+is+dependent+on+p53+status"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DYu%26aufirst%3DQ.%26atitle%3DSusceptibility%2520to%2520cell%2520death%2520induced%2520by%2520blockade%2520of%2520MAPK%2520pathway%2520in%2520human%2520colorectal%2520cancer%2520cells%2520carrying%2520Ras%2520mutations%2520is%2520dependent%2520on%2520p53%2520status%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D322%26spage%3D609%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tristani-Firouzi, M.</span><span> </span><span class="NLM_article-title">hERG potassium channels and cardiac arrhythmia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">440</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnature04710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=16554806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=463-469&author=M.+C.+Sanguinettiauthor=M.+Tristani-Firouzi&title=hERG+potassium+channels+and+cardiac+arrhythmia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">hERG potassium channels and cardiac arrhythmia</span></div><div class="casAuthors">Sanguinetti, Michael C.; Tristani-Firouzi, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7083</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  HERG potassium channels are essential for normal elec. activity in the heart.  Inherited mutations in the HERG gene cause long QT syndrome, a disorder that predisposes individuals to life-threatening arrhythmias.  Arrhythmia can also be induced by a blockage of hERG channels by a surprisingly diverse group of drugs.  This side effect is a common reason for drug failure in preclin. safety trials.  Insights gained from the crystal structures of other potassium channels have helped our understanding of the block of hERG channels and the mechanisms of gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopS3WBEpuAUrVg90H21EOLACvtfcHk0lhPnl69ICCtkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D&md5=3f355dcd51da3488d73c7c91cbe8d3b8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature04710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04710%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DTristani-Firouzi%26aufirst%3DM.%26atitle%3DhERG%2520potassium%2520channels%2520and%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D463%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">James, J.; Ruggeri, B.; Armstrong, R. C.; Rowbottom, M. W.; Jones-Bolin, S.; Gunawardane, R. N.; Dobrzanski, P.; Gardner, M. F.; Zhao, H.; Cramer, M. D.; Hunter, K.; Nepomuceno, R. R.; Cheng, M.; Gitnick, D.; Yazdanian, M.; Insko, D. E.; Ator, M. A.; Apuy, J. L.; Faraoni, R.; Dorsey, B. D.; Williams, M.; Bhagwat, S. S.; Holladay, M. W.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=James%2C+J.%3B+Ruggeri%2C+B.%3B+Armstrong%2C+R.+C.%3B+Rowbottom%2C+M.+W.%3B+Jones-Bolin%2C+S.%3B+Gunawardane%2C+R.+N.%3B+Dobrzanski%2C+P.%3B+Gardner%2C+M.+F.%3B+Zhao%2C+H.%3B+Cramer%2C+M.+D.%3B+Hunter%2C+K.%3B+Nepomuceno%2C+R.+R.%3B+Cheng%2C+M.%3B+Gitnick%2C+D.%3B+Yazdanian%2C+M.%3B+Insko%2C+D.+E.%3B+Ator%2C+M.+A.%3B+Apuy%2C+J.+L.%3B+Faraoni%2C+R.%3B+Dorsey%2C+B.+D.%3B+Williams%2C+M.%3B+Bhagwat%2C+S.+S.%3B+Holladay%2C+M.+W.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancer Genome Project</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=M.+S.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=Cancer+Genome+Projectauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lgiffC5eOX7mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DM.%2BS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3D%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">The authors observed that both wt-BRAF and BRAF<sup>V600E</sup> kinase domains adopt essentially identical conformations in the presence of the inhibitor sorafenib.</p></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Weyerstahl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kressin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nerdel, F.</span><span> </span><span class="NLM_article-title">Fragmentation reactions of carbonyl compounds with electronegative β-substituents, XV. On the reaction of electronegatively β-substituted pivalic acid esters</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1969</span><span class="NLM_x">, </span> <span class="NLM_volume">725</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=725&publication_year=1969&pages=106-115&author=P.+Weyerstahlauthor=H.+Kressinauthor=F.+Nerdel&title=Fragmentation+reactions+of+carbonyl+compounds+with+electronegative+%CE%B2-substituents%2C+XV.+On+the+reaction+of+electronegatively+%CE%B2-substituted+pivalic+acid+esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeyerstahl%26aufirst%3DP.%26aulast%3DKressin%26aufirst%3DH.%26aulast%3DNerdel%26aufirst%3DF.%26atitle%3DFragmentation%2520reactions%2520of%2520carbonyl%2520compounds%2520with%2520electronegative%2520%25CE%25B2-substituents%252C%2520XV.%2520On%2520the%2520reaction%2520of%2520electronegatively%2520%25CE%25B2-substituted%2520pivalic%2520acid%2520esters%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D1969%26volume%3D725%26spage%3D106%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvino, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5149</span><span class="NLM_x">–</span> <span class="NLM_lpage">5171</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800475y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5149-5171&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=D.+A.+Pippinauthor=J.+M.+Salvinoauthor=J.+P.+Mallamo&title=Knowledge+based+prediction+of+ligand+binding+modes+and+rational+inhibitor+design+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Pippin, Douglas A.; Salvino, Joseph M.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5149-5171</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review describing the use of Protein Data Bank (PDB) entries specifically for kinase inhibitor drug discovery.  Topics discussed include: the current state of structure-aided ligand design, kinase structure queries and extn. from the PDB, alignment of protein structures, structural classification of ligands, anal. of ligands and binding modes, and ligand design strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDINDYVE15cbVg90H21EOLACvtfcHk0lgiffC5eOX7mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM&md5=a1afc4d6c7f6fa4dd6aa9da8d78f1ee3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm800475y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800475y%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DPippin%26aufirst%3DD.%2BA.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge%2520based%2520prediction%2520of%2520ligand%2520binding%2520modes%2520and%2520rational%2520inhibitor%2520design%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5149%26epage%3D5171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5a','cit5b','cit5c','cit5d','cit5e','cit5f','cit5g','cit5h','cit5i','cit5j'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c','cit9d'],'ref10':['cit10a','cit10b'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c','cit15d'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref22':['cit22'],'ref21':['cit21']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 39 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Bohdan A. Chalyk, Andrii Khutorianskyi, Andrii Lysenko, Yulia Fil, Yuliya O. Kuchkovska, Konstantin S. Gavrilenko, Iulia Bakanovych, Yurii S. Moroz, Alina O. Gorlova, <span class="NLM_string-name hlFld-ContribAuthor">Oleksandr O. Grygorenko</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective Synthesis of Functionalized 3- or 5-Fluoroalkyl Isoxazoles and Pyrazoles from Fluoroalkyl Ynones and Binucleophiles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (23)
                                     , 15212-15225. <a href="https://doi.org/10.1021/acs.joc.9b02258" title="DOI URL">https://doi.org/10.1021/acs.joc.9b02258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b02258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b02258%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRegioselective%252BSynthesis%252Bof%252BFunctionalized%252B3-%252Bor%252B5-Fluoroalkyl%252BIsoxazoles%252Band%252BPyrazoles%252Bfrom%252BFluoroalkyl%252BYnones%252Band%252BBinucleophiles%26aulast%3DChalyk%26aufirst%3DBohdan%2BA.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19082019%26date%3D08112019%26date%3D29102019%26volume%3D84%26issue%3D23%26spage%3D15212%26epage%3D15225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wen-Qiang Shi, Shuai Liu, Chen-Ze Wang, Yangen Huang, Feng-Ling Qing, <span class="NLM_string-name hlFld-ContribAuthor">Xiu-Hua Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of CMe2CF3-Containing Heteroarenes via Tandem 1,1-Dimethyltrifluoroethylation and Cyclization of Isonitriles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (24)
                                     , 15236-15244. <a href="https://doi.org/10.1021/acs.joc.8b02506" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02506</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02506%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BCMe2CF3-Containing%252BHeteroarenes%252Bvia%252BTandem%252B1%25252C1-Dimethyltrifluoroethylation%252Band%252BCyclization%252Bof%252BIsonitriles%26aulast%3DShi%26aufirst%3DWen-Qiang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D28092018%26date%3D04122018%26date%3D23112018%26volume%3D83%26issue%3D24%26spage%3D15236%26epage%3D15244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shuai Liu, Yangen Huang, Feng-Ling Qing, <span class="NLM_string-name hlFld-ContribAuthor">Xiu-Hua Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Transition-Metal-Free Decarboxylation of 3,3,3-Trifluoro-2,2-dimethylpropanoic Acid for the Preparation of C(CF3)Me2-Containing Heteroarenes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (17)
                                     , 5497-5501. <a href="https://doi.org/10.1021/acs.orglett.8b02451" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b02451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b02451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b02451%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DTransition-Metal-Free%252BDecarboxylation%252Bof%252B3%25252C3%25252C3-Trifluoro-2%25252C2-dimethylpropanoic%252BAcid%252Bfor%252Bthe%252BPreparation%252Bof%252BC%252528CF3%252529Me2-Containing%252BHeteroarenes%26aulast%3DLiu%26aufirst%3DShuai%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D01082018%26date%3D27082018%26volume%3D20%26issue%3D17%26spage%3D5497%26epage%3D5501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bogos Agianian, <span class="NLM_string-name hlFld-ContribAuthor">Evripidis Gavathiotis</span>. </span><span class="cited-content_cbyCitation_article-title">Current Insights of BRAF Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 5775-5793. <a href="https://doi.org/10.1021/acs.jmedchem.7b01306" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01306%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BInsights%252Bof%252BBRAF%252BInhibitors%252Bin%252BCancer%26aulast%3DAgianian%26aufirst%3DBogos%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01092017%26date%3D06032018%26date%3D20022018%26volume%3D61%26issue%3D14%26spage%3D5775%26epage%3D5793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 5822-5880. <a href="https://doi.org/10.1021/acs.jmedchem.7b01788" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFluorine%252Band%252BFluorinated%252BMotifs%252Bin%252Bthe%252BDesign%252Band%252BApplication%252Bof%252BBioisosteres%252Bfor%252BDrug%252BDesign%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D05122017%26date%3D05022018%26volume%3D61%26issue%3D14%26spage%3D5822%26epage%3D5880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Floriana  Morgillo</span>, <span class="hlFld-ContribAuthor ">Giorgio  Amendola</span>, <span class="hlFld-ContribAuthor ">Carminia Maria  Della Corte</span>, <span class="hlFld-ContribAuthor ">Chiara  Giacomelli</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Botta</span>, <span class="hlFld-ContribAuthor ">Salvatore  Di Maro</span>, <span class="hlFld-ContribAuthor ">Anna  Messere</span>, <span class="hlFld-ContribAuthor ">Vincenza  Ciaramella</span>, <span class="hlFld-ContribAuthor ">Sabrina  Taliani</span>, <span class="hlFld-ContribAuthor ">Luciana  Marinelli</span>, <span class="hlFld-ContribAuthor ">Maria Letizia  Trincavelli</span>, <span class="hlFld-ContribAuthor ">Claudia  Martini</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Fortunato  Ciardiello</span>, and <span class="hlFld-ContribAuthor ">Sandro  Cosconati</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (17)
                                     , 7447-7458. <a href="https://doi.org/10.1021/acs.jmedchem.7b00794" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00794%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BMET%252Band%252BSMO%252BNegative%252BModulators%252BOvercome%252BResistance%252Bto%252BEGFR%252BInhibitors%252Bin%252BHuman%252BNonsmall%252BCell%252BLung%252BCancer%26aulast%3DMorgillo%26aufirst%3DFloriana%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D31052017%26date%3D22082017%26date%3D14092017%26date%3D08082017%26volume%3D60%26issue%3D17%26spage%3D7447%26epage%3D7458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eric P.  Gillis</span>, <span class="hlFld-ContribAuthor ">Kyle J.  Eastman</span>, <span class="hlFld-ContribAuthor ">Matthew D.  Hill</span>, <span class="hlFld-ContribAuthor ">David J.  Donnelly</span>, and <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">Applications of Fluorine in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (21)
                                     , 8315-8359. <a href="https://doi.org/10.1021/acs.jmedchem.5b00258" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DApplications%252Bof%252BFluorine%252Bin%252BMedicinal%252BChemistry%26aulast%3DGillis%26aufirst%3DEric%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D13022015%26date%3D22072015%26date%3D12112015%26volume%3D58%26issue%3D21%26spage%3D8315%26epage%3D8359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hang  Shen</span>, <span class="hlFld-ContribAuthor ">Jiaqiang  Li</span>, <span class="hlFld-ContribAuthor ">Qing  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Pan</span>, <span class="hlFld-ContribAuthor ">Ruofeng  Huang</span>, and <span class="hlFld-ContribAuthor ">Yan  Xiong</span>  . </span><span class="cited-content_cbyCitation_article-title">Umpolung Strategy for Synthesis of β-Ketonitriles through Hypervalent Iodine-Promoted Cyanation of Silyl Enol Ethers. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>80 </em>
                                    (14)
                                     , 7212-7218. <a href="https://doi.org/10.1021/acs.joc.5b01102" title="DOI URL">https://doi.org/10.1021/acs.joc.5b01102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b01102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b01102%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DUmpolung%252BStrategy%252Bfor%252BSynthesis%252Bof%252B%2525CE%2525B2-Ketonitriles%252Bthrough%252BHypervalent%252BIodine-Promoted%252BCyanation%252Bof%252BSilyl%252BEnol%252BEthers%26aulast%3DShen%26aufirst%3DHang%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D17052015%26date%3D25062015%26date%3D17072015%26date%3D11062015%26volume%3D80%26issue%3D14%26spage%3D7212%26epage%3D7218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna  Wlochal</span>, <span class="hlFld-ContribAuthor ">Robert D. M.  Davies</span>, and <span class="hlFld-ContribAuthor ">Jonathan  Burton</span>  . </span><span class="cited-content_cbyCitation_article-title">Cubanes in Medicinal Chemistry: Synthesis of Functionalized Building Blocks. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2014,</strong> <em>16 </em>
                                    (16)
                                     , 4094-4097. <a href="https://doi.org/10.1021/ol501750k" title="DOI URL">https://doi.org/10.1021/ol501750k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol501750k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol501750k%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCubanes%252Bin%252BMedicinal%252BChemistry%25253A%252BSynthesis%252Bof%252BFunctionalized%252BBuilding%252BBlocks%26aulast%3DWlochal%26aufirst%3DJoanna%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18062014%26date%3D28072014%26date%3D15082014%26volume%3D16%26issue%3D16%26spage%3D4094%26epage%3D4097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huimin  Cheng</span>, <span class="hlFld-ContribAuthor ">Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Qingwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Jibu  Lu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (6)
                                     , 2692-2703. <a href="https://doi.org/10.1021/jm500007h" title="DOI URL">https://doi.org/10.1021/jm500007h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500007h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500007h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Band%252BOptimization%252Bof%252BNew%252BDual%252BInhibitors%252Bof%252BB-Raf%252Band%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BKinases%252Bfor%252BOvercoming%252BResistance%252Bagainst%252BVemurafenib%26aulast%3DCheng%26aufirst%3DHuimin%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D03012014%26date%3D18032014%26date%3D27032014%26date%3D03032014%26volume%3D57%26issue%3D6%26spage%3D2692%26epage%3D2703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karol R.  Francisco</span>, <span class="hlFld-ContribAuthor ">Carmine  Varricchio</span>, <span class="hlFld-ContribAuthor ">Thomas J.  Paniak</span>, <span class="hlFld-ContribAuthor ">Marisa C.  Kozlowski</span>, <span class="hlFld-ContribAuthor ">Andrea  Brancale</span>, <span class="hlFld-ContribAuthor ">Carlo  Ballatore</span>. </span><span class="cited-content_cbyCitation_article-title">Structure property relationships of N-acylsulfonamides and related bioisosteres. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113399. <a href="https://doi.org/10.1016/j.ejmech.2021.113399" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113399</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113399%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252Bproperty%252Brelationships%252Bof%252BN-acylsulfonamides%252Band%252Brelated%252Bbioisosteres%26aulast%3DFrancisco%26aufirst%3DKarol%2BR.%26date%3D2021%26volume%3D218%26spage%3D113399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cong-Cong  Jia</span>, <span class="hlFld-ContribAuthor ">Wang  Chen</span>, <span class="hlFld-ContribAuthor ">Zi-Li  Feng</span>, <span class="hlFld-ContribAuthor ">Zhao-Peng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     , 45-62. <a href="https://doi.org/10.4155/fmc-2020-0170" title="DOI URL">https://doi.org/10.4155/fmc-2020-0170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0170%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bof%252BRET%252Bprotein%252Bkinase%252Binhibitors%252Bwith%252Bdiverse%252Bscaffolds%252Bas%252Bhinge%252Bbinders%26aulast%3DJia%26aufirst%3DCong-Cong%26date%3D2021%26volume%3D13%26issue%3D1%26spage%3D45%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pulla Reddy  Boggu</span>, <span class="hlFld-ContribAuthor ">Eeda  Venkateswararao</span>, <span class="hlFld-ContribAuthor ">Manoj  Manickam</span>, <span class="hlFld-ContribAuthor ">Niti  Sharma</span>, <span class="hlFld-ContribAuthor ">Jong Seong  Kang</span>, <span class="hlFld-ContribAuthor ">Sang-Hun  Jung</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of diphenylalkylisoxazol-5-amine scaffold as novel activator of cardiac myosin. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (22)
                                     , 115742. <a href="https://doi.org/10.1016/j.bmc.2020.115742" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115742</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115742%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bdiphenylalkylisoxazol-5-amine%252Bscaffold%252Bas%252Bnovel%252Bactivator%252Bof%252Bcardiac%252Bmyosin%26aulast%3DBoggu%26aufirst%3DPulla%2BReddy%26date%3D2020%26volume%3D28%26issue%3D22%26spage%3D115742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia-Nian  Chen</span>, <span class="hlFld-ContribAuthor ">Ting  Li</span>, <span class="hlFld-ContribAuthor ">Li  Cheng</span>, <span class="hlFld-ContribAuthor ">Tai-Sheng  Qin</span>, <span class="hlFld-ContribAuthor ">Ye-Xiang  Sun</span>, <span class="hlFld-ContribAuthor ">Chu-Ting  Chen</span>, <span class="hlFld-ContribAuthor ">Yue-Zhen  He</span>, <span class="hlFld-ContribAuthor ">Guang  Liu</span>, <span class="hlFld-ContribAuthor ">Di  Yao</span>, <span class="hlFld-ContribAuthor ">Ying  Wei</span>, <span class="hlFld-ContribAuthor ">Qiu-Yin  Li</span>, <span class="hlFld-ContribAuthor ">Guang-Ji  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112661. <a href="https://doi.org/10.1016/j.ejmech.2020.112661" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112661%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bin%2525C2%2525A0vitro%252Banti-bladder%252Bcancer%252Bactivity%252Bevaluation%252Bof%252Bquinazolinyl-arylurea%252Bderivatives%26aulast%3DChen%26aufirst%3DJia-Nian%26date%3D2020%26volume%3D205%26spage%3D112661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeepsinh  Chavda</span>, <span class="hlFld-ContribAuthor ">Hardik  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112675. <a href="https://doi.org/10.1016/j.ejmech.2020.112675" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112675%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystemic%252Breview%252Bon%252BB-RafV600E%252Bmutation%252Bas%252Bpotential%252Btherapeutic%252Btarget%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DChavda%26aufirst%3DJaydeepsinh%26date%3D2020%26volume%3D206%26spage%3D112675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soha R. Abd El  Hadi</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Dalia H.  Soliman</span>, <span class="hlFld-ContribAuthor ">Eman Z.  Elrazaz</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 103961. <a href="https://doi.org/10.1016/j.bioorg.2020.103961" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103961%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DScaffold%252Bhopping%252Band%252Bredesign%252Bapproaches%252Bfor%252Bquinazoline%252Bbased%252Burea%252Bderivatives%252Bas%252Bpotent%252BVEGFR-2%252Binhibitors%26aulast%3DHadi%26aufirst%3DSoha%2BR.%2BAbd%2BEl%26date%3D2020%26volume%3D101%26spage%3D103961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruo-Jun  Man</span>, <span class="hlFld-ContribAuthor ">Ya-Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Ai-Qin  Jiang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">A patent review of RAF kinase inhibitors (2010–2018). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (9)
                                     , 675-688. <a href="https://doi.org/10.1080/13543776.2019.1651842" title="DOI URL">https://doi.org/10.1080/13543776.2019.1651842</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1651842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1651842%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Breview%252Bof%252BRAF%252Bkinase%252Binhibitors%252B%2525282010%2525E2%252580%2525932018%252529%26aulast%3DMan%26aufirst%3DRuo-Jun%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D9%26spage%3D675%26epage%3D688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chong  Zhang</span>, <span class="hlFld-ContribAuthor ">Yiqin  Luo</span>, <span class="hlFld-ContribAuthor ">Qiaoling  He</span>, <span class="hlFld-ContribAuthor ">Shuai  Liu</span>, <span class="hlFld-ContribAuthor ">Andong  He</span>, <span class="hlFld-ContribAuthor ">Jie  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium-induced colitis. </span><span class="cited-content_cbyCitation_journal-name">Clinical Science</span><span> <strong>2019,</strong> <em>133 </em>
                                    (8)
                                     , 919-932. <a href="https://doi.org/10.1042/CS20181081" title="DOI URL">https://doi.org/10.1042/CS20181081</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/CS20181081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FCS20181081%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Science%26atitle%3DA%252Bpan-RAF%252Binhibitor%252BLY3009120%252Binhibits%252Bnecroptosis%252Bby%252Bpreventing%252Bphosphorylation%252Bof%252BRIPK1%252Band%252Balleviates%252Bdextran%252Bsulfate%252Bsodium-induced%252Bcolitis%26aulast%3DZhang%26aufirst%3DChong%26date%3D2019%26date%3D2019%26volume%3D133%26issue%3D8%26spage%3D919%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vladimir S.  D’yachenko</span>, <span class="hlFld-ContribAuthor ">Dmitry V.  Danilov</span>, <span class="hlFld-ContribAuthor ">Tatyana K.  Shkineva</span>, <span class="hlFld-ContribAuthor ">Irina А.  Vatsadze</span>, <span class="hlFld-ContribAuthor ">Vladimir V.  Burmistrov</span>, <span class="hlFld-ContribAuthor ">Gennady M.  Butov</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and properties of 1-[(adamantan-1-yl)methyl]-3-pyrazolyl ureas. </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2019,</strong> <em>55 </em>
                                    (2)
                                     , 129-134. <a href="https://doi.org/10.1007/s10593-019-02428-2" title="DOI URL">https://doi.org/10.1007/s10593-019-02428-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-019-02428-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-019-02428-2%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DSynthesis%252Band%252Bproperties%252Bof%252B1-%25255B%252528adamantan-1-yl%252529methyl%25255D-3-pyrazolyl%252Bureas%26aulast%3DD%25E2%2580%2599yachenko%26aufirst%3DVladimir%2BS.%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D2%26spage%3D129%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chung-Pu  Wu</span>, <span class="hlFld-ContribAuthor ">Sheng-Chieh  Hsu</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 169-185. <a href="https://doi.org/10.1016/B978-0-12-816435-8.00011-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-816435-8.00011-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816435-8.00011-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816435-8.00011-0%26sid%3Dliteratum%253Aachs%26atitle%3DSmall%252BMolecule%252BChemosensitizing%252BAgents%25253A%252BPolo-Like%252BKinase%252B1%252B%252528Plk1%252529%25252C%252BBRAF%252Band%252BJanus%252BKinase%252B%252528JAK%252529%252BInhibitors%26aulast%3DWu%26aufirst%3DChung-Pu%26date%3D2019%26spage%3D169%26epage%3D185%26pub%3DElsevier%26atitle%3DProtein%252BKinase%252BInhibitors%252Bas%252BSensitizing%252BAgents%252Bfor%252BChemotherapy%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingkun  Shi</span>, <span class="hlFld-ContribAuthor ">Hongqing  Xiao</span>, <span class="hlFld-ContribAuthor ">Xiu-Hua  Xu</span>, <span class="hlFld-ContribAuthor ">Yangen  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Transition metal free decarboxylative fluoroalkylation of
              N
              -acrylamides with 3,3,3-trifluoro-2,2-dimethylpropanoic acid (TFDMPA). </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (44)
                                     , 8472-8476. <a href="https://doi.org/10.1039/C8OB02457J" title="DOI URL">https://doi.org/10.1039/C8OB02457J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02457J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02457J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DTransition%252Bmetal%252Bfree%252Bdecarboxylative%252Bfluoroalkylation%252Bof%252BN%252B-acrylamides%252Bwith%252B3%25252C3%25252C3-trifluoro-2%25252C2-dimethylpropanoic%252Bacid%252B%252528TFDMPA%252529%26aulast%3DShi%26aufirst%3DYingkun%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D44%26spage%3D8472%26epage%3D8476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  Chen</span>, <span class="hlFld-ContribAuthor ">Jiyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Zhen  Tian</span>, <span class="hlFld-ContribAuthor ">Xueying  Liu</span>, <span class="hlFld-ContribAuthor ">Shengyong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, cytotoxic activity and binding model analysis of novel isoxazole-docetaxel analogues with C3′-N modification. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2018,</strong> <em>27 </em>
                                    (5)
                                     , 1355-1365. <a href="https://doi.org/10.1007/s00044-018-2151-7" title="DOI URL">https://doi.org/10.1007/s00044-018-2151-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-018-2151-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-018-2151-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DSynthesis%25252C%252Bcytotoxic%252Bactivity%252Band%252Bbinding%252Bmodel%252Banalysis%252Bof%252Bnovel%252Bisoxazole-docetaxel%252Banalogues%252Bwith%252BC3%2525E2%252580%2525B2-N%252Bmodification%26aulast%3DChen%26aufirst%3DMing%26date%3D2018%26date%3D2018%26volume%3D27%26issue%3D5%26spage%3D1355%26epage%3D1365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. Yu.  Volkonskii</span>, <span class="hlFld-ContribAuthor ">A. S.  Peregudov</span>, <span class="hlFld-ContribAuthor ">T. V.  Strelkova</span>, <span class="hlFld-ContribAuthor ">N. D.  Kagramanov</span>. </span><span class="cited-content_cbyCitation_article-title">E,Z-Isomers of 3-ethoxy-4,4,4-trifluorobut-2-enenitrile and N-methylpyrrolidines derived from them. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Bulletin</span><span> <strong>2018,</strong> <em>67 </em>
                                    (1)
                                     , 164-167. <a href="https://doi.org/10.1007/s11172-018-2053-3" title="DOI URL">https://doi.org/10.1007/s11172-018-2053-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11172-018-2053-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11172-018-2053-3%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Bulletin%26atitle%3DE%25252CZ-Isomers%252Bof%252B3-ethoxy-4%25252C4%25252C4-trifluorobut-2-enenitrile%252Band%252BN-methylpyrrolidines%252Bderived%252Bfrom%252Bthem%26aulast%3DVolkonskii%26aufirst%3DA.%2BYu.%26date%3D2018%26date%3D2018%26volume%3D67%26issue%3D1%26spage%3D164%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cuiping  Jiang</span>, <span class="hlFld-ContribAuthor ">Lin  Xie</span>, <span class="hlFld-ContribAuthor ">Yiding  Zhang</span>, <span class="hlFld-ContribAuthor ">Masayuki  Fujinaga</span>, <span class="hlFld-ContribAuthor ">Wakana  Mori</span>, <span class="hlFld-ContribAuthor ">Yusuke  Kurihara</span>, <span class="hlFld-ContribAuthor ">Tomoteru  Yamasaki</span>, <span class="hlFld-ContribAuthor ">Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Ming-Rong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic Evaluation of [
              11
              C]CEP-32496 in Nude Mice Bearing BRAF
              V600E
              Mutation-Induced Melanomas. </span><span class="cited-content_cbyCitation_journal-name">Molecular Imaging</span><span> <strong>2018,</strong> <em>17 </em>, 153601211879595. <a href="https://doi.org/10.1177/1536012118795952" title="DOI URL">https://doi.org/10.1177/1536012118795952</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1536012118795952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1536012118795952%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Imaging%26atitle%3DPharmacokinetic%252BEvaluation%252Bof%252B%25255B%252B11%252BC%25255DCEP-32496%252Bin%252BNude%252BMice%252BBearing%252BBRAF%252BV600E%252BMutation-Induced%252BMelanomas%26aulast%3DJiang%26aufirst%3DCuiping%26date%3D2018%26date%3D2018%26volume%3D17%26spage%3D153601211879595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sushobhan  Mukhopadhyay</span>, <span class="hlFld-ContribAuthor ">Dinesh S.  Barak</span>, <span class="hlFld-ContribAuthor ">Ilesha  Avasthi</span>, <span class="hlFld-ContribAuthor ">Sanjay  Batra</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Transformation of Alkyl 3-nitro-5-(aryl/alkyl)isoxazole-4-carboxylates into 3-amino- and 3-hydrazinyl-5-aryl/alkyl-isoxazole-4-carboxylates in Aqueous Solution. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2017,</strong> <em>359 </em>
                                    (22)
                                     , 4050-4056. <a href="https://doi.org/10.1002/adsc.201700881" title="DOI URL">https://doi.org/10.1002/adsc.201700881</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201700881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201700881%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DEfficient%252BTransformation%252Bof%252BAlkyl%252B3-nitro-5-%252528aryl%25252Falkyl%252529isoxazole-4-carboxylates%252Binto%252B3-amino-%252Band%252B3-hydrazinyl-5-aryl%25252Falkyl-isoxazole-4-carboxylates%252Bin%252BAqueous%252BSolution%26aulast%3DMukhopadhyay%26aufirst%3DSushobhan%26date%3D2017%26date%3D2017%26volume%3D359%26issue%3D22%26spage%3D4050%26epage%3D4056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang G.  Li</span>, <span class="hlFld-ContribAuthor ">Romel  Somwar</span>, <span class="hlFld-ContribAuthor ">James  Joseph</span>, <span class="hlFld-ContribAuthor ">Roger S.  Smith</span>, <span class="hlFld-ContribAuthor ">Takuo  Hayashi</span>, <span class="hlFld-ContribAuthor ">Leenus  Martin</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Franovic</span>, <span class="hlFld-ContribAuthor ">Anni  Schairer</span>, <span class="hlFld-ContribAuthor ">Eric  Martin</span>, <span class="hlFld-ContribAuthor ">Gregory J.  Riely</span>, <span class="hlFld-ContribAuthor ">Jason  Harris</span>, <span class="hlFld-ContribAuthor ">Shunqi  Yan</span>, <span class="hlFld-ContribAuthor ">Ge  Wei</span>, <span class="hlFld-ContribAuthor ">Jennifer W.  Oliver</span>, <span class="hlFld-ContribAuthor ">Rupal  Patel</span>, <span class="hlFld-ContribAuthor ">Pratik  Multani</span>, <span class="hlFld-ContribAuthor ">Marc  Ladanyi</span>, <span class="hlFld-ContribAuthor ">Alexander  Drilon</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor Activity of RXDX-105 in Multiple Cancer Types with
              RET
              Rearrangements or Mutations. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2017,</strong> <em>23 </em>
                                    (12)
                                     , 2981-2990. <a href="https://doi.org/10.1158/1078-0432.CCR-16-1887" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-16-1887</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-16-1887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-16-1887%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DAntitumor%252BActivity%252Bof%252BRXDX-105%252Bin%252BMultiple%252BCancer%252BTypes%252Bwith%252BRET%252BRearrangements%252Bor%252BMutations%26aulast%3DLi%26aufirst%3DGang%2BG.%26date%3D2017%26date%3D2016%26volume%3D23%26issue%3D12%26spage%3D2981%26epage%3D2990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleš  Machara</span>, <span class="hlFld-ContribAuthor ">Jan  Konvalinka</span>, <span class="hlFld-ContribAuthor ">Martin  Kotora</span>. </span><span class="cited-content_cbyCitation_article-title">A MODULAR SYNTHESIS OF
              N
              -BENZOTRIAZOLE UREAS USING ALKYLATION OF 5-NITROBENZOTRIAZOLE. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2016,</strong> <em>1 </em>
                                    (1)
                                     , 101-107. <a href="https://doi.org/10.1002/slct.201600025" title="DOI URL">https://doi.org/10.1002/slct.201600025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201600025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201600025%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DA%252BMODULAR%252BSYNTHESIS%252BOF%252BN%252B-BENZOTRIAZOLE%252BUREAS%252BUSING%252BALKYLATION%252BOF%252B5-NITROBENZOTRIAZOLE%26aulast%3DMachara%26aufirst%3DAle%25C5%25A1%26date%3D2016%26date%3D2016%26volume%3D1%26issue%3D1%26spage%3D101%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vinod  Kumar</span>, <span class="hlFld-ContribAuthor ">Kamalneet  Kaur</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorinated isoxazolines and isoxazoles: A synthetic perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2015,</strong> <em>180 </em>, 55-97. <a href="https://doi.org/10.1016/j.jfluchem.2015.09.004" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2015.09.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2015.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2015.09.004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DFluorinated%252Bisoxazolines%252Band%252Bisoxazoles%25253A%252BA%252Bsynthetic%252Bperspective%26aulast%3DKumar%26aufirst%3DVinod%26date%3D2015%26volume%3D180%26spage%3D55%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Shasha  Wu</span>, <span class="hlFld-ContribAuthor ">Longsheng  Ma</span>, <span class="hlFld-ContribAuthor ">Jinying  Bai</span>, <span class="hlFld-ContribAuthor ">Zijian  Liu</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor activity of novel 6,7-dimethoxyquinazoline derivatives containing diaryl urea moiety. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Chinese Universities</span><span> <strong>2015,</strong> <em>31 </em>
                                    (5)
                                     , 766-773. <a href="https://doi.org/10.1007/s40242-015-5036-z" title="DOI URL">https://doi.org/10.1007/s40242-015-5036-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40242-015-5036-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40242-015-5036-z%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Chinese%2520Universities%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252Bnovel%252B6%25252C7-dimethoxyquinazoline%252Bderivatives%252Bcontaining%252Bdiaryl%252Burea%252Bmoiety%26aulast%3DHou%26aufirst%3DYunlei%26date%3D2015%26date%3D2015%26volume%3D31%26issue%3D5%26spage%3D766%26epage%3D773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Liu</span>, <span class="hlFld-ContribAuthor ">Sunny  Abraham</span>, <span class="hlFld-ContribAuthor ">Xing  Liu</span>, <span class="hlFld-ContribAuthor ">Shimin  Xu</span>, <span class="hlFld-ContribAuthor ">Allison M.  Rooks</span>, <span class="hlFld-ContribAuthor ">Ron  Nepomuceno</span>, <span class="hlFld-ContribAuthor ">Alan  Dao</span>, <span class="hlFld-ContribAuthor ">Daniel  Brigham</span>, <span class="hlFld-ContribAuthor ">Dana  Gitnick</span>, <span class="hlFld-ContribAuthor ">Darren E.  Insko</span>, <span class="hlFld-ContribAuthor ">Michael F.  Gardner</span>, <span class="hlFld-ContribAuthor ">Patrick P.  Zarrinkar</span>, <span class="hlFld-ContribAuthor ">Ron  Christopher</span>, <span class="hlFld-ContribAuthor ">Barbara  Belli</span>, <span class="hlFld-ContribAuthor ">Robert C.  Armstrong</span>, <span class="hlFld-ContribAuthor ">Mark W.  Holladay</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (17)
                                     , 3436-3441. <a href="https://doi.org/10.1016/j.bmcl.2015.07.023" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.07.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.07.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252Boptimization%252Bof%252Ba%252Bhighly%252Befficacious%252Bclass%252Bof%252B5-aryl-2-aminopyridines%252Bas%252BFMS-like%252Btyrosine%252Bkinase%252B3%252B%252528FLT3%252529%252Binhibitors%26aulast%3DLiu%26aufirst%3DGang%26date%3D2015%26volume%3D25%26issue%3D17%26spage%3D3436%26epage%3D3441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoko  Shimoda</span>, <span class="hlFld-ContribAuthor ">Joji  Yui</span>, <span class="hlFld-ContribAuthor ">Masayuki  Fujinaga</span>, <span class="hlFld-ContribAuthor ">Lin  Xie</span>, <span class="hlFld-ContribAuthor ">Katsushi  Kumata</span>, <span class="hlFld-ContribAuthor ">Masanao  Ogawa</span>, <span class="hlFld-ContribAuthor ">Tomoteru  Yamasaki</span>, <span class="hlFld-ContribAuthor ">Akiko  Hatori</span>, <span class="hlFld-ContribAuthor ">Kazunori  Kawamura</span>, <span class="hlFld-ContribAuthor ">Ming-Rong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">[11C-carbonyl]CEP-32496: Radiosynthesis, biodistribution and PET study of brain uptake in P-gp/BCRP knockout mice. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (15)
                                     , 3574-3577. <a href="https://doi.org/10.1016/j.bmcl.2014.05.045" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.05.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.05.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.05.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D%25255B11C-carbonyl%25255DCEP-32496%25253A%252BRadiosynthesis%25252C%252Bbiodistribution%252Band%252BPET%252Bstudy%252Bof%252Bbrain%252Buptake%252Bin%252BP-gp%25252FBCRP%252Bknockout%252Bmice%26aulast%3DShimoda%26aufirst%3DYoko%26date%3D2014%26volume%3D24%26issue%3D15%26spage%3D3574%26epage%3D3577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolina  Hertzman Johansson</span>, <span class="hlFld-ContribAuthor ">Suzanne  Egyhazi Brage</span>. </span><span class="cited-content_cbyCitation_article-title">BRAF inhibitors in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2014,</strong> <em>142 </em>
                                    (2)
                                     , 176-182. <a href="https://doi.org/10.1016/j.pharmthera.2013.11.011" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2013.11.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2013.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2013.11.011%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DBRAF%252Binhibitors%252Bin%252Bcancer%252Btherapy%26aulast%3DHertzman%2BJohansson%26aufirst%3DCarolina%26date%3D2014%26volume%3D142%26issue%3D2%26spage%3D176%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hala Bakr  El-Nassan</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in the identification of BRAF inhibitors as anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>72 </em>, 170-205. <a href="https://doi.org/10.1016/j.ejmech.2013.11.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.11.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.11.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bthe%252Bidentification%252Bof%252BBRAF%252Binhibitors%252Bas%252Banti-cancer%252Bagents%26aulast%3DEl-Nassan%26aufirst%3DHala%2BBakr%26date%3D2014%26volume%3D72%26spage%3D170%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satyanarayana  Battula</span>, <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Qazi Naveed  Ahmed</span>. </span><span class="cited-content_cbyCitation_article-title">Cu–benzotriazole-catalyzed electrophilic cyclization of N-arylimines: a methodical tandem approach to O-protected-4hydroxyquinazolines-. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2014,</strong> <em>4 </em>
                                    (72)
                                     , 38375. <a href="https://doi.org/10.1039/C4RA07377K" title="DOI URL">https://doi.org/10.1039/C4RA07377K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4RA07377K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4RA07377K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DCu%2525E2%252580%252593benzotriazole-catalyzed%252Belectrophilic%252Bcyclization%252Bof%252BN-arylimines%25253A%252Ba%252Bmethodical%252Btandem%252Bapproach%252Bto%252BO-protected-4hydroxyquinazolines-%26aulast%3DBattula%26aufirst%3DSatyanarayana%26date%3D2014%26date%3D2014%26volume%3D4%26issue%3D72%26spage%3D38375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana Marta  Matos</span>, <span class="hlFld-ContribAuthor ">Ana Paula  Francisco</span>. </span><span class="cited-content_cbyCitation_article-title">Targets, Structures, and Recent Approaches in Malignant Melanoma Chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2013,</strong> <em>8 </em>
                                    (11)
                                     , 1751-1765. <a href="https://doi.org/10.1002/cmdc.201300248" title="DOI URL">https://doi.org/10.1002/cmdc.201300248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201300248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201300248%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DTargets%25252C%252BStructures%25252C%252Band%252BRecent%252BApproaches%252Bin%252BMalignant%252BMelanoma%252BChemotherapy%26aulast%3DMatos%26aufirst%3DAna%2BMarta%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D11%26spage%3D1751%26epage%3D1765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert E.  Martell</span>, <span class="hlFld-ContribAuthor ">David G.  Brooks</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Keith  Wilcoxen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Drugs for Promising Targets. </span><span class="cited-content_cbyCitation_journal-name">Clinical Therapeutics</span><span> <strong>2013,</strong> <em>35 </em>
                                    (9)
                                     , 1271-1281. <a href="https://doi.org/10.1016/j.clinthera.2013.08.005" title="DOI URL">https://doi.org/10.1016/j.clinthera.2013.08.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.clinthera.2013.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.clinthera.2013.08.005%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Therapeutics%26atitle%3DDiscovery%252Bof%252BNovel%252BDrugs%252Bfor%252BPromising%252BTargets%26aulast%3DMartell%26aufirst%3DRobert%2BE.%26date%3D2013%26volume%3D35%26issue%3D9%26spage%3D1271%26epage%3D1281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Subhasis  Samai</span>, <span class="hlFld-ContribAuthor ">Tanmoy  Chanda</span>, <span class="hlFld-ContribAuthor ">Hiriyakkanavar  Ila</span>, <span class="hlFld-ContribAuthor ">Maya Shankar  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Three-Component Heteroannulation of β-Oxo Dithioesters, Amines and Hydroxylamine: Regioselective, Facile and Straightforward Entry to 5-Substituted 3-Aminoisoxazoles. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2013,</strong> <em>2013 </em>
                                    (19)
                                     , 4026-4031. <a href="https://doi.org/10.1002/ejoc.201300038" title="DOI URL">https://doi.org/10.1002/ejoc.201300038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201300038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201300038%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BThree-Component%252BHeteroannulation%252Bof%252B%2525CE%2525B2-Oxo%252BDithioesters%25252C%252BAmines%252Band%252BHydroxylamine%25253A%252BRegioselective%25252C%252BFacile%252Band%252BStraightforward%252BEntry%252Bto%252B5-Substituted%252B3-Aminoisoxazoles%26aulast%3DSamai%26aufirst%3DSubhasis%26date%3D2013%26date%3D2013%26volume%3D2013%26issue%3D19%26spage%3D4026%26epage%3D4031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Baoxiang  Hu</span>, <span class="hlFld-ContribAuthor ">Xiaochu  Zhang</span>, <span class="hlFld-ContribAuthor ">Lili  Sheng</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Zhenlu  Shen</span>, <span class="hlFld-ContribAuthor ">Xinquan  Hu</span>, <span class="hlFld-ContribAuthor ">Nan  Sun</span>, <span class="hlFld-ContribAuthor ">Weimin  Mo</span>. </span><span class="cited-content_cbyCitation_article-title">Hexachlorocyclotriphosphazene (HCCP)-Mediated Direct Formation of Thioethers and Ethers from Quinazolin-4(3H)-ones. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2013,</strong> <em>18 </em>
                                    (5)
                                     , 5580-5593. <a href="https://doi.org/10.3390/molecules18055580" title="DOI URL">https://doi.org/10.3390/molecules18055580</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules18055580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules18055580%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DHexachlorocyclotriphosphazene%252B%252528HCCP%252529-Mediated%252BDirect%252BFormation%252Bof%252BThioethers%252Band%252BEthers%252Bfrom%252BQuinazolin-4%2525283H%252529-ones%26aulast%3DHu%26aufirst%3DBaoxiang%26date%3D2013%26date%3D2013%26volume%3D18%26issue%3D5%26spage%3D5580%26epage%3D5593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joyce  James</span>, <span class="hlFld-ContribAuthor ">Bruce  Ruggeri</span>, <span class="hlFld-ContribAuthor ">Robert C.  Armstrong</span>, <span class="hlFld-ContribAuthor ">Martin W.  Rowbottom</span>, <span class="hlFld-ContribAuthor ">Susan  Jones-Bolin</span>, <span class="hlFld-ContribAuthor ">Ruwanthi N.  Gunawardane</span>, <span class="hlFld-ContribAuthor ">Pawel  Dobrzanski</span>, <span class="hlFld-ContribAuthor ">Michael F.  Gardner</span>, <span class="hlFld-ContribAuthor ">Hugh  Zhao</span>, <span class="hlFld-ContribAuthor ">Merryl D.  Cramer</span>, <span class="hlFld-ContribAuthor ">Kathryn  Hunter</span>, <span class="hlFld-ContribAuthor ">Ronald R.  Nepomuceno</span>, <span class="hlFld-ContribAuthor ">Mangeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Dana  Gitnick</span>, <span class="hlFld-ContribAuthor ">Mehran  Yazdanian</span>, <span class="hlFld-ContribAuthor ">Darren E.  Insko</span>, <span class="hlFld-ContribAuthor ">Mark A.  Ator</span>, <span class="hlFld-ContribAuthor ">Julius L.  Apuy</span>, <span class="hlFld-ContribAuthor ">Raffaella  Faraoni</span>, <span class="hlFld-ContribAuthor ">Bruce D.  Dorsey</span>, <span class="hlFld-ContribAuthor ">Michael  Williams</span>, <span class="hlFld-ContribAuthor ">Shripad S.  Bhagwat</span>, <span class="hlFld-ContribAuthor ">Mark W.  Holladay</span>. </span><span class="cited-content_cbyCitation_article-title">CEP-32496: A Novel Orally Active BRAF
              V600E
              Inhibitor with Selective Cellular and
              In Vivo
              Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2012,</strong> <em>11 </em>
                                    (4)
                                     , 930-941. <a href="https://doi.org/10.1158/1535-7163.MCT-11-0645" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-11-0645</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-11-0645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-11-0645%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DCEP-32496%25253A%252BA%252BNovel%252BOrally%252BActive%252BBRAF%252BV600E%252BInhibitor%252Bwith%252BSelective%252BCellular%252Band%252BIn%252BVivo%252BAntitumor%252BActivity%26aulast%3DJames%26aufirst%3DJoyce%26date%3D2012%26date%3D2012%26volume%3D11%26issue%3D4%26spage%3D930%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of known RAF inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Evolution of the 4-quinazolinyloxy-diaryl urea series of b-Raf<sup>V600E</sup> inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Formation of Aminoisoxazoles from Ketonitriles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Isoxazol-5-yl-carbamates <b>7a</b>–<b>k</b> and Isoxazol-3-yl-carbamates <b>9a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, MeCN, THF, 75 °C, 15 h, 29–93%; (b) hydroxylamine hydrochloride, NaOH, water, 100 °C, 2.5 h, or hydroxylamine sulfate, NaOH, water/EtOH, 80 °C, 15 h; or (for <b>6e</b>) (i) TMSCHN<sub>2</sub>, Et<sub>2</sub>O, rt, 15 h, (ii) hydroxylamine hydrochloride, NaOMe, MeOH, 60 °C, 15 h, (iii) HCl, aq EtOH, 60 °C, 2 h; 11–100%; (c) PhOC(O)Cl or 4-Cl-PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 33–100%; (d) (i) hydroxylamine sulfate, NaHCO<sub>3</sub>, water/MeOH, 65 °C, or hydroxylamine hydrochloride, NaOH, water/EtOH, 65 °C, (ii) conc HCl, reflux, 26–71%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Isoxazol-3-yl-carbamates <b>9h</b>–<b>j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethylene glycol, TMSCl, DCM, reflux, 15 h, 57–78%; (b) (i) hydroxylamine hydrochloride, NH<sub>3</sub>/MeOH, 8-hydroxyquinoline, 70 °C, 15 h, (ii) conc HCl, EtOH, reflux, 68–69% (over two steps); (c) PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 77–89%; (d) TMSCHN<sub>2</sub>, Et<sub>2</sub>O, rt, 15 h, 90%; (e) (i) hydroxylamine hydrochloride, NaOMe, MeOH, 70 °C, 16 h, (ii) conc HCl, 80 °C, 30 min, 13%; (f) 4-Cl-PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 100%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 1<i>H</i>-Pyrazol-5-yl-carbamates <b>13a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>2</sup>NHNH<sub>2</sub>, EtOH, reflux, 36–51%; (b) PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, DCM or THF, 0 °C or rt, 30–100%.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Quinazoline Derivatives <b>18</b>–<b>51</b> and <b>54</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) X = O, (i) Cs<sub>2</sub>CO<sub>3</sub>, THF, rt, 30 min, (ii) 4-chloro-6,7-dimethoxyquinazoline, 50 °C, 24 h, 100%; X = S, (i) NaH, THF, rt, 30 min, (ii) 4-chloro-6,7-dimethoxyquinazoline, rt, 15 h, 85%; (b) ArNCO, DMF, 50 °C; or <b>7a</b>–<b>k</b> or <b>9a</b>–<b>j</b> or <b>13a</b>–<b>g</b>, DIEA, cat. DMAP, THF, rt or 50 °C, 5–75%; (c) PhOC(O)Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 15 h, 89%; (d) 3-aminophenol, THF, 120 °C, 2 h, 20%; (e) (i) Cs<sub>2</sub>CO<sub>3</sub>, THF, rt, 1 h, (ii) 4-chloro-6,7-dimethoxyquinazoline, 55 °C, 15 h, 43%.</p></p></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. KINOME<i>scan</i> tree spot graphic illustrating the selectivity profile for compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> versus a panel of 290 wild-type kinase targets (plotted as percent of control at 10 μM concentration, where 0 and 35% of control equals 100 and 65% competition, respectively). Images courtesy of KINOME<i>scan</i> (<a href="http://www.kinomescan.com" class="extLink">http://www.kinomescan.com</a>) and used with permission from KINOME<i>scan</i>, a division of DiscoveRx Corporation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy results upon oral dosing of compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> at 10, 30, and 100 mg/kg BID (dosed in 22% HPβCD) for 14 days to athymic nu/nu nude mice bearing established Colo-205 human colon tumor subcutaneous xenografts with the BRAF<sup>V600E</sup> genotype (10 animals per treatment group). A dose response relationship (left panel) for complete Colo-205 tumor growth inhibition and incidence of tumor regressions (right panel) was observed. Mice were monitored for signs of morbidity (behavior and body weight loss), and tumors were measured 3 times per week. Statistical significance (<i>p</i> < 0.05) for antitumor efficacy, based upon tumor growth inhibition relative to vehicle-treated controls, for both the 30 and 100 mg/kg groups was reached by day 5 of administration and extended to the termination of the study, with a final significance for tumor growth inhibition of <i>p</i> < 0.008 (30 mg/kg group) and <i>p</i> < 0.0001 (100 mg/kg group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) In vivo inhibition of normalized MEK phosphorylation in Colo-205 tumor xenograft-bearing mice over a 24 h period following a single oral dose of either vehicle (22% HPβCD) or compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> (10, 30, and 55 mg/kg, dosed in 22% HPβCD), and (b) corresponding compound levels in both plasma and tumor samples. At appropriate time points over a 24 h period, animals were sacrificed and plasma and tumor samples were collected and lysates prepared. Amounts of total MEK and pMEK in tumor lysates were measured by immunoblotting and ELISA methods. Compound levels in plasma and tumor tissue samples were analyzed and quantitated by LC-MS/MS. Values shown are mean + SEM from two studies; <i>n</i> = 3 tumor-bearing mice per time point per study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/medium/jm-2011-009925_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Binding mode of the isoxazol-3-yl urea compounds, based on docking experiments with DFG-out BRAF<sup>V600E</sup>, illustrated with compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> (carbon-magenta). The urea forms two hydrogen bonding interactions: one between the urea-O and the NH of Asp594 (DFG motif); the other between the urea NH’s and the carboxylate of Glu501 (α-C helix). A hydrogen bond (electrostatic interaction) between one of the fluorines of the CF<sub>3</sub> and the Thr508 OH may contribute a key binding interaction. (b) Comparison of the binding mode of sorafenib (carbon-light green) from the X-ray structure and compound <b><a class="ref internalNav" href="#g1" aria-label="40">40</a></b> (carbon-magenta) from the docking studies. (c) Subtle changes in the binding mode of compound <b>30</b> (carbon-magenta). (d) Chemical structure of sorafenib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2009925/production/images/large/jm-2011-009925_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2009925&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i156">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78216" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78216" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 22 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Peyssonnaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eychéne, A.</span><span> </span><span class="NLM_article-title">The Raf/MEK/ERK pathway: New concepts of activation</span> <span class="citation_source-journal">Biol. Cell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1016%2FS0248-4900%2801%2901125-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=11730323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=53-62&author=C.+Peyssonnauxauthor=A.+Eych%C3%A9ne&title=The+Raf%2FMEK%2FERK+pathway%3A+New+concepts+of+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Raf/MEK/ERK pathway: New concepts of activation</span></div><div class="casAuthors">Peyssonnaux, Carole; Eychene, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  The Raf/MEK/ERK signaling was the first MAP kinase cascade to be characterized.  It is probably one of the most well known signal transduction pathways among biologists because of its implication in a wide variety of cellular functions as diverse -and occasionally contradictory- as cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis.  Discovery and understanding of this pathway have benefited from the combination of both genetic studies in worms and flies and biochem. studies in mammalian cells.  However, ten years after, this field is still under debate and new mol. partners in the cascade continue to increase the complexity of its regulation.  This review deals with the emergence of new concepts in the activation and regulation of the Raf/MEK/ERK module.  In particular, the preponderant role of B-Raf is underlined, and the role of novel regulators such as KSR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyjiXSFlBQ6rVg90H21EOLACvtfcHk0lhQOG9j1Y5dJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D&md5=cde3db5b205a1305dc2e6262deea65ec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0248-4900%2801%2901125-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0248-4900%252801%252901125-X%26sid%3Dliteratum%253Aachs%26aulast%3DPeyssonnaux%26aufirst%3DC.%26aulast%3DEych%25C3%25A9ne%26aufirst%3DA.%26atitle%3DThe%2520Raf%252FMEK%252FERK%2520pathway%253A%2520New%2520concepts%2520of%2520activation%26jtitle%3DBiol.%2520Cell.%26date%3D2001%26volume%3D93%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the <i>BRAF</i> gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lhQOG9j1Y5dJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.-S.</span><span> </span><span class="NLM_article-title">Clinicopathologic significance of <i>BRAF</i> V600E mutation in papillary carcinomas of the thyroid: A meta-analysis</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=38-46&author=J.+H.+Leeauthor=E.-S.+Leeauthor=Y.-S.+Kim&title=Clinicopathologic+significance+of+BRAF+V600E+mutation+in+papillary+carcinomas+of+the+thyroid%3A+A+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DE.-S.%26aulast%3DKim%26aufirst%3DY.-S.%26atitle%3DClinicopathologic%2520significance%2520of%2520BRAF%2520V600E%2520mutation%2520in%2520papillary%2520carcinomas%2520of%2520the%2520thyroid%253A%2520A%2520meta-analysis%26jtitle%3DCancer%26date%3D2007%26volume%3D110%26spage%3D38%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Samowitz, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertsen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtaugh, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slattery, M. L.</span><span> </span><span class="NLM_article-title">Poor survival associated with the <i>BRAF</i> V600E mutation in microsatellite-stable colon cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">6063</span><span class="NLM_x">–</span> <span class="NLM_lpage">6069</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=6063-6069&author=W.+S.+Samowitzauthor=C.+Sweeneyauthor=J.+Herrickauthor=H.+Albertsenauthor=T.+R.+Levinauthor=M.+A.+Murtaughauthor=R.+K.+Wolffauthor=M.+L.+Slattery&title=Poor+survival+associated+with+the+BRAF+V600E+mutation+in+microsatellite-stable+colon+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamowitz%26aufirst%3DW.%2BS.%26aulast%3DSweeney%26aufirst%3DC.%26aulast%3DHerrick%26aufirst%3DJ.%26aulast%3DAlbertsen%26aufirst%3DH.%26aulast%3DLevin%26aufirst%3DT.%2BR.%26aulast%3DMurtaugh%26aufirst%3DM.%2BA.%26aulast%3DWolff%26aufirst%3DR.%2BK.%26aulast%3DSlattery%26aufirst%3DM.%2BL.%26atitle%3DPoor%2520survival%2520associated%2520with%2520the%2520BRAF%2520V600E%2520mutation%2520in%2520microsatellite-stable%2520colon%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D6063%26epage%3D6069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Houben, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terheyden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bröcker, E.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, U. R.</span><span> </span><span class="NLM_article-title">Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis</span> <span class="citation_source-journal">J. Carcinog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1186%2F1477-3163-3-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=15046639" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=6-18&author=R.+Houbenauthor=J.+C.+Beckerauthor=A.+Kappelauthor=P.+Terheydenauthor=E.-B.+Br%C3%B6ckerauthor=R.+Goetzauthor=U.+R.+Rapp&title=Constitutive+activation+of+the+Ras-Raf+signaling+pathway+in+metastatic+melanoma+is+associated+with+poor+prognosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1186%2F1477-3163-3-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1477-3163-3-6%26sid%3Dliteratum%253Aachs%26aulast%3DHouben%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DKappel%26aufirst%3DA.%26aulast%3DTerheyden%26aufirst%3DP.%26aulast%3DBr%25C3%25B6cker%26aufirst%3DE.-B.%26aulast%3DGoetz%26aufirst%3DR.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26atitle%3DConstitutive%2520activation%2520of%2520the%2520Ras-Raf%2520signaling%2520pathway%2520in%2520metastatic%2520melanoma%2520is%2520associated%2520with%2520poor%2520prognosis%26jtitle%3DJ.%2520Carcinog.%26date%3D2004%26volume%3D3%26spage%3D6%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Cantwell-Dorris, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Leary, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheils, O. M.</span><span> </span><span class="NLM_article-title">BRAF<sup>V600E</sup>: Implications for carcinogenesis and molecular therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1158%2F1535-7163.MCT-10-0799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=21388974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVCku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=385-394&author=E.+R.+Cantwell-Dorrisauthor=J.+J.+O%E2%80%99Learyauthor=O.+M.+Sheils&title=BRAFV600E%3A+Implications+for+carcinogenesis+and+molecular+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">BRAFV600E: Implications for Carcinogenesis and Molecular Therapy</span></div><div class="casAuthors">Cantwell-Dorris, Emma R.; O'Leary, John J.; Sheils, Orla M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-394</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is frequently mutated in human cancer.  This pathway consists of a small GTP protein of the RAS family that is activated in response to extracellular signaling to recruit a member of the RAF kinase family to the cell membrane.  Active RAF signals through MAP/ERK kinase to activate ERK and its downstream effectors to regulate a wide range of biol. activities including cell differentiation, proliferation, senescence, and survival.  Mutations in the v-raf murine sarcoma viral oncogenes homolog B1 (BRAF) isoform of the RAF kinase or KRAS isoform of the RAS protein are found as activating mutations in approx. 30% of all human cancers.  The BRAF pathway has become a target of interest for mol. therapy, with promising results emerging from clin. trials.  Here, the role of the most common BRAF mutation BRAFV600E in human carcinogenesis is investigated through a review of the literature, with specific focus on its role in melanoma, colorectal, and thyroid cancers and its potential as a therapeutic target.  Mol Cancer Ther; 10(3); 385-94.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcfrh5aNWzwbVg90H21EOLACvtfcHk0lgi8H-PqiSu1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVCku7o%253D&md5=dbe88681162d6cc363205028606ccba5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0799%26sid%3Dliteratum%253Aachs%26aulast%3DCantwell-Dorris%26aufirst%3DE.%2BR.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BJ.%26aulast%3DSheils%26aufirst%3DO.%2BM.%26atitle%3DBRAFV600E%253A%2520Implications%2520for%2520carcinogenesis%2520and%2520molecular%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D385%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="note"><p class="first last">Select examples include the following:</p></div><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ramurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costales, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashash, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renhowe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhagen, J.</span><span> </span><span class="NLM_article-title">Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3286</span><span class="NLM_x">–</span> <span class="NLM_lpage">3289</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3286-3289&author=S.+Ramurthyauthor=M.+Aikawaauthor=P.+Amiriauthor=A.+Costalesauthor=A.+Hashashauthor=J.+M.+Jansenauthor=S.+Linauthor=S.+Maauthor=P.+A.+Renhoweauthor=C.+M.+Shaferauthor=S.+Subramanianauthor=L.+Sungauthor=J.+Verhagen&title=Design+and+synthesis+of+5%2C6-fused+heterocyclic+amides+as+Raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DAikawa%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DCostales%26aufirst%3DA.%26aulast%3DHashash%26aufirst%3DA.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DSung%26aufirst%3DL.%26aulast%3DVerhagen%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%25205%252C6-fused%2520heterocyclic%2520amides%2520as%2520Raf%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3286%26epage%3D3289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrendt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malesky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newhouse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddatz, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturgis, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span> </span><span class="NLM_article-title">Pyrazolopyridine inhibitors of B-Raf<sup>V600E</sup>. Part 1: The development of selective, orally available, and efficacious inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml200025q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=342-347&author=S.+Wenglowskyauthor=L.+Renauthor=K.+A.+Arrendtauthor=E.+R.+Lairdauthor=I.+Aliagasauthor=B.+Alickeauthor=A.+J.+Buckmelterauthor=E.+F.+Chooauthor=V.+Dinkelauthor=B.+Fengauthor=S.+L.+Gloorauthor=S.+E.+Gouldauthor=S.+Grossauthor=J.+Gunzner-Tosteauthor=J.+D.+Hansenauthor=G.+Hatzivassiliouauthor=B.+Liuauthor=K.+Maleskyauthor=S.+Mathieuauthor=B.+Newhouseauthor=N.+J.+Raddatzauthor=Y.+Ranauthor=S.+Ranaauthor=N.+Randolphauthor=T.+Risomauthor=J.+Rudolphauthor=S.+Savageauthor=L.+T.+Selbyauthor=M.+Shragauthor=K.+Songauthor=H.+L.+Sturgisauthor=W.+C.+Voegtliauthor=Z.+Wenauthor=B.+S.+Willisauthor=R.+D.+Woessnerauthor=W.-I.+Wuauthor=W.+B.+Youngauthor=J.+Grina&title=Pyrazolopyridine+inhibitors+of+B-RafV600E.+Part+1%3A+The+development+of+selective%2C+orally+available%2C+and+efficacious+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1021%2Fml200025q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200025q%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DArrendt%26aufirst%3DK.%2BA.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DMalesky%26aufirst%3DK.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNewhouse%26aufirst%3DB.%26aulast%3DRaddatz%26aufirst%3DN.%2BJ.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DRandolph%26aufirst%3DN.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DSelby%26aufirst%3DL.%2BT.%26aulast%3DShrag%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DWillis%26aufirst%3DB.%2BS.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DGrina%26aufirst%3DJ.%26atitle%3DPyrazolopyridine%2520inhibitors%2520of%2520B-RafV600E.%2520Part%25201%253A%2520The%2520development%2520of%2520selective%252C%2520orally%2520available%252C%2520and%2520efficacious%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D342%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miknis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rast, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlachter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callejo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbraith, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span> </span><span class="NLM_article-title">Non-oxime inhibitors of B-Raf<sup>V600E</sup> kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1243</span><span class="NLM_x">–</span> <span class="NLM_lpage">1247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1243-1247&author=L.+Renauthor=S.+Wenglowskyauthor=G.+Miknisauthor=B.+Rastauthor=A.+J.+Buckmelterauthor=R.+J.+Elyauthor=S.+Schlachterauthor=E.+R.+Lairdauthor=N.+Randolphauthor=M.+Callejoauthor=M.+Martinsonauthor=S.+Galbraithauthor=B.+J.+Brandhuberauthor=G.+Vigersauthor=T.+Moralesauthor=W.+C.+Voegtliauthor=J.+Lyssikatos&title=Non-oxime+inhibitors+of+B-RafV600E+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMiknis%26aufirst%3DG.%26aulast%3DRast%26aufirst%3DB.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DEly%26aufirst%3DR.%2BJ.%26aulast%3DSchlachter%26aufirst%3DS.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DRandolph%26aufirst%3DN.%26aulast%3DCallejo%26aufirst%3DM.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DGalbraith%26aufirst%3DS.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DLyssikatos%26aufirst%3DJ.%26atitle%3DNon-oxime%2520inhibitors%2520of%2520B-RafV600E%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1243%26epage%3D1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gould, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adhikari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afroze, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calderwood, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chouitar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffey, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsyth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaulin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenspan, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iartchouk, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janowick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulkarni, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langston, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizutani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paske, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezaei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowland, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sintchak, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tregay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veiby, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vos, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyskocil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, K. M.</span><span> </span><span class="NLM_article-title">Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1836</span><span class="NLM_x">–</span> <span class="NLM_lpage">1846</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101479y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1836-1846&author=A.+E.+Gouldauthor=R.+Adamsauthor=S.+Adhikariauthor=K.+Aertgeertsauthor=R.+Afrozeauthor=C.+Blackburnauthor=E.+F.+Calderwoodauthor=R.+Chauauthor=J.+Chouitarauthor=M.+O.+Duffeyauthor=D.+B.+Englandauthor=C.+Farrerauthor=N.+Forsythauthor=K.+Garciaauthor=J.+Gaulinauthor=P.+D.+Greenspanauthor=R.+Guoauthor=S.+J.+Harrisonauthor=S.-C.+Huangauthor=N.+Iartchoukauthor=D.+Janowickauthor=M.-S.+Kimauthor=B.+Kulkarniauthor=S.+P.+Langstonauthor=J.+X.+Liuauthor=L.-T.+Maauthor=S.+Menonauthor=H.+Mizutaniauthor=E.+Paskeauthor=C.+C.+Renouauthor=M.+Rezaeiauthor=R.+S.+Rowlandauthor=M.+D.+Sintchakauthor=M.+D.+Smithauthor=S.+G.+Stroudauthor=M.+Tregayauthor=Y.+Tianauthor=O.+P.+Veibyauthor=T.+J.+Vosauthor=S.+Vyskocilauthor=J.+Williamsauthor=T.+Xuauthor=J.+J.+Yangauthor=J.+Yanoauthor=H.+Zengauthor=D.+M.+Zhangauthor=Q.+Zhangauthor=K.+M.+Galvin&title=Design+and+optimization+of+potent+and+orally+bioavailable+tetrahydronaphthalene+Raf+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors</span></div><div class="casAuthors">Gould, Alexandra E.; Adams, Ruth; Adhikari, Sharmila; Aertgeerts, Kathleen; Afroze, Roushan; Blackburn, Christopher; Calderwood, Emily F.; Chau, Ryan; Chouitar, Jouhara; Duffey, Matthew O.; England, Dylan B.; Farrer, Cheryl; Forsyth, Nancy; Garcia, Khristofer; Gaulin, Jeffery; Greenspan, Paul D.; Guo, Ribo; Harrison, Sean J.; Huang, Shih-Chung; Iartchouk, Natalia; Janowick, Dave; Kim, Mi-Sook; Kulkarni, Bheemashankar; Langston, Steven P.; Liu, Jane X.; Ma, Li-Ting; Menon, Saurabh; Mizutani, Hirotake; Paske, Erin; Renou, Christelle C.; Rezaei, Mansoureh; Rowland, R. Scott; Sintchak, Michael D.; Smith, Michael D.; Stroud, Stephen G.; Tregay, Ming; Tian, Yuan; Veiby, Ole P.; Vos, Tricia J.; Vyskocil, Stepan; Williams, Juliet; Xu, Tianlin; Yang, Johnny J.; Yano, Jason; Zeng, Hongbo; Zhang, Dong Mei; Zhang, Qin; Galvin, Katherine M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1836-1846</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth.  Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity.  This article describes the design and optimization of tetrahydronaphthalene-derived compds. as potent inhibitors of the Raf pathway in vitro and in vivo.  These compds. possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNulHRlb4oULVg90H21EOLACvtfcHk0lgzTNIoiBCO_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWls7g%253D&md5=568fb1b26a6685df082ac0337494a9c5</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1021%2Fjm101479y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101479y%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DA.%2BE.%26aulast%3DAdams%26aufirst%3DR.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DAfroze%26aufirst%3DR.%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DCalderwood%26aufirst%3DE.%2BF.%26aulast%3DChau%26aufirst%3DR.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DDuffey%26aufirst%3DM.%2BO.%26aulast%3DEngland%26aufirst%3DD.%2BB.%26aulast%3DFarrer%26aufirst%3DC.%26aulast%3DForsyth%26aufirst%3DN.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DGaulin%26aufirst%3DJ.%26aulast%3DGreenspan%26aufirst%3DP.%2BD.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DHarrison%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DS.-C.%26aulast%3DIartchouk%26aufirst%3DN.%26aulast%3DJanowick%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DM.-S.%26aulast%3DKulkarni%26aufirst%3DB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DMa%26aufirst%3DL.-T.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DPaske%26aufirst%3DE.%26aulast%3DRenou%26aufirst%3DC.%2BC.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DRowland%26aufirst%3DR.%2BS.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DStroud%26aufirst%3DS.%2BG.%26aulast%3DTregay%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DVeiby%26aufirst%3DO.%2BP.%26aulast%3DVos%26aufirst%3DT.%2BJ.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%2BM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGalvin%26aufirst%3DK.%2BM.%26atitle%3DDesign%2520and%2520optimization%2520of%2520potent%2520and%2520orally%2520bioavailable%2520tetrahydronaphthalene%2520Raf%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1836%26epage%3D1846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preece, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span> </span><span class="NLM_article-title">A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of <sup>V600E</sup>BRAF</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">8036</span><span class="NLM_x">–</span> <span class="NLM_lpage">8044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=8036-8044&author=S.+Whittakerauthor=D.+M%C3%A9nardauthor=R.+Kirkauthor=L.+Ogilvieauthor=D.+Hedleyauthor=A.+Zambonauthor=F.+Lopesauthor=N.+Preeceauthor=H.+Manneauthor=S.+Ranaauthor=M.+Lambrosauthor=J.+S.+Reis-Filhoauthor=R.+Maraisauthor=C.+J.+Springer&title=A+novel%2C+selective%2C+and+efficacious+nanomolar+pyridopyrazinone+inhibitor+of+V600EBRAF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DM%25C3%25A9nard%26aufirst%3DD.%26aulast%3DKirk%26aufirst%3DR.%26aulast%3DOgilvie%26aufirst%3DL.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DManne%26aufirst%3DH.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%252C%2520and%2520efficacious%2520nanomolar%2520pyridopyrazinone%2520inhibitor%2520of%2520V600EBRAF%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D8036%26epage%3D8044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zambon, A.; Ménard, D.; Suijkerbuijk, B. M. J. M.; Niculescu-Duvaz, I.; Whittaker, S.; Niculescu-Duvaz, D.; Nourry, A.; Davies, L.; Manne, H. A.; Lopes, F.; Preece, N.; Hedley, D.; Ogilvie, L. M.; Kirk, R.; Marais, R.; Springer, C. J.</span><span> </span><span class="NLM_article-title">Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors</span>.  <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5639</span><span class="NLM_x">–</span> <span class="NLM_lpage">5655</span> (and references contained therein).</span><div class="citationLinks">[<a href="/doi/10.1021/jm100383b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5639-5655&author=A.+Zambon&author=D.+M%C3%A9nard&author=B.+M.+J.+M.+Suijkerbuijk&author=I.+Niculescu-Duvaz&author=S.+Whittaker&author=D.+Niculescu-Duvaz&author=A.+Nourry&author=L.+Davies&author=H.+A.+Manne&author=F.+Lopes&author=N.+Preece&author=D.+Hedley&author=L.+M.+Ogilvie&author=R.+Kirk&author=R.+Marais&author=C.+J.+Springer&title=Novel+hinge+binder+improves+activity+and+pharmacokinetic+properties+of+BRAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5f&amp;dbid=16384&amp;doi=10.1021%2Fjm100383b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100383b%26sid%3Dliteratum%253Aachs%26aulast%3DZambon%26aufirst%3DA.%26atitle%3DNovel%2520hinge%2520binder%2520improves%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520BRAF%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5639%26epage%3D5655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salaski, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojciechowicz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frommer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span> </span><span class="NLM_article-title">Indazolylpyrazolopyrimidines as highly potent B-Raf inhibitors with in vivo activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7878</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1007566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7874-7878&author=X.+Wangauthor=D.+M.+Bergerauthor=E.+J.+Salaskiauthor=N.+Torresauthor=M.+Dutiaauthor=C.+Hannaauthor=Y.+Huauthor=J.+L.+Levinauthor=D.+Powellauthor=D.+Wojciechowiczauthor=K.+Collinsauthor=E.+Frommerauthor=J.+Lucas&title=Indazolylpyrazolopyrimidines+as+highly+potent+B-Raf+inhibitors+with+in+vivo+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5g&amp;dbid=16384&amp;doi=10.1021%2Fjm1007566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1007566%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DSalaski%26aufirst%3DE.%2BJ.%26aulast%3DTorres%26aufirst%3DN.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLevin%26aufirst%3DJ.%2BL.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DWojciechowicz%26aufirst%3DD.%26aulast%3DCollins%26aufirst%3DK.%26aulast%3DFrommer%26aufirst%3DE.%26aulast%3DLucas%26aufirst%3DJ.%26atitle%3DIndazolylpyrazolopyrimidines%2520as%2520highly%2520potent%2520B-Raf%2520inhibitors%2520with%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7874%26epage%3D7878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF<sup>V600E</sup> mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3042</span><span class="NLM_x">–</span> <span class="NLM_lpage">3051</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3042-3051&author=K.+P.+Hoeflichauthor=S.+Herterauthor=J.+Tienauthor=L.+Wongauthor=L.+Berryauthor=J.+Chanauthor=C.+O%E2%80%99Brienauthor=Z.+Modrusanauthor=S.+Seshagiriauthor=M.+Lacknerauthor=H.+Sternauthor=E.+Chooauthor=L.+Murrayauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Antitumor+efficacy+of+the+novel+RAF+inhibitor+GDC-0879+is+predicted+by+BRAFV600E+mutational+status+and+sustained+extracellular+signal-regulated+kinase%2Fmitogen-activated+protein+kinase+pathway+suppression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DHerter%26aufirst%3DS.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DLackner%26aufirst%3DM.%26aulast%3DStern%26aufirst%3DH.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DAntitumor%2520efficacy%2520of%2520the%2520novel%2520RAF%2520inhibitor%2520GDC-0879%2520is%2520predicted%2520by%2520BRAFV600E%2520mutational%2520status%2520and%2520sustained%2520extracellular%2520signal-regulated%2520kinase%252Fmitogen-activated%2520protein%2520kinase%2520pathway%2520suppression%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D3042%26epage%3D3051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMorin, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paras, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petkus, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nixey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnahan, J.</span><span> </span><span class="NLM_article-title">Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6189</span><span class="NLM_x">–</span> <span class="NLM_lpage">6192</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901081g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6189-6192&author=A.+L.+Smithauthor=F.+F.+DeMorinauthor=N.+A.+Parasauthor=Q.+Huangauthor=J.+K.+Petkusauthor=E.+M.+Dohertyauthor=T.+Nixeyauthor=J.+L.+Kimauthor=D.+A.+Whittingtonauthor=L.+F.+Epsteinauthor=M.+R.+Leeauthor=M.+J.+Roseauthor=C.+Babijauthor=M.+Fernandoauthor=K.+Hessauthor=Q.+Leauthor=P.+Beltranauthor=J.+Carnahan&title=Selective+inhibitors+of+the+mutant+B-Raf+pathway%3A+discovery+of+a+potent+and+orally+bioavailable+aminoisoquinoline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5i&amp;dbid=16384&amp;doi=10.1021%2Fjm901081g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901081g%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DDeMorin%26aufirst%3DF.%2BF.%26aulast%3DParas%26aufirst%3DN.%2BA.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DPetkus%26aufirst%3DJ.%2BK.%26aulast%3DDoherty%26aufirst%3DE.%2BM.%26aulast%3DNixey%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DK.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DBeltran%26aufirst%3DP.%26aulast%3DCarnahan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibitors%2520of%2520the%2520mutant%2520B-Raf%2520pathway%253A%2520discovery%2520of%2520a%2520potent%2520and%2520orally%2520bioavailable%2520aminoisoquinoline%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6189%26epage%3D6192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Ramurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costales, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dove, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pick, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renhowe, P. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7049</span><span class="NLM_x">–</span> <span class="NLM_lpage">7052</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801050k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7049-7052&author=S.+Ramurthyauthor=S.+Subramanianauthor=M.+Aikawaauthor=P.+Amiriauthor=A.+Costalesauthor=J.+Doveauthor=S.+Fongauthor=J.+M.+Jansenauthor=B.+Levineauthor=S.+Maauthor=C.+M.+McBrideauthor=J.+Michaelianauthor=T.+Pickauthor=D.+J.+Poonauthor=S.+Girishauthor=C.+M.+Shaferauthor=D.+Stuartauthor=L.+Sungauthor=P.+A.+Renhowe&title=Design+and+synthesis+of+orally+bioavailable+benzimidazoles+as+Raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5j&amp;dbid=16384&amp;doi=10.1021%2Fjm801050k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801050k%26sid%3Dliteratum%253Aachs%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DAikawa%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DCostales%26aufirst%3DA.%26aulast%3DDove%26aufirst%3DJ.%26aulast%3DFong%26aufirst%3DS.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DLevine%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DMichaelian%26aufirst%3DJ.%26aulast%3DPick%26aufirst%3DT.%26aulast%3DPoon%26aufirst%3DD.%2BJ.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DSung%26aufirst%3DL.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520orally%2520bioavailable%2520benzimidazoles%2520as%2520Raf%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7049%26epage%3D7052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span>See the Novartis website (<a href="http://www.novartisoncology.com/research-innovation/pipeline/raf265" class="extLink">http://www.novartisoncology.com/research-innovation/pipeline/raf265</a>) (accessed April 10, 2011) and the ClinicalTrials.gov website (<a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>) (NCT00304525, accessed on April 10, 2011). Also see: <span class="NLM_contrib-group">Stuart, D.; Aardalen, K.; Venetsanakos, E.; Lorenzana, E.; Salangsang, F.; Nagel, T.; Wallroth, M.; Batt, D.; Ramurthy, S.; Poon, D.; Faure, M.; Aikawa, M.; Dove, J.; Garrett, L.; Kaplan, A.; Amiri, P.; Pryer, N.; Renhowe, P.</span><span> </span><span class="NLM_article-title">RAF265 is a potent Raf inhibitor with selective anti-proliferative activity in vitro and in vivo</span>. AACR Annu. Meet.<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">, </span>Abstract  <span class="NLM_fpage">4876</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+Stuart&author=K.+Aardalen&author=E.+Venetsanakos&author=E.+Lorenzana&author=F.+Salangsang&author=T.+Nagel&author=M.+Wallroth&author=D.+Batt&author=S.+Ramurthy&author=D.+Poon&author=M.+Faure&author=M.+Aikawa&author=J.+Dove&author=L.+Garrett&author=A.+Kaplan&author=P.+Amiri&author=N.+Pryer&author=P.+Renhowe&title=RAF265+is+a+potent+Raf+inhibitor+with+selective+anti-proliferative+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DStuart%26aufirst%3DD.%26atitle%3DRAF265%2520is%2520a%2520potent%2520Raf%2520inhibitor%2520with%2520selective%2520anti-proliferative%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAACR%2520Annu.%2520Meet.%26date%3D2008%26spage%3D4876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span>See the Exelixis website (<a href="http://www.exelixis.com/pipeline" class="extLink">http://www.exelixis.com/pipeline</a>) (accessed April 10, 2011) and the ClinicalTrials.gov website (<a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>) (NCT01086267, accessed on April 10, 2011). See also: <span class="NLM_contrib-group">Schwartz, G. L.; Robertson, S.; Shen, A.; Wang, E.; Pace, L.; Dials, H.; Mendelson, D.; Shannon, P.; Gordon, M.</span><span> </span><span class="NLM_article-title">A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span>, 15sAbstr.  <span class="NLM_fpage">3513</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1200%2FJCO.2008.20.3745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3513&author=G.+L.+Schwartz&author=S.+Robertson&author=A.+Shen&author=E.+Wang&author=L.+Pace&author=H.+Dials&author=D.+Mendelson&author=P.+Shannon&author=M.+Gordon&title=A+phase+I+study+of+XL281%2C+a+selective+oral+RAF+kinase+inhibitor%2C+in+patients+%28Pts%29+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.20.3745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.20.3745%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BL.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520XL281%252C%2520a%2520selective%2520oral%2520RAF%2520kinase%2520inhibitor%252C%2520in%2520patients%2520%2528Pts%2529%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D3513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span>See the GlaxoSmithKline website (<a href="http://www.gsk.com/investors/pp-pipeline-standard" class="extLink">http://www.gsk.com/investors/pp-pipeline-standard</a>) (accessed April 10, 2011) and the ClinicalTrials.gov website (<a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>) (NCT01227889, accessed on April 10, 2011). See also: <span class="NLM_contrib-group">Kefford, R.; Arkenau, H.; Brown, M. P.; Millward, M.; Infante, J. R.; Long, G. V.; Ouellet, D.; Curtis, M.; Lebowitz, P. F.; Falchook, G. S.</span><span> </span><span class="NLM_article-title">Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span>, 15sAbstr.  <span class="NLM_fpage">8503</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=8503&author=R.+Kefford&author=H.+Arkenau&author=M.+P.+Brown&author=M.+Millward&author=J.+R.+Infante&author=G.+V.+Long&author=D.+Ouellet&author=M.+Curtis&author=P.+F.+Lebowitz&author=G.+S.+Falchook&title=Phase+I%2FII+study+of+GSK2118436%2C+a+selective+inhibitor+of+oncogenic+mutant+BRAF+kinase%2C+in+patients+with+metastatic+melanoma+and+other+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKefford%26aufirst%3DR.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520GSK2118436%252C%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520mutant%2520BRAF%2520kinase%252C%2520in%2520patients%2520with%2520metastatic%2520melanoma%2520and%2520other%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D8503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="note"><p class="first last">For the most current information, refer to the Plexxikon (<a href="http://www.plexxikon.com" class="extLink">http://www.plexxikon.com</a>), Daiichi-Sankyo (<a href="http://www.daiichisankyo.com" class="extLink">http://www.daiichisankyo.com</a>), and Roche Web sites (<a href="http://www.roche.com" class="extLink">http://www.roche.com</a>) and the following references:</p></div><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0liPmm5suE1PWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vultur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">Targeting BRAF in advanced melanoma: A first step toward manageable disease</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1658</span><span class="NLM_x">–</span> <span class="NLM_lpage">1663</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1158%2F1078-0432.CCR-10-0174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=21447722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1658-1663&author=A.+Vulturauthor=J.+Villanuevaauthor=M.+Herlyn&title=Targeting+BRAF+in+advanced+melanoma%3A+A+first+step+toward+manageable+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease</span></div><div class="casAuthors">Vultur, Adina; Villanueva, Jessie; Herlyn, Meenhard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1658-1663</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Melanoma is the deadliest form of skin cancer and its incidence has been increasing worldwide.  The disease manifests itself as clin. and genetically distinct subgroups, indicating the need for patient-specific diagnostic and treatment tools.  The discovery of activating mutations (V600E) in the BRAF kinase in approx. 50% of patients spurred the development of compds. to inhibit aberrant BRAF activity, and the first drug candidate to show promising clin. activity is PLX4032 (also known as RG7204).  Most recent clin. data from a phase II trial indicate that PLX4032 causes tumor regression and stabilized disease in >50% of advanced melanoma patients harboring BRAF V600E tumors.  These data validate the effectiveness of oncogene-targeted therapy against advanced melanoma and offer hope that the disease can be overcome.  However, as melanoma is dynamic and heterogeneous, careful treatment strategies and combination therapies are warranted to obtain long-term clin. effects.  Clin Cancer Res; 17(7); 1658-63.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRWKQUyFvFObVg90H21EOLACvtfcHk0liPmm5suE1PWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOisrw%253D&md5=eca5a7d0b4ab7c3dc5c0dc93ab264716</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0174%26sid%3Dliteratum%253Aachs%26aulast%3DVultur%26aufirst%3DA.%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DTargeting%2520BRAF%2520in%2520advanced%2520melanoma%253A%2520A%2520first%2520step%2520toward%2520manageable%2520disease%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D1658%26epage%3D1663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lgtRhz_3_yegQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lgtRhz_3_yegQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="note"><p class="first last">See <a href="http://www.kinomescan.com" class="extLink">http://www.kinomescan.com</a> and</p></div><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A qualitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+qualitative+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520qualitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lhX4RPFTTn-JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Posy, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermsmeir, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaccaro, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todderud, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughney, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span> </span><span class="NLM_article-title">Trends in kinase selectivity: Insights for target class-focused library screening</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101195a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFSms7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=54-66&author=S.+L.+Posyauthor=M.+A.+Hermsmeirauthor=W.+Vaccaroauthor=K.-H.+Ottauthor=G.+Todderudauthor=J.+S.+Lippyauthor=G.+L.+Trainorauthor=D.+A.+Loughneyauthor=S.+R.+Johnson&title=Trends+in+kinase+selectivity%3A+Insights+for+target+class-focused+library+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in Kinase Selectivity: Insights for Target Class-Focused Library Screening</span></div><div class="casAuthors">Posy, Shana L.; Hermsmeier, Mark A.; Vaccaro, Wayne; Ott, Karl-Heinz; Todderud, Gordon; Lippy, Jonathan S.; Trainor, George L.; Loughney, Deborah A.; Johnson, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-66</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A kinome-wide selectivity screen of >20000 compds. with a rich representation of many structural classes has been completed.  Anal. of the selectivity patterns for each class shows that a broad spectrum of structural scaffolds can achieve specificity for many kinase families.  Kinase selectivity and potency are inversely correlated, a trend that is also found in a large set of kinase functional data.  Although selective and nonselective compds. are mostly similar in their physicochem. characteristics, we identify specific features that are present more frequently in compds. that bind to many kinases.  Our results support a scaffold-oriented approach for building compd. collections to screen kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJlqg1ZszRmLVg90H21EOLACvtfcHk0lioirccnSRCtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFSms7jJ&md5=f824b454904fb99d1ddd1ac6396cb784</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fjm101195a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101195a%26sid%3Dliteratum%253Aachs%26aulast%3DPosy%26aufirst%3DS.%2BL.%26aulast%3DHermsmeir%26aufirst%3DM.%2BA.%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DOtt%26aufirst%3DK.-H.%26aulast%3DTodderud%26aufirst%3DG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DLoughney%26aufirst%3DD.%2BA.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26atitle%3DTrends%2520in%2520kinase%2520selectivity%253A%2520Insights%2520for%2520target%2520class-focused%2520library%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D54%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">High-throughput kinase profiling as a platform for drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnrd2541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=18404149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=391-397&author=D.+M.+Goldsteinauthor=N.+S.+Grayauthor=P.+P.+Zarrinkar&title=High-throughput+kinase+profiling+as+a+platform+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput kinase profiling as a platform for drug discovery</span></div><div class="casAuthors">Goldstein, David M.; Gray, Nathanael S.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">391-397</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  High-throughput profiling of compd. libraries against large panels of kinases is becoming tech. feasible.  In contrast to the traditional linear, target-centric approach to discovery, this approach may provide a choice of targets to pursue that is guided by the quality of lead compds. available, rather than by target biol. alone, and could thereby significantly improve the productivity of kinase inhibitor discovery.  To fully exploit the potential of kinases as drug targets, novel strategies for the efficient discovery of inhibitors are required.  In contrast to the traditional, linear process of inhibitor discovery, high-throughput kinase profiling enables a parallel approach by interrogating compds. against hundreds of targets in a single screen.  Compd. potency and selectivity are detd. simultaneously, providing a choice of targets to pursue that is guided by the quality of lead compds. available, rather than by target biol. alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwnJ59cVxbJbVg90H21EOLACvtfcHk0lioirccnSRCtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbs%253D&md5=eaa61fd2958ff04fecf86a993f91833d</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1038%2Fnrd2541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2541%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DHigh-throughput%2520kinase%2520profiling%2520as%2520a%2520platform%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D391%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Holladay, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowbottom, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitnick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span> </span><span class="NLM_article-title">4-Quinazolinyloxy-diaryl ureas as novel BRAF<sup>V600E</sup> inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5342</span><span class="NLM_x">–</span> <span class="NLM_lpage">5346</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5342-5346&author=M.+W.+Holladayauthor=B.+T.+Campbellauthor=M.+W.+Rowbottomauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=A.+G.+Laiauthor=S.+Abrahamauthor=E.+Settiauthor=R.+Faraoniauthor=L.+Tranauthor=R.+C.+Armstrongauthor=R.+N.+Gunawardaneauthor=M.+F.+Gardnerauthor=M.+D.+Cramerauthor=D.+Gitnickauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=B.+R.+Ruggeriauthor=M.+Williamsauthor=S.+S.+Bhagwatauthor=J.+James&title=4-Quinazolinyloxy-diaryl+ureas+as+novel+BRAFV600E+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DSetti%26aufirst%3DE.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DRuggeri%26aufirst%3DB.%2BR.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26aulast%3DJames%26aufirst%3DJ.%26atitle%3D4-Quinazolinyloxy-diaryl%2520ureas%2520as%2520novel%2520BRAFV600E%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5342%26epage%3D5346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Abraham, S.; Bhagwat, S.; Campbell, B. T.; Chao, Q.; Faraoni, R.; Holladay, M. W.; Lai, A. G.; Rowbottom, M. W.; Setti, E.; Sprankle, K. G.</span><span> </span><span class="NLM_article-title">Preparation of quinazoline derivatives as RAF kinase modulators for treating cancers, inflammations and immune diseases</span>. Patent Application WO 2009117080 A1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Abraham%2C+S.%3B+Bhagwat%2C+S.%3B+Campbell%2C+B.+T.%3B+Chao%2C+Q.%3B+Faraoni%2C+R.%3B+Holladay%2C+M.+W.%3B+Lai%2C+A.+G.%3B+Rowbottom%2C+M.+W.%3B+Setti%2C+E.%3B+Sprankle%2C+K.+G.+Preparation+of+quinazoline+derivatives+as+RAF+kinase+modulators+for+treating+cancers%2C+inflammations+and+immune+diseases.+Patent+Application+WO+2009117080+A1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520quinazoline%2520derivatives%2520as%2520RAF%2520kinase%2520modulators%2520for%2520treating%2520cancers%252C%2520inflammations%2520and%2520immune%2520diseases" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Takase, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murabayashi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumimoto, S.</span><span> </span><span class="NLM_article-title">Practical synthesis of 3-amino-5-<i>tert</i>-butylisoxazole from 4,4-dimethyl-3-oxopentanenitrile with hydroxylamine</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=1153-1158&author=A.+Takaseauthor=A.+Murabayashiauthor=S.+Sumimoto&title=Practical+synthesis+of+3-amino-5-tert-butylisoxazole+from+4%2C4-dimethyl-3-oxopentanenitrile+with+hydroxylamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakase%26aufirst%3DA.%26aulast%3DMurabayashi%26aufirst%3DA.%26aulast%3DSumimoto%26aufirst%3DS.%26atitle%3DPractical%2520synthesis%2520of%25203-amino-5-tert-butylisoxazole%2520from%25204%252C4-dimethyl-3-oxopentanenitrile%2520with%2520hydroxylamine%26jtitle%3DHeterocycles%26date%3D1991%26volume%3D32%26spage%3D1153%26epage%3D1158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="note"><p class="first last">The <i>tert</i>-butyl motif is often incorporated into drug candidates, and it is a component of numerous approved drugs. However, it is known that, with certain drugs containing a <i>tert</i>-butyl group, the <i>tert</i>-butyl itself may be subject to phase I oxidative processes <i>in vivo</i>, resulting in formation of the corresponding hydroxylated <i>tert</i>-butyl derivatives (which can be further oxidized to the corresponding carboxylates). For specific examples, see:</p></div><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Garteiz, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okerholm, R. A.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and biotransformation studies of terfenadine in man</span> <span class="citation_source-journal">Arzneim. Forsch. Drug Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1185</span><span class="NLM_x">–</span> <span class="NLM_lpage">1190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=6817765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADyaL3sXhsFA%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1982&pages=1185-1190&author=D.+A.+Garteizauthor=R.+H.+Hookauthor=B.+J.+Walkerauthor=R.+A.+Okerholm&title=Pharmacokinetics+and+biotransformation+studies+of+terfenadine+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and biotransformation studies of terfenadine in man</span></div><div class="casAuthors">Garteiz, D. A.; Hook, R. H.; Walker, B. J.; Okerholm, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9A</span>),
    <span class="NLM_cas:pages">1185-90</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    </div><div class="casAbstract">In normal human subjects, comparison of the plasma level data obtained from a dose-response study to that of a 14C-material balance study indicates that 99.48% of the terfenadine (I)  [50679-08-8]-related material absorbed undergoes biotransformation.  From the balance study, it has been detd. that fecal excretion accounts for ca. 60% of the dose administered.  Thin-layer chromatog. anal. of urine and feces revealed the presence of 2 major metabolic products.  These compds. have been isolated and their structures detd. by gas chromatog.-mass spectroscopy.  One of the metabolic products, a carboxylic acid analog of terfenadine  [83799-24-0] had antihistaminic activity and may play a role in the activity of the parent drug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqscH5aP4FNNrVg90H21EOLACvtfcHk0lj-PeeeU2i_pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhsFA%253D&md5=2a24c77c63188bc4b89bf8cab09b38e3</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarteiz%26aufirst%3DD.%2BA.%26aulast%3DHook%26aufirst%3DR.%2BH.%26aulast%3DWalker%26aufirst%3DB.%2BJ.%26aulast%3DOkerholm%26aufirst%3DR.%2BA.%26atitle%3DPharmacokinetics%2520and%2520biotransformation%2520studies%2520of%2520terfenadine%2520in%2520man%26jtitle%3DArzneim.%2520Forsch.%2520Drug%2520Res.%26date%3D1982%26volume%3D32%26spage%3D1185%26epage%3D1190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulford, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surber, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukulka, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrero, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shet, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estabrook, R. W.</span><span> </span><span class="NLM_article-title">In vitro metabolism of terfenadine by purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase: Comparison to human liver microsomes and precision-cut liver tissue slices</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=765-775&author=A.+D.+Rodriguesauthor=D.+J.+Mulfordauthor=R.+D.+Leeauthor=B.+W.+Surberauthor=M.+J.+Kukulkaauthor=J.+L.+Ferreroauthor=S.+B.+Thomasauthor=M.+S.+Shetauthor=R.+W.+Estabrook&title=In+vitro+metabolism+of+terfenadine+by+purified+recombinant+fusion+protein+containing+cytochrome+P4503A4+and+NADPH-P450+reductase%3A+Comparison+to+human+liver+microsomes+and+precision-cut+liver+tissue+slices"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DMulford%26aufirst%3DD.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BD.%26aulast%3DSurber%26aufirst%3DB.%2BW.%26aulast%3DKukulka%26aufirst%3DM.%2BJ.%26aulast%3DFerrero%26aufirst%3DJ.%2BL.%26aulast%3DThomas%26aufirst%3DS.%2BB.%26aulast%3DShet%26aufirst%3DM.%2BS.%26aulast%3DEstabrook%26aufirst%3DR.%2BW.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520terfenadine%2520by%2520purified%2520recombinant%2520fusion%2520protein%2520containing%2520cytochrome%2520P4503A4%2520and%2520NADPH-P450%2520reductase%253A%2520Comparison%2520to%2520human%2520liver%2520microsomes%2520and%2520precision-cut%2520liver%2520tissue%2520slices%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1995%26volume%3D23%26spage%3D765%26epage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Carlin, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christofalo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arison, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosegay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, S. H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenheuvel, W. J. A.</span><span> </span><span class="NLM_article-title">Disposition and metabolism of finasteride in dogs</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=100-109&author=J.+R.+Carlinauthor=P.+Christofaloauthor=B.+H.+Arisonauthor=R.+E.+Ellsworthauthor=A.+Rosegayauthor=R.+R.+Millerauthor=S.+H.+L.+Chiuauthor=W.+J.+A.+Vandenheuvel&title=Disposition+and+metabolism+of+finasteride+in+dogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlin%26aufirst%3DJ.%2BR.%26aulast%3DChristofalo%26aufirst%3DP.%26aulast%3DArison%26aufirst%3DB.%2BH.%26aulast%3DEllsworth%26aufirst%3DR.%2BE.%26aulast%3DRosegay%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DChiu%26aufirst%3DS.%2BH.%2BL.%26aulast%3DVandenheuvel%26aufirst%3DW.%2BJ.%2BA.%26atitle%3DDisposition%2520and%2520metabolism%2520of%2520finasteride%2520in%2520dogs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1997%26volume%3D25%26spage%3D100%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Prakash, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colizza, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span> </span><span class="NLM_article-title">Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2822</span><span class="NLM_x">–</span> <span class="NLM_lpage">2832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1002%2Frcm.3153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=17661339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSnsrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2822-2832&author=C.+Prakashauthor=J.+Linauthor=K.+Colizzaauthor=Z.+Miao&title=Characterization+of+metabolites+of+a+NK1+receptor+antagonist%2C+CJ-11%2C972%2C+in+human+liver+microsomes+and+recombinant+human+CYP+isoforms+by+liquid+chromatography%2Ftandem+mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15dR"><div class="casContent"><span class="casTitleNuber">15d</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry</span></div><div class="casAuthors">Prakash, Chandra; Lin, Jinyan; Colizza, Kevin; Miao, Zhuang</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2822-2832</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The in vitro metab. of CJ-11,972, (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-tert-butyl-2-methoxybenzyl)amine, an NK1 receptor antagonist, was studied in human liver microsomes and recombinant human CYP isoforms.  Liq. chromatog./mass spectrometry (LC/MS) and tandem mass spectrometry (LC/MS/MS) coupled to radioactive detection were used to detect and identify the metabolites.  CJ-11,972 was extensively metabolized in human liver microsomes and recombinant human CYP3A4/3A5 isoforms.  A total of fourteen metabolites were identified by a combination of various MS techniques.  The major metabolic pathways were due to oxidn. of the tert-Bu moiety to form an alc. (M6) and/or O-demethylation of the anisole moiety.  The alc. metabolite M6 was further oxidized to the corresponding aldehyde (M7) and carboxylic acid (M4).  Two unusual metabolites (M13, M17), formed by C-demethylation of the tert-Bu group, were identified as 2-{3-[(2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-ylamino)methyl]-4-methoxyphenyl}propan-2-ol and (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-isopropenyl-2-methoxybenzyl)amine.  A plausible mechanism for C-demethylation may involve oxidn. of M6 to form an aldehyde metabolite (M7), followed by cytochrome P 450-mediated deformylation leaving an unstable carbon-centered radical, which would quickly form either the alc. metabolite M13 and the olefin metabolite M17.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_dgJ2mV5orLVg90H21EOLACvtfcHk0liSKDYaiQYX_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSnsrzP&md5=85f43a40f501349655a92837f324799c</span></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1002%2Frcm.3153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.3153%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DColizza%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DZ.%26atitle%3DCharacterization%2520of%2520metabolites%2520of%2520a%2520NK1%2520receptor%2520antagonist%252C%2520CJ-11%252C972%252C%2520in%2520human%2520liver%2520microsomes%2520and%2520recombinant%2520human%2520CYP%2520isoforms%2520by%2520liquid%2520chromatography%252Ftandem%2520mass%2520spectrometry%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2007%26volume%3D21%26spage%3D2822%26epage%3D2832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Park, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitteringham, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neil, P. M.</span><span> </span><span class="NLM_article-title">Metabolism of fluorine-containing drugs</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1146%2Fannurev.pharmtox.41.1.443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=11264465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVaqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=443-470&author=K.+B.+Parkauthor=N.+R.+Kitteringhamauthor=P.+M.+O%E2%80%99Neil&title=Metabolism+of+fluorine-containing+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of fluorine-containing drugs</span></div><div class="casAuthors">Park, B. Kevin; Kitteringham, Neil R.; O'Neill, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">443-470</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 109 refs.  This article reviews current knowledge of the metab. of drugs that contain fluorine.  The strategic value of fluorine substitution in drug design is discussed in terms of chem. structure and basic concepts in drug metab. and drug toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAja3Ht70KbVg90H21EOLACvtfcHk0lg8aNMy8sHPbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVaqtrc%253D&md5=0e2ee242da0f4cef8d203e92aee03180</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.41.1.443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.41.1.443%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DK.%2BB.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DP.%2BM.%26atitle%3DMetabolism%2520of%2520fluorine-containing%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2001%26volume%3D41%26spage%3D443%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hodgetts, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combs, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elder, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, G. C.</span><span> </span><span class="NLM_article-title">The role of fluorine in the discovery and optimization of CNS agents: Modulation of drug-like properties</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=429-448&author=K.+J.+Hodgettsauthor=K.+J.+Combsauthor=A.+M.+Elderauthor=G.+C.+Harriman&title=The+role+of+fluorine+in+the+discovery+and+optimization+of+CNS+agents%3A+Modulation+of+drug-like+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHodgetts%26aufirst%3DK.%2BJ.%26aulast%3DCombs%26aufirst%3DK.%2BJ.%26aulast%3DElder%26aufirst%3DA.%2BM.%26aulast%3DHarriman%26aufirst%3DG.%2BC.%26atitle%3DThe%2520role%2520of%2520fluorine%2520in%2520the%2520discovery%2520and%2520optimization%2520of%2520CNS%2520agents%253A%2520Modulation%2520of%2520drug-like%2520properties%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D429%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Q.</span><span> </span><span class="NLM_article-title">Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">613</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2004&pages=609-613&author=Z.+Wangauthor=Y.+Liauthor=E.+T.+Liuauthor=Q.+Yu&title=Susceptibility+to+cell+death+induced+by+blockade+of+MAPK+pathway+in+human+colorectal+cancer+cells+carrying+Ras+mutations+is+dependent+on+p53+status"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DYu%26aufirst%3DQ.%26atitle%3DSusceptibility%2520to%2520cell%2520death%2520induced%2520by%2520blockade%2520of%2520MAPK%2520pathway%2520in%2520human%2520colorectal%2520cancer%2520cells%2520carrying%2520Ras%2520mutations%2520is%2520dependent%2520on%2520p53%2520status%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D322%26spage%3D609%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tristani-Firouzi, M.</span><span> </span><span class="NLM_article-title">hERG potassium channels and cardiac arrhythmia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">440</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1038%2Fnature04710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=16554806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=463-469&author=M.+C.+Sanguinettiauthor=M.+Tristani-Firouzi&title=hERG+potassium+channels+and+cardiac+arrhythmia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">hERG potassium channels and cardiac arrhythmia</span></div><div class="casAuthors">Sanguinetti, Michael C.; Tristani-Firouzi, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7083</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  HERG potassium channels are essential for normal elec. activity in the heart.  Inherited mutations in the HERG gene cause long QT syndrome, a disorder that predisposes individuals to life-threatening arrhythmias.  Arrhythmia can also be induced by a blockage of hERG channels by a surprisingly diverse group of drugs.  This side effect is a common reason for drug failure in preclin. safety trials.  Insights gained from the crystal structures of other potassium channels have helped our understanding of the block of hERG channels and the mechanisms of gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopS3WBEpuAUrVg90H21EOLACvtfcHk0lg8aNMy8sHPbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D&md5=3f355dcd51da3488d73c7c91cbe8d3b8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature04710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04710%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DTristani-Firouzi%26aufirst%3DM.%26atitle%3DhERG%2520potassium%2520channels%2520and%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D463%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">James, J.; Ruggeri, B.; Armstrong, R. C.; Rowbottom, M. W.; Jones-Bolin, S.; Gunawardane, R. N.; Dobrzanski, P.; Gardner, M. F.; Zhao, H.; Cramer, M. D.; Hunter, K.; Nepomuceno, R. R.; Cheng, M.; Gitnick, D.; Yazdanian, M.; Insko, D. E.; Ator, M. A.; Apuy, J. L.; Faraoni, R.; Dorsey, B. D.; Williams, M.; Bhagwat, S. S.; Holladay, M. W.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=James%2C+J.%3B+Ruggeri%2C+B.%3B+Armstrong%2C+R.+C.%3B+Rowbottom%2C+M.+W.%3B+Jones-Bolin%2C+S.%3B+Gunawardane%2C+R.+N.%3B+Dobrzanski%2C+P.%3B+Gardner%2C+M.+F.%3B+Zhao%2C+H.%3B+Cramer%2C+M.+D.%3B+Hunter%2C+K.%3B+Nepomuceno%2C+R.+R.%3B+Cheng%2C+M.%3B+Gitnick%2C+D.%3B+Yazdanian%2C+M.%3B+Insko%2C+D.+E.%3B+Ator%2C+M.+A.%3B+Apuy%2C+J.+L.%3B+Faraoni%2C+R.%3B+Dorsey%2C+B.+D.%3B+Williams%2C+M.%3B+Bhagwat%2C+S.+S.%3B+Holladay%2C+M.+W.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancer Genome Project</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm2009925&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm2009925&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=M.+S.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=Cancer+Genome+Projectauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lgEyoxOisRJIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DM.%2BS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3D%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">The authors observed that both wt-BRAF and BRAF<sup>V600E</sup> kinase domains adopt essentially identical conformations in the presence of the inhibitor sorafenib.</p></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Weyerstahl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kressin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nerdel, F.</span><span> </span><span class="NLM_article-title">Fragmentation reactions of carbonyl compounds with electronegative β-substituents, XV. On the reaction of electronegatively β-substituted pivalic acid esters</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1969</span><span class="NLM_x">, </span> <span class="NLM_volume">725</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=725&publication_year=1969&pages=106-115&author=P.+Weyerstahlauthor=H.+Kressinauthor=F.+Nerdel&title=Fragmentation+reactions+of+carbonyl+compounds+with+electronegative+%CE%B2-substituents%2C+XV.+On+the+reaction+of+electronegatively+%CE%B2-substituted+pivalic+acid+esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeyerstahl%26aufirst%3DP.%26aulast%3DKressin%26aufirst%3DH.%26aulast%3DNerdel%26aufirst%3DF.%26atitle%3DFragmentation%2520reactions%2520of%2520carbonyl%2520compounds%2520with%2520electronegative%2520%25CE%25B2-substituents%252C%2520XV.%2520On%2520the%2520reaction%2520of%2520electronegatively%2520%25CE%25B2-substituted%2520pivalic%2520acid%2520esters%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D1969%26volume%3D725%26spage%3D106%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvino, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5149</span><span class="NLM_x">–</span> <span class="NLM_lpage">5171</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800475y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm2009925&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5149-5171&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=D.+A.+Pippinauthor=J.+M.+Salvinoauthor=J.+P.+Mallamo&title=Knowledge+based+prediction+of+ligand+binding+modes+and+rational+inhibitor+design+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Pippin, Douglas A.; Salvino, Joseph M.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5149-5171</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review describing the use of Protein Data Bank (PDB) entries specifically for kinase inhibitor drug discovery.  Topics discussed include: the current state of structure-aided ligand design, kinase structure queries and extn. from the PDB, alignment of protein structures, structural classification of ligands, anal. of ligands and binding modes, and ligand design strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDINDYVE15cbVg90H21EOLACvtfcHk0lgnZb8ZeTbarw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM&md5=a1afc4d6c7f6fa4dd6aa9da8d78f1ee3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm800475y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800475y%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DPippin%26aufirst%3DD.%2BA.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge%2520based%2520prediction%2520of%2520ligand%2520binding%2520modes%2520and%2520rational%2520inhibitor%2520design%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5149%26epage%3D5171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1uwj" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1uwj','PDB','1uwj'); return false;">PDB: 1uwj</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1uwh" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1uwh','PDB','1uwh'); return false;">PDB: 1uwh</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i152"><a href="/doi/suppl/10.1021/jm2009925">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_00636"></div></div></div></div></div><hr /></hr><p class="last">The complete list of the 290 individual wild-type kinase targets used for the KINOME<i>scan</i> selectivity profiling of the compounds. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm2009925/suppl_file/jm2009925_si_001.pdf">jm2009925_si_001.pdf (119.67 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm2009925&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm2009925%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-3%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm2009925" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66798670b8622495","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
